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ABSTRACT 
 
INTRODUCTION 
Functional constipation (FC) is a common condition which affects patients’ quality of life (QoL), is of 
uncertain pathophysiology, and is poorly treated. The aims of this research were to conduct a 
randomised, placebo-controlled trial investigating an opiate antagonist (Naloxone - Nalcol™) on 
symptom relief in FC and secondly to describe the colonic microbiota in FC and determine the effect of 
Nalcol™ on it. 
MATERIAL AND METHODS 
The trial consisted of; a 2 week screening period (Period I), a 4 week trial period of Nalcol™ vs. Placebo 
(Period II), and a 4 week open label period with all patients taking Nalcol™ (Period III). The primary 
outcome was patients’ assessment of ‘satisfactory improvement in the preceding 2 weeks’ after each 
period. The secondary outcomes were: changes in QoL, stool type and frequency, and transit time. A 
subset of patients donated stool samples at the end of each period for microbiological analysis which 
were compared with controls without FC. Faecal samples were analysed using denaturing gradient gel 
electrophoresis (DGGE), fluorescence in situ hybridisation (FISH), and pyrosequencing.  
RESULTS 
41 females were recruited (median age 45, range 23-76 years) .There were no significant differences in 
‘satisfactory improvement in the preceding 2 weeks’, (Nalcol™ vs. Placebo, 20% vs. 24%, p=1.00, n=41) or 
any secondary outcomes. Nalcol™ use was associated with more bloating (40% vs. 5%, p=0.009). 
Patients with FC had significant reductions in the Firmicutes phylum (25% vs. 45%, p=0.004) and 
Bifidiobacteria spp. (0.67 vs. 0.88 log10 cell/g, p=0.03), with increases in the Bacteroidetes phylum (66% 
vs. 41%, p=0.002) compared to controls. 
CONCLUSION 
Nalcol™ had no clinical benefits for managing FC in this trial and cannot be recommended in this group 
of patients. Differences in the colonic microbiota in FC warrant further investigation to see how it is 
implicated in the pathophysiology of FC. 
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CHAPTER 1 
 
 
PATHOPHYSIOLOGY AND MANAGEMENT OF FUNCTIONAL 
CONSTIPATION 
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1.1 DEFINITION OF CONSTIPATION 
 
Constipation is defined as defecation that is unsatisfactory because of infrequent stools, 
difficult stool passage, or seemingly incomplete defecation. Stools are often hard and dry, and 
may be abnormally large or small. Constipation is a subjective symptom and therefore 
attempts have been made to define constipation using objective criteria, most notably the 
Rome III criteria1 (see below). Constipation is a common condition with an estimated 
prevalence of 12-19% in the US2 and 29-35%3,4 in Europe and the prevalence increases with 
age. The exact prevalence is difficult to determine due to significant underreporting by the 
population who often manage the condition with over the counter remedies and the differing 
criteria used to define constipation. The condition is commoner in women and the elderly and 
there is some correlation with low socioeconomic class. Constipation has a significant 
economic burden and in the US in 2004 was responsible for 6.3 million healthcare visits with a 
cost of $1.7 billion5. In England, in 2009 almost 14 million prescriptions were filled for laxatives, 
at a cost of almost £60 million6. 
 
1.2 FUNCTIONAL GASTROINTESTINAL DISORDERS (FGID) AND FUNCTIONAL 
 CONSTIPATION  
Constipation can be divided into two subtypes; functional or primary constipation and 
secondary constipation. Functional constipation is one of a collection of disorders known as 
functional gastrointestinal disorders (FGID) where there is no structural explanation to explain 
the patient’s symptoms. There are significant psychosocial and physiological factors which 
interact to manifest clinically in FGIDs which are summarised in the figure 1.1. Gastrointestinal 
transit time is often delayed in healthy women around the time of the menses7-9 and this has 
often been used to explain why FGID such as irritable bowel syndrome (IBS) and functional 
constipation are more prevalent in women. However, not all women are affected by FGID and 
therefore the sex hormones and their variation over the menstrual cycle cannot be the sole 
cause for the symptoms of FGID and are more likely a component of a multifactorial problem.   
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Constipation probably involves a combination of genetic, physiological, environmental, 
and psychosocial factors. 
 
  
Early Life 
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Figure 1.1 - The relationships between psychosocial and physiological 
factors, functional GI symptoms, and clinical outcome for FGID14. 
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Genetic factors may predispose some patients to FGID by altering levels of neurotransmitters 
such as serotonin (5-HT) or noradrenaline with subsequent effects on gut motility. Functionally 
distinct alpha adrenoceptor and serotonin transporter polymorphisms are associated with 
constipation and high somatic symptoms in patients with lower FGID10. The finding that FGID 
cluster in some families and that 1st degree relatives often exist with similar symptoms to the 
patient11-13 support the implication of genetic factors in the aetiology of FGID.  
Whilst not specific to the FGIDs, psychological and social influences can affect the patient’s 
perception of their symptoms and their subsequent outcome and health care use. Children 
learn behaviours from parents who have FGIDs which puts them at a higher risk of developing 
FGIDs than from genetics alone15. Environmental stresses, emotional and sexual abuse in 
childhood and adulthood also predispose to FGIDs, especially in women, with associated poor 
health-related quality of life and an increase in health care use16. There is also an increased 
prevalence of FGIDs in those patients who suffer with depression and/or anxiety compared to 
healthy controls17.  
 
 
ROME III CRITERIA FOR FUNCTIONAL CONSTIPATION 
1. Must include two or more of the following: 
 
a. Straining (during at least 25% of defecations). 
b. Lumpy or hard stools (on at least 25% of defecations). 
c. Sensation of incomplete defecation (on at least 25% of defecations). 
d. Sensation of anorectal obstruction/blockage (on at least 25% of defecations). 
e. Manual manoeuvres to facilitate defecation (on at least 25% of defecations). 
f. Fewer than three defecations a week. 
 
2. Loose stools rarely present unless induced by laxatives. 
 
3. Would not normally include patients who satisfy criteria for IBS-C 
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1.2.1 FUNCTIONAL CONSTIPATION 
In the absence of structural or metabolic causes to explain constipation, functional 
constipation is divided into three broad categories: (i) normal transit, (ii) slow transit, and (iii) 
evacuation disorders. There is however significant overlap. In a study of 1009 patients, 59% 
had normal colonic transit and normal pelvic floor function, 25% had pelvic floor dysfunction, 
13% had slow transit constipation and 3% had both slow transit constipation and pelvic floor 
dysfunction18. 
 
1.3 INVESTIGATION OF FUNCTIONAL CONSTIPATION 
In current clinical practice, investigation is limited to the assessment of intra-luminal transit 
and the assessment of pelvic floor function. The use of colonic manometry to assess contractile 
activity is slowly gaining clinical acceptance. 
 
1.3.1 TRANSIT STUDIES.  
Transit studies address the question: ‘Does the patient have normal colonic transit?’ Two 
techniques are widely used for the assessment of colonic transit time, namely: radio-opaque 
markers and radionuclide scintigraphy. The former involves the ingestion of radio-opaque 
markers and then assessing their progress through the GI tract by plain X-rays, and were first 
described by Hinton et al in 196919. There are two widely accepted techniques. The first of 
which is the ‘simple’ radio-opaque marker test. A single gelatine capsule containing 20-50 
markers is swallowed on day 0 and a single X-ray is taken on day 5. The ‘multiple markers’ 
study involves ingestion of a capsule on 3 consecutive days, each containing a different set of 
shapes, with a plain X-ray taken on day 59. The simple method allows the distinction between 
normal transit and slow transit whereas the multiple marker study allows assessment of the 
residence times of the markers in defined colonic regions. This is of potential significance if 
segmental resection is to be contemplated (see ‘surgical management of constipation’, section 
1.7.5, page 40). 
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The second method, radionucleide scintigraphy, assesses transit time by monitoring the 
progress of a radioisotopic chemical through the GI tract using a gamma camera and is based 
on a technique described by Krevsky et al20. Intra-luminal movement is expressed by 
calculating the geometric centre of the isotope mass with a low centre implying most of the 
marker is in the caecum, with a high value indicating that the marker has been expelled. The 
progression of the geometric centre over time can be calculated as the time the marker resides 
in specific areas of the colon. Radio-opaque markers are cheap, simple to perform and are 
widely available. Radionucleide scintigraphy allows for more precise quantification and is 
physiologically more accurate, but analysis is more complex and time consuming than radio-
opaque markers, with the test often only available in specialist centres. 
More recently techniques that use MRI have been reported which compare well with the 
radio-opaque marker studies but have the advantage of not using ionising radiation in a 
population of which a substantial proportion are women of child bearing age21. However it is 
not yet widely available and requires greater exertise that the traditional radio-opaque marker 
studies 
 
1.3.2  ANORECTAL PHYSIOLOGY. 
There are a number of methods for assessing anorectal structure and function, however in 
clinical practice this routinely consists of anorectal manometry (Figure 1.2) and defecating 
proctography.  
 
1.3.2.1  Anorectal Manometry 
Anorectal manometry is a widely available tool and encompasses a series of measurements 
designed to test for; 
I. Deficits in anal sphincter function. 
II. Presence or absence of rectoanal reflexes. 
III. Rectal sensory function and compliance. 
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Testing allows evaluation of both incontinence and constipation and may be useful as an 
indicator for biofeedback, assessment prior to surgery, and as an objective measurement of 
treatment efficacy. 
The equipment consists of four major components: a thin intraluminal pressure catheter, 
pressure transducers, a balloon for inflation in the rectum and an amplification-recording-
display system22. Equipment must be accurately calibrated to yield both reproducible and 
accurate results. Unfortunately, the lack of consistency in equipment used and the technique 
performed makes comparison of results from different laboratories difficult and this is 
compounded by the lack of normative data stratified for age and gender23,24. A detailed 
protocol for the conduction of anorectal manometry is outlined below24:  
I. Patient preparation  Bowel preparation and consent is optional. Patients 
    should be placed in the left lateral position. 
II. Probe placement  Once the probe is inserted a rest period of 5 minutes 
    should  be allowed for the patient to relax and  
    sphincter tone to return to basal levels. 
III. Squeeze (Anal)   For a maximum of 30 seconds, rest, then repeat. 
IV. Cough reflex test  Tests the reflex increase in anal sphincter pressure 
    during  abrupt changes in intrabdominal pressure. 
V. Attempted defecation  Assesses the rectal and anal sphincter response. 
VI. Rectoanal inhibitory reflex The rectoanal reflex is the transient relaxation of the 
    internal anal sphincter and contraction of the external 
    anal sphincter on distension of the rectum.  
    Functionally it allows the anorectum complex to assess 
    the contents of the rectum. Rectal balloon is rapidly 
    distended with 50 ml of air.   
    The reflex is typically absent in Hirschsprung’s disease. 
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VII. Rectal sensation  Intermittent balloon distension of the rectum to 
    provide an assessment of rectal sensation, rectoanal 
    inhibitory reflex and rectal compliance. 
VIII. Balloon expulsion test  Balloon is filled with 50 mls of water and expulsion is 
    attempted (within 3 minutes). 
IX. Simulated defecation  Performed if the balloon expulsion test is abnormal 
    and is an assessment in suspected pelvic floor  
    dyssynergia. 
Rao et al recommended that sufferers of constipation undergo resting pressure measurement, 
attempted defecation, assessment of the rectoanal inhibitory reflex and rectal sensation, and 
balloon expulsion24. 
 
1.3.2.2 Defecating Proctography 
This involves the use of video fluoroscopy whilst the patient evacuates barium paste of stool 
consistency. Barium-soaked guaze may be inserted into the vagina and paste also added to the 
perineum to aid in assessing perineal descent and the anorectal angle.  Furthermore the small 
bowel may be opacified with oral contrast to assess for enteroceles. Defecating proctography 
assesses anorectal structure but also gives real-time assessment of function.  The most 
clinically important feature of the assessment is the duration and extent of evacuation rather 
than the presence of anatomical changes such as rectoceles. Normal evacuation should be 90% 
complete. If this is less then the presence of structural abnormalities are clinically significant25. 
Some centres use dynamic MRI rather than video fluoroscopy. Using modified sequences pelvic 
floor motion can be imaged by comparison at rest and on straining and has less interobserver 
error than barium studies whilst obviating the use of radiation. More recently the role of 
dynamic three-dimensional ultrasonography compares well with the other techniques 
described but is cheaper and better tolerated. 
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The catheter (diameter 0.5 cm) with a balloon at its tip is inserted into the rectum. The 
catheter has lateral openings arranged radially at the tip that detect the pressure exerted by 
the rectal wall. The principle on which this system is based is that the pressure exerted by the 
rectum on the catheter has an impact on the water column present along the capillaries up to 
the transducers, which detect the pressure and transmit it to the computer that determines 
the pressure profile. 
  
Figure1.2 – Anorectal manometry catheter and transducer 
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1.4 PHYSIOLOGY OF COLONIC MOTILITY 
To understand the pathophysiology of functional constipation it is first necessary to 
understand the normal physiology of the colon. The principal function of the colon is to absorb 
water and electrolytes from small bowel contents to form solid faeces and to store and expel 
faecal matter. Effective function of the colon depends upon a functioning muscular system 
under enteric neuronal control with both sympathetic and parasympathetic modulation. 
 
1.4.1 INNERVATION OF THE COLON 
The colon is innervated by the sympathetic and parasympathetic nervous systems (extrinsic 
innervation) and the enteric system (intrinsic innervations) (Figures 1.3 and 1.4). The 
sympathetic fibres, via the splanchnic nerves (T5-L2), do not directly innervate structures in the 
GI tract but instead terminate on neurones in the intramural plexuses where they release 
noradrenaline. Noradrenaline inhibits colonic motility through the inhibition of smooth muscle 
contraction. Sympathetic fibres also cause vasoconstriction of mesenteric and submucosal 
blood vessels and modulate secretory activity.  Parasympathetic neurones consist of both the 
vagus nerve and the pelvic nerves. The vagus nerve innervates the upper GI tract to the 
proximal half of the colon with the pelvic nerves (hypogastric plexus) supplying the distal colon 
and rectum. The parasympathetic system, in general, is responsible for an enhancement in 
colonic motility through an increase in excitability of enteric neurones via nicotinic cholinergic 
synapses. 
However, the great majority of neural control of gut function is through the enteric nervous 
system. This lies entirely in the wall of the gut and is organised into the myenteric and 
submucosal plexuses. The myenteric plexus lies between the circular and longitudinal muscle 
layers, extending the length of the intestine. Stimulation increases muscular tone of the wall, 
peristaltic wave frequency and the intensity and rhythm of contractions. The submucosal 
plexus controls local secretory and absorptive activity. These plexuses consist of afferent and 
efferent fibres and ganglion cell bodies which are connected via interneurons. This allows  
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Autonomic Nervous System 
 
Parasympathetic Division     Sympathetic Division 
 
 
 
 
 
 
 
 
 
 
 
 
Dysfunction in these neurological pathways are likely to be involved in the aetiology of 
constipation through, as yet, undetermined mechanisms. 
  
Enteric Nervous System 
Myenteric Plexus  Submucosal Plexus 
Sacral 
Spinal 
Sympathetic 
Ganglia 
Central 
Nervous 
System 
Vagal 
Blood 
Vessels 
Endocrine 
Cells 
Secretory 
Cells 
Smooth 
Muscle 
Figure 1.3 – The major features of the autonomic innervations of the GI tract.  
(Modified from Berne and Levy, 200526) 
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Abbreviations: A , C, mechanosensitive primary afferents; AR, -adrenergic receptors; DR g, dorsal root ganglion; 
EAS, external anal sphincter; g, ganglion; IAS, internal anal sphincter; IM g, inferior mesenteric ganglion; mAChR, 
muscarinic cholinergic receptors; n, nerve; nAChR, nicotinic cholinergic receptors; NO, nitric oxide; (+) denotes 
excitatory synapses; (-) denotes inhibitory synapses. (Taken from Inskip et al27) 
 
 
  
Figure 1.4 -Innervation of the distal gastrointestinal (GI) tract.  
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
20 
 
coordinated activity in the absence of extrinsic innervations through the monitoring of wall 
tension and changes in luminal content by releasing numerous neurotransmitters from the 
enteric nerve endings. The principal excitatory agent is acetylcholine which acts through 
muscarinic receptors on smooth muscle cells whilst noradrenaline produces gut relaxation. 
Other neurotransmitters include dopamine, serotonin, vasoactive intestinal peptide, substance 
P, endorphins, Nitric oxide, carbon monoxide and amines. Gastrointestinal hormones also 
affect motor activity. The role of serotonin and endorphins will be discussed in more detail (see 
‘Management of Functional Constipation’, section 1.7, page 28). 
Extrinsic sensory innervation is split between the vagus nerve (proximal colon) and spinal 
afferent neurones (distal colon and rectum). These afferents may give rise to the pain felt from 
distension of the colon and are responsible for the conscious awareness of rectal distension, 
playing an important role in preserving continence. 
 
1.4.2 COLONIC MOVEMENTS 
Colonic movements are divided into mixing (segmental) and propulsive (peristaltic). Mixing 
movements occur mainly in the caecum and ascending colon. Approximately 2.5 cm of circular 
muscle contracts almost to the point of occluding the lumen and this is followed by contraction 
on the longitudinal muscle. These contractions occur for 30 seconds then disappear after 60 
seconds and then reoccur nearby. The repeated action causes the faecal matter to be ’dug into 
and rolled over’ exposing it to the mucosal surface. The second movement is propulsive and 
known as a ‘mass movement’. These occur from the mid transverse colon to the rectum and 
consist of a wave of contraction. A constrictive ring appears in response to a distended or 
irritated point in the colon. Twenty or more cm distal to this there is contraction as a unit 
forcing the faecal matter in this segment en masse distally. The contraction lasts for 30 seconds 
and is then followed by 2-3 minutes of relaxation. There are then further mass contractions 
distally and this is continued for 10-30 minutes. This occurs every half to one day and when the 
rectum is full defecation occurs (see ‘Normal Defecation’, section 1.4.4, page 22).  
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1.4.3 COLONIC CONTRACTILE PATTERNS 
To achieve colonic movements three complex motility patterns exist; segmental (non-
propagating), propagated and rectal motor complexes. 
 
1.4.3.1 Segmental activity   
This is also known as low amplitude propagating contractions (LAPCs). This constitutes most of 
the overall colonic motility producing frequent, low pressure waves resulting in slow 
propulsion of faecal matter distally allowing optimal time for absorption of water, electrolytes, 
short chain fatty acids and bacterial metabolites28. The electrical activity promoting contraction 
of the colon is generated by the interstitial cells of Cajal (ICCs), an internal pacemaker within 
the GI musculature. These cells act as an electrical syncytium to allow action potentials and 
pacemaker potentials to spread via gap junctions between muscle fibres and accounts for the 
self-excitable characteristics of the muscle29. The action of the ICCs is blocked by inhibitory 
motor neurones to prevent disordered contraction of muscle, with the circular muscle only 
responding to the pacemaker when the inhibitory motor neurones are inactivated. In this way 
the slow peristaltic wave of contraction is regulated and ordered, forming the basis of colonic 
motility. 
 
1.4.3.2 Propagated Activity 
This is also known as high amplitude propagated contractions (HAPCs)28.  HAPCs occur 
infrequently but are of a much higher pressure and correspond to the concept of ‘mass 
movements’. These powerful contractions are strongly associated with defecation, preceding 
the expulsion of stools, and are considered one of the driving events of defecation28,30.  
 
1.4.3.3 Rectal motor complexes 
Within the sigmoid and rectum periodic contractile activity predominates, although this activity 
can be recorded throughout the colon. These are known as the ‘rectal motor complex’. They 
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consist of strong sustained contractions with frequencies of three to six a minute. They last for 
3-30 minutes, occurring every 80-90 minutes in the day, and more frequently at night when 
there is less central nervous system influence. Their significance is unknown, but they are 
triggered by pressure waves from the proximal colon and by the arrival of stool or gas into the 
rectum, suggesting a role in defecation. Their number and frequency is reduced in women with 
slow transit constipation (see ‘Pathophysiology of Functional Constipation’, section 1.5, page 
23). 
 
1.4.4 NORMAL DEFECATION 
The process of normal defection is initiated by rectal distension and occurs involuntarily in 
response to faeces filling the rectum. Passive distension occurs until the threshold is reached 
whereby conscious awareness is triggered. As the rectum continues to fill the urge to defecate 
increases. Distension of the rectum causes it to contract, the internal anal sphincter (IAS) to 
relax, and the external anal sphincter (EAS) to contract. This allows passage of rectal contents 
into the upper anal canal where their nature can be determined. 
For defecation to occur the intrarectal pressure must exceed the anal canal pressure and this is 
achieved by relaxation of puborectalis resulting in straightening of the anal canal and descent 
of the pelvic floor, combined with relaxation of the EAS. The valsalva manoeuvre assists with 
defecation to a variable extent by increasing intrarectal pressure. Contraction of the colonic 
and rectal smooth muscle is necessary to expel the stool. This ‘mass movement’ correlates with 
an increase in HAPCs which have been clearly associated with defecation and faecal 
expulsion30,31. There is also an increase in the frequency and amplitude of LAPCs prior to 
defecation30. 
Once the faeces have been expelled the puborectalis contracts restoring the anorectal angle 
and the EAS temporarily contracts. This is joined by contraction of the IAS and passive 
distension of the anal cushions to close the anal canal and maintain continence. 
Disturbances of these physiological processes may result in the symptoms of constipation and 
are discussed next.  
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1.5 PATHOPHYSIOLOGY OF FUNCTIONAL CONSTIPATION 
The pathophysiology of functional constipation is poorly understood. However, there are 
demonstrable differences in both histology and physiology between normal volunteers and 
sufferers of chronic constipation which allows a possible mechanism be formulated to explain 
the pathophysiology of functional constipation. 
 
1.5.1 ABNORMALITIES IN HISTOLOGY 
Changes in histology in patients with functional constipation allow an understanding of the 
possible mechanisms involved. 
 
1.5.1.1 Conventional histology 
 Routine light microscopy of the ENS using Hematoxylin and Eosin staining (H&E) has not 
revealed any marked differences between the normal colon and that of sufferers of STC except 
for the presence of melanosis coli, a black/brown discolouration of the colonic mucosa. This 
condition is related to the use of anthraquinone laxatives rather than abnormalities of the 
ENS32.  
 
1.5.1.2 Silver Staining techniques 
The addition of silver as a stain to highlight proteins has revealed that colons from STC 
sufferers have neuronal and axonal abnormailites, with less argyrophilic neurones in the 
myenteric plexus. Preston et al33 reported that this occurred in 90% of colons from patients 
with STC, findings which were confirmed by a semi-blind, controlled trial of 12 patients34. 
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1.5.1.3 Immunohistochemistry (IHC) 
The use of IHC combined with neuronal markers has given conflicting results with some reports 
noting no change in neuronal numbers, whilst others demonstrating a reduction. These 
differences probably represent a lack of homogeneity in sample selection35. 
 
1.5.1.4 Glial Cells 
Enteric glial cells (EGC) make up 80% of the ENS with the remainder comprising the enteric 
neurones. Whilst first thought of as supportive tissue for the neuronal elements it has since 
been discovered that they have specific functions in maintaining ion and neurotransmitter 
concentrations and thereby promote the health of neurones. This is supported by the finding 
that if the glia is disrupted there is neuronal degeneration36. 
The role of EGC in the aetiology of STC was demonstrated by Bassotti et al37 who, in a 
controlled study of 26 patients who underwent surgery for STC, showed a significant reduction 
in EGC cell number in the myenteric and submucosal plexuses. There was also a decrease in 
enteric neurones and ICCs.  Further work by Bassotti et al36 reported a similar loss of EGC, but 
not of ICCs, in patients with obstructed defecation. There is no clear hypothesis to explain the 
reduction in EGC number and hence it is uncertain whether the decrease in cell number is the 
cause of the functional constipation or the result of it. A reduction in gilal cells is seen in other 
gastrointestinal conditions associated with constipation that have different pathophysiologies 
to FC suggesting that the loss of EGC is secondary to a reduction in transit time38-40. This 
reduction in EGC number could be explained by the change in luminal content associated with 
prolonged transit which has been demonstrated to modulate the EGC population41. Therefore 
whilst it is clear that a reduction in EGC number is associated with FC, further work is needed 
to fully explain their role, if any, in the pathophysiology of the disease. 
 
1.5.1.5 Interstitial Cells of Cajal 
 ICCs are important in controlling gastrointestinal motility and thus fewer numbers could be an 
aetiological factor in reduced colonic motility and functional constipation. The first study to 
demonstrate such a reduction  in patients with functional constipation revealed that whilst the 
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ICCs were present in the same layers of the sigmoid colon, the number was significantly 
reduced42 (see table 1.1). This was associated with a blunting of ICC processes and a reduction 
in neuronal structures compared to healthy controls. Results have been confirmed by 
subsequent studies43,44.  One study45 was unable to detect any difference between controls and 
sufferers of constipation, but this may be explained by the methodology used. Here the 
samples were formalin fixed and paraffin embedded and this leads to an underestimate of ICC 
numbers compared to fixation in paraformaldehyde solution46. 
Despite good evidence to support the hypothesis of reduced numbers of ICCs in functional 
constipation it is unclear what causes the decrease and the associated loss of enteric nerves. 
Whether a common factor is responsible or whether one cell type is dependent on the other is 
unknown. 
 
1.5.2 PHYSIOLOGICAL DIFFERENCES IN FUNCTIONAL CONSTIPATION 
Physiological abnormalities in functional constipation have been demonstrated by colonic 
manometry. Developments in fibre-optic sensing technology have seen a large increase in the 
number of sensors from 6-10 @ 7-15 cm intervals in solid-state colonic catheters to up to 120 
sensors @ 1cm intervals. This has allowed more detailed recording and analysis to be 
undertaken. 
 
1.5.2.1 Non-propagating motor activity (Segmental activity) (LAPCs)  
These make up the bulk of colonic activity and are thought to be associated with mixing and 
propulsion of colonic contents. In constipated subjects these are increased in the rectum and 
sigmoid47,48, and decreased more proximally49, and this uncoordinated activity distally may 
impede propulsion. 
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ICCs are important in controlling gastrointestinal motility and thus fewer numbers could be an 
aetiological factor in reduced colonic motility and functional constipation. ICC are decreased 
in all layers of the colonic wall in sufferers of functional constipation compared to 
healthy controls but it is unclear what causes this decrease in cell numbers. 
 
  
Layer of sigmoid 
colon 
Control Functional Constipation 
He et al42 Lyford et al43 He et al42 Lyford et al43 
Longitudinal 
Muscle 
5.5% +/- 0.7 4.7% +/- 0.4 1.5% +/- 0.2 0.8% +/- 0.3 
Myenteric Plexus 21.3% +/- 1.9 20.3% +/- 1.8 7.9% +/- 1 8.0% +/- 1.4 
Circular Muscle 7% +/- 1.3 4.4% +/- 0.4 2.5% +/- 0.3 2.6% +/- 0.4 
Submucosa 10% +/- 1.4% 6.3% +/- 1.0 2.8% +/- 0.7 2.0% +/- 0.7 
Table 1.1 – c-Kit positive immunoreactive structures in the sigmoid colon in 
functional constipation and healthy controls as a percentage of total volume. 
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1.5.2.2 Propagating motor activity (HAPCs)  
HPACs are associated with powerful contractions stimulating luminal transit in the colon, which 
are decreased or absent in functional constipation. Bassotti et al49 demonstrated that in slow 
transit constipation the average number per subject per day was significantly decreased 
compared to controls (0.62 +/- 0.2 vs. 5-5 +/- 0.78, p<0.001), but there were no differences in 
HPAC amplitude. A similar finding demonstrated a reduction from 6 a day in healthy volunteers 
to 1.9 in sufferers of functional constipation50. Along with a decrease in frequency and the 
amplitude of HPACs, Dinning et al51 have also demonstrated a reduction in the linkage of 
HPACs in an organised spatiotemporal pattern throughout the colon. This linkage of HPACs 
along the bowel ensures that they span the entire colon and are important for the transport of 
contents over longer distances. 
 
 
1.5.2.3 Meal Response and Diurnal Variation 
In healthy individuals there is an increase in the frequency of HPACs in response to a meal52 
and these are reduced or absent in functional constipation53. Colonic motor activity at night is 
suppressed54 and early morning waking results in an increase in colonic activity in the healthy. 
This circadian pattern is altered in patients with functional constipation, with a general 
decrease in contractile activity throughout the day but normal activity at the night. There is an 
absent response to early morning waking54. This lack in diurnal variation, probably mediated 
via the CNS in the healthy, may support a neuropathic cause for the symptoms of sufferers of 
FC. 
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1.6 HYPOTHESIS TO EXPLAIN FUNCTIONAL CONSTIPATION 
From the evidence above, it can be proposed that some sufferers of functional constipation 
have histological abnormalities in the enteric neuronal networks leading to a decrease in 
propagating colonic motor activity promoting the symptoms of constipation. However, this 
hypothesis does not explain whether the histological abnormalities are inherited or acquired or 
whether they are the cause of FC or the consequence of it. Further work is needed to fully 
understand the pathophysiology of this complex and probably multi-factorial disease. 
 
1.7 MANAGEMENT OF FUNCTIONAL CONSTIPATION 
The management of functional constipation can be divided into six categories; 
I. lifestyle modifications. 
II. biofeedback . 
III. conventional pharmacological interventions. 
IV. sacral nerve stimulation. 
V. surgery. 
VI. novel pharmacological interventions. 
 
1.7.1 LIFESTYLE MODIFICATION 
There is a commonly held belief that increases in dietary fibre, water, and exercise improves 
the symptoms of constipation. These are often indicated as first line treatments but there is 
little clinical evidence to justify their use. Stool from sufferers of constipation has less water 
compared to healthy volunteers55, thereby changing its consistency by increasing the water 
content may alleviate the symptoms of constipation. A clinical study by Anti et al56 reported an 
improvement in those patients who increased their fluid intake to more than 2 litres a day 
compared to controls. However, the water group drank mineral water containing magnesium 
and this may have actually been responsible for the symptomatic improvement. Lindeman et 
al57 and Chung et al58 did not demonstrate an increase in stool output with fluid consumption 
of greater than 2 litres supporting the earlier results of Klauser et al59. They demonstrated that 
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a fluid restriction of less than 500 mls was associated with a decrease in stool volume and 
therefore recommended that low fluid intakes should be corrected. Therefore an increase in 
fluid intake over 2 litres is unlikely to improve symptoms of constipation and this is supported 
by two recent reviews60,61. 
Fibre supplementation decreases colonic transit time, holds water within the stool, and 
increases stool weight, resulting in reduced intracolic pressures and softer stools62-64. This is felt 
to benefit constipation sufferers even though there is no difference in the  amounts of dietary 
fibre in their diets  compared to controls65. Evidence for the use of bran comes from studies in 
healthy volunteers and although a meta-analysis by Muller-Lissner66 confirmed the above 
effects of fibre in healthy volunteers, it did not show that bran was an effective treatment for 
constipation. Badiali et al67 failed to show an improvement with bran compared to placebo and 
two other randomised studies reported minimal68 or absent69 effect on stool frequency and 
moisture. These findings may be explained by the fact that increasing dietary fibre is associated 
with bloating and flatulence and therefore some constipated patients may not ingest enough 
to alleviate their symptoms70. Probably it is more likely that in but all of the most mild cases, 
constipation has a more complex aetiology than simply a lack of fibre. Therefore it would be 
appropriate to recommend fibre to patients with a diet in which it is lacking but should not be 
recommended to patients with functional constipation with normal fibre consumption as it is 
unlikely to benefit and may indeed exacerbate symptoms.  
The effect of exercise on colonic transit times is unclear. Studies in healthy volunteers have 
shown that exercise both increases and decreases colonic motility, but the discrepancies may 
be related to the existing fitness of subjects and the intensity of exercise prescribed71-73. In one 
study regular exercise did not improve the constipation indices in sufferers of constipation 
leading the authors to conclude that ‘regular exercise does not play a role in the management 
of chronic constipation’74. Despite the lack of evidence to confirm exercise as an effective 
treatment it should still be recommended because it improves general quality of life and has 
other beneficial health effects including improved cardiovascular health and prevention of 
obesity and osteoporosis. 
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1.7.2 BIOFEEDBACK  
The aim of biofeedback is for the patient to learn to relax the pelvic floor muscle and respond 
appropriately to physiological stimuli. The steps involved in biofeedback vary depending on the 
clinical laboratory but there is a growing consensus that six sessions of 45 minutes each are 
required, led by well trained and experienced therapists to produce clinical benefits. Patients 
must be motivated to increase their chances of a response. 
Whitehead et al75 recommended in a review article that biofeedback should consist of the 
following steps: 
 
I. Patient education – explanation of normal defecatory physiology and what the patient 
may be doing incorrectly. 
II. Straining Training – Patient is taught to increase intra-abdominal pressure when 
attempting to defecate. Feedback on rectal balloon pressures or abdominal wall EMG 
during straining. 
III. Pelvic Floor Relaxation training – through the use of electronic feedback on anal canal 
pressures or pelvic floor EMG, the patient learns to relax the pelvic floor muscles whilst 
straining abdominal muscles. 
IV. Stimulated Defecation – patient practice to evacuate a water-filled rectal balloon 
whilst the therapist slowly withdraws it from the rectum. The amount of assistance 
provided is decreased as the patient relearns the sensations associated with 
defecation. 
V. Sensory Retraining – by distending a rectal balloon above and below the pressures 
needed to elicit the sensation of defecation the patient can be taught to identify 
weaker sensations for defecation. 
 
The use of visual stimuli during biofeedback has been debated. Koutsomanis et al76 studied 60 
adult patients referred for biofeedback. Subjects were randomised to ‘muscular coordination 
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training’ (MCT) or to biofeedback with the use of EMG tracing. Both groups had significant 
improvement after the treatment periods in physiological parameters and subjective 
measurements and these responses were similar. The MCT group needed slightly fewer 
sessions to achieve adequate training. This treatment does not require a physiological 
laboratory, is less expensive than biofeedback treatment and can be done by paramedical 
personnel. 
Biofeedback is effective in the management of constipation secondary to pelvic floor 
dyssynergia but debate exists over its role in the management of slow transit constipation. 
Heymen et al77 demonstrated that patients with pelvic floor dyssynergia who underwent 
biofeedback had significantly more unassisted bowel movements at follow-up compared to 
patients in the placebo group and those treated with diazepam. Rao et al78 undertook a 
randomised controlled trial comparing biofeedback against both sham feedback (placebo) and 
standard constipation treatments. This demonstrated that biofeedback was more likely to 
correct dyssynergia and produced more complete spontaneous bowel movements compared 
to other groups. The colonic transit time was also improved in those patients who underwent 
biofeedback and this finding was supported by the work of Wang et al79 and Chiotakakou-
Faliakou et al80. Generally biofeedback is of benefit in all patients who suffer with functional 
constipation. However, the improvement of transit times in these studies may be due to the 
treatment of the pelvic floor dyssynergia (PFD) rather than direct effects on colonic motility, 
i.e. these patients may not suffer with true slow transit constipation, but it may be secondary 
to pelvic floor dyssynergia. This view is supported by results of a randomised controlled trial of 
52 patients with slow transit constipation on transit studies81. These were divided into three 
groups based on their response to anal manometry and balloon defecation testing. The three 
groups consisted of patients with STC only (n=12), STC and PFD (n=36), and a group with STC 
and an element of PFD who did not meet the criteria for a diagnosis of PFD (n=6). After a 
course of biofeedback there was significant improvement in those patients with PFD compared 
to their baseline measurements and when compared to the STC only group. Satisfaction was 
reported by 71% of the PFD group and 76% had greater than 3 bowel movements per week 
compared to 8% and 8% in the STC group (P < 0.001). Whilst there was no improvement noted 
in the STC arm in any of the outcomes measured, the improvements in the PFD group were 
maintained after 24 months of follow-up. This led the authors to conclude that biofeedback is 
only successful in PFD and that transit studies are unreliable in patients with PFD, as the delay 
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is most likely secondary to PFD. Further work is needed to better understand the 
pathophysiology of functional constipation and a recent study by Singh et al82 attempted this. 
Using 24 h ambulatory colonic manometry, sufferers with slow transit constipation were 
classified as having normal manometry, a colonic myopathy or a colonic neuropathy. Clinical 
response to pharmacological, biofeedback and surgical management at 1 year was correlated 
with manometric findings. This reported that 65% of patients with colonic myopathy or normal 
manometry, versus 15% with colonic neuropathy, improved with medical/biofeedback therapy 
(p<0.01). Almost three-quarters of the study population had either normal manometry or a 
colonic myopathy. Given the cost, time, and facilities needed for anorectal manometry and the 
potential embarrassment to the patient it seems reasonable to perform biofeedback therapy 
on all patients referred to secondary care who have failed simple medical management. 
 
1.7.3 CONVENTIONAL PHARMACOLOGICAL INTERVENTION 
Pharmacological intervention can be divided into the traditional laxatives and the newer 
pharmacological agents whose mode of action is through influencing colonic receptors. 
Currently these are principally 5-HT4 agonists, Chloride (Cl-) channel blockers, opiate receptor 
antagonists and more recently Guanylate Cyclase C (GC-C) activators. 
There are a number of traditional laxatives (listed below) that are available over the counter. 
The evidence to support their use is often limited and rarely derived from randomised, double-
blind, placebo-controlled trials.  
 
 Bulk agents    e.g. Bran, Ispaghula Husk, Psyllium Husk (Fybogel). 
 Emollient Stool Softeners e.g. Docusate Sodium, Arachis Oil. 
 Stimulant Laxatives   e.g. Senna, Sodium Picosulphate (SPS) and Bisocodyl 
     (Dulcolax). 
 Osmotic Laxatives   e.g. Lactulose, Polyethylene Glycol (Movicol). 
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1.7.3.1 Bulk Agents 
Their mechanism of action is through increasing stool weight and water-absorbent properties 
of the stool with a resultant improvement in stool consistency. Of three placebo-controlled 
trials of bulk laxatives83-85 two reported an improvement in stool frequency, consistency and 
ease of evacuation83,84, whilst one failed to show this, but noted a trend towards an increase in 
stool frequency85. The study by Ashraf et al84 also measured transit time with colonic 
manometry and found that psyllium husk did not alter the colonic transit time and proposed 
that its’ primary action was through facilitating the defecatory process. 
Psyllium husk has been compared to other traditional treatments with a mixed response. A 
study by Attaluri et al86 compared psyllium with dried prunes in an 8 week single-blind, 
randomised cross-over study with the subjects using each treatment for 3 weeks with a 1 week 
washout period. The authors demonstrated that prunes resulted in a significant improvement 
in complete spontaneous bowel movements (CSBM)/week (3.5 +/- 0.2 vs. 2.8 +/- 0.2, p= 0.006) 
and stool consistency scores compared to psyllium (3.2 vs. 2.8, p=0.02). A CSBM is defined as a 
spontaneous bowel movement (SBM) with a complete sense of evacuation. However, this 
cross-over study was flawed by its short duration of 3 weeks in each arm as it has been 
proposed that psyllium takes at least 14 days to have any beneficial effect. When compared to 
lactulose87 and sodium docusate88 psyllium improved the symptoms of constipation, which was 
enhanced with the addition of senna compared to psyllium alone89. These studies are all 
limited by their short trial periods of a maximum of 4 weeks and as such there is little evidence 
on the long-term efficacy of bulking agents. Common side effects demonstrated in all studies 
were flatulence, bloating and abdominal distension, and very rarely colonic obstruction. 
The role of bran has been described earlier but there is little evidence to support its current 
usage in anything but the mildest forms of constipation. 
 
1.7.3.2 Stool Softeners 
 Stool softeners are anionic surfactants of which sodium docusate is the most commonly used. 
They allow water to interact more effectively with solid stool thereby softening it. Their 
efficacy relates to their ability to bind to stool and they often only have a modest effect. There 
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is limited data to support their use. Whilst one placebo controlled trial showed a benefit from 
docusate in improving stool frequency90 a second study did not support these findings91. A 
further single blind study92 compared Docusate at two strengths and was only able to show a 
non-significant slight increase in stool frequency compared to placebo. However stool 
softeners have minimal adverse events and are therefore often combined with other laxatives. 
 
1.7.3.3 Stimulant Laxatives 
 These agents stimulate the colonic myenteric plexus to increase peristalsis and subsequent 
colonic motility93, but also activate sensory nerve endings with the unwanted effect of colic. 
They may also act by inhibiting water absorption by the colon. In practice they consist of senna, 
bisocodyl and sodium picosulphate (SPS). Bisocodyl and SPS are prodrugs which are converted 
into the same active metabolite and will be discussed together. 
 
1.7.3.3.1 Senna 
Senna and its main active metabolites, the sennosides, are effective in the treatment of 
functional constipation, but there are no double-blind, placebo-controlled trials to support its 
use. Senna has been shown in elderly residents, in long-term hospital or nursing home care, to 
be an effective treatment94,95 with an improvement in stool consistency and ease of 
evacuation, whilst being well tolerated. However, in both of these studies senna was combined 
with fibre and it therefore cannot be determined what effect the senna contributed to. The 
beneficial effect of combining senna with psyllium was investigated earlier when Martlett et 
al89 compared psyllium and senna with psyllium alone. Whilst both groups demonstrated a 
subjective relief from the treatments there was a significant improvement in objective 
measures (attributed to an increase in water content of the stool) from the combined 
preparation compared to psyllium alone. When senna was compared directly to lactulose in a 
multicentre trial96 lactulose resulted in 58% of patients passing a normal stool by day 7 
compared to 42% in those taking senna (p=0.04), with a prolonged carry-over effect in the 
lactulose group. 
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Senna, although well tolerated, may cause melanosis coli91 and concern has been raised about 
the incidence of carcinogenicity and cathartic colon following prolonged administration98,99. 
However, Morales et al100 were unable to establish the following from a review of the current 
literature: 
I. Any convincing evidence to suggest that chronic use of senna resulted in 
structural +/- functional alteration of enteric nerves of the smooth intestinal 
muscle. 
II. A link between senna extract and GI tumours in rats, even after a 2 year daily 
dose. 
 
1.7.3.3.2 Bisacodyl/Sodium Picosulphate (SPS) 
 
 
 
The evidence for the use of bisacodyl and SPS is better than that for senna. A double-blind, 
randomised controlled trial101 demonstrated that bisacodyl significantly improved the mean 
number of stools per day (1.8 vs 0.95, p=0.006) and also stool consistency whilst being well 
tolerated. The study was limited by its short duration of only 3 days and therefore information 
on long-term efficacy and safety were not assessed. Importantly, the participants were 
recruited from primary care and while efficacy is confirmed in this group it is uncertain 
whether the results are applicable to patients treated in either secondary or tertiary care who 
have more severe symptoms.  This study does support the use of bisacodyl as a bowel 
preparation in procedures such as colonoscopy and as a rescue treatment in other constipation 
treatement trials102,103. A further randomised, double-blind, placebo-controlled study recruiting 
368 patients in 2011104 confirmed the short-term effects seen by Kienzle-Horn et al101 and 
proved that they continued over a 4 week period, with a significant improvement in overall 
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PAC-QOL score, whilst remaining well tolerated. Two randomised, double-blind, placebo-
controlled trials for SPS105,106 have also confirmed an improvement in stool frequency and 
consistency over placebo. The results of Wulkow et al105 are again limited by the short trial 
period of 3 days, but the study by Mueller-Lissner106 involved 367 patients and ran for 4 weeks. 
This confirmed that SPS treatment was also associated with a significant increase in quality of 
life and was well tolerated. There was no clinical difference between bisacodyl and SPS with 
both treatments being well tolerated and effective107 with abdominal pain and diarrhoea 
reported as common side-effects. 
 
 
1.7.3.4 Osmotic Laxatives  
Osmotic laxatives retain water in the lumen since the laxative contains poorly absorbed ions or 
molecules which create an osmotic gradient within the lumen of the colon promoting water 
retention. This leads to softer stools and improved propulsion. Both lactulose and polyethylene 
glycol (PEG) have been shown to accelerate colonic transit but this effect is greater following 
administration of PEG108 (see section 1.7.3.4.3 for further discussion).  
 
1.7.3.4.1 Lactulose 
 
 
 
Lactulose has long been used to treat the symptoms of constipation and its therapeutic effect 
is dose dependent109,110. Despite lactulose having a proven benefit over fibre111 it performs less 
well compared to bulk laxative combined with senna94,95,112 with no difference compared to 
sorbitol113.  
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1.7.3.4.2 Polyethylene Glycol 
Of all the conventional laxatives PEG has been the most extensively studied in five randomised, 
double-blind, placebo-controlled studies114-118. In each study stool frequency and consistency 
was significantly improved. PEG was more effective than either tegresod (5HT4 agonist – see 
later) with a better side effect profile119 and isphaghula husk120. In an open label study 
conducted over 12 months, PEG was shown to be safe with continued efficacy119. Similar to 
other laxatives, PEG is associated with diarrhoea and loose stools, abdominal distension, 
flatulence, and nausea. The incidence of GI symptoms in the trials ranged from 12-40% and 
although they were usually rated from mild to moderate, the withdrawal rate varied between 
0-7%. 
 
1.7.3.4.3 PEG vs Lactulose 
When compared to lactulose, a Cochrane review121 presented data from all ten RCT and 
concluded that PEG had better outcomes of stool frequency/week, form of stool, relief of 
abdominal pain and need for additional products compared to lactulose. This was seen in both 
adults and children and is not associated with the osmotic load of lactulose and PEG108. It has 
been proposed that both the metabolism of lactulose by the colonic microbiota resulting in a 
lower osmotic effect and the production of short chain fatty acids after lactulose metabolism, 
which inhibits colonic transit, are the reasons for the reduced clinical response of lactulose 
compared to PEG108. PEG has also been shown to be more cost-effective than lactulose with a 
greater likelihood of both treatment success and quality-adjusted life years122,123.  
 
1.7.4 SACRAL NERVE STIMULATION (SNS)  
SNS has long been used as a treatment for neurogenic bladder dysfunction and faecal 
incontinence and it was through its use in the management of neurogenic bladder dysfunction 
that a role in functional constipation was noted. SNS is still in its infancy and there is a paucity 
of robust clinical trials with the evidence based on prospective studies with small numbers and 
a few randomised controlled trials. An example is shown in figure 1.5. 
The initial small prospective studies reported mixed success with rates ranging from 25%124 to 
75%125. Both studies had small numbers (8 and 12 respectively) and therefore any benefits 
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could be due a placebo effect. There has been only one, small, double-blind placebo-controlled 
crossover study published by Kenefick et al126. Two women with severe resistant functional 
constipation were managed successfully with SNS. During this time, the stimulators were 
switched ‘on’ and ‘off’ for two two-week intervals to which the patient and investigator were 
both blinded. When the stimulator was switched off, bowel frequency, abdominal pain and 
bloating all reverted to baseline levels before the stimulators were inserted, suggesting that 
benefit patients derived was from sacral nerve stimulation alone.  
Further evidence has supported the use of SNS. Kamm et al127 undertook a large multi-centre 
prospective study which recruited patients with functional constipation of various aetiologies. 
Here 45 of the 62 (73%) patients recruited gained benefit from temporary SNS and therefore 
underwent permanent sacral nerve stimulator implantation. Treatment success was achieved 
in 39 patients (89%) after a median follow up of 28 months (1-55 months). This study 
demonstrated SNS to be effective and that the effects were long-lasting. Govaert et al128 
reported on 117 patients who were eligible for trial of a SNS. This retrospective review of 
prospectively collected data demonstrated a 58% (68 patients) improvement in symptoms 
after the insertion of the temporary SNS. This benefit continued after a permanent SNS was 
inserted in 61 of these 68 patients (90%) with a median follow-up of 37 months (range 4-96 
months). However, not all studies report a benefit. One by Holzer et al129 reported that 
temporary SNS was successful in 42% of patients (n=8/19) and that the benefit continued after 
permanent SNS in the first month after implantation. However after 12 months only 5 patients 
derived benefit and on an ITT basis this equated to 25% compared to 63% (39/62)127 and 52% 
(61/117)122 in other trials. This lower ITT figure was recently shown by Ortiz et al130 in their 
retrospective review where 29% of patients (n=14) still had a successful outcome a median of 2 
years after insertion (range 6-96 months) with 6 of the 14 patients (43%) still requiring the use 
of laxatives. This discrepancy in the results reporting the success of SNS is unsurprising given 
the multifactorial nature of functional constipation and the heterogeneity between subjects 
recruited into the various studies and the outcome measures used. 
SNS is not without adverse events. Maeda et al131 reported that 22 adverse events in 38 
patients whilst Kamm et al127 reported 101 adverse events in 48 patients. Furthermore Maeda 
et al132 reported adverse events in 150 of 176 patients (85%) who had a SNS for faecal  
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SNS has long been used as a treatment for neurogenic bladder dysfunction and faecal 
incontinence and it was through its use in the management of neurogenic bladder dysfunction 
that a role in functional constipation was noted. A sacral nerve stimulator is inserted under 
general anaesthetic and activates the S3 nerve root to exert its effect.  
Figure 1.5 - A sacral nerve stimulator (Image used with permission from Medtronic Inc, USA)  
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incontinence. The majority of adverse events in these 3 trials were related to a loss or lack of 
efficacy (up to 66%) with the next most frequently reported complication being pain or 
discomfort which may have required explantation of the stimulator. 
 
There is also limited data on the precise mechanism of SNS. A study by Dinning et al133 utilised 
pancolonic manometry to demonstrate that the clinical improvement that patients noticed 
correlated with an increase in antegrade and retrograde PS frequency and HAPCs frequency 
and amplitude in an antegrade direction.  Further work by the same author134 confirmed the 
ability of SNS to stimulate HAPCs but only at a suprasensory level (i.e. a voltage above that 
perceived by the patient) and not at a subsensory level. This important point needs to been 
taken into account in study design to avoid inappropriately misinterpreting SNS as ineffective. 
 
SNS appears to be a promising treatment modality in patients who have failed conventional 
treatment. However, further RCTs are needed to confirm this and also to identify which 
patients SNS will be useful for. Further research needs to be done to understand the 
mechanisms by which SNS brings about symptomatic improvement. SNS, however, has the 
advantage over colonic resection since it can be reversed and although the adverse events are 
common they are not as significant has those associated with surgery (see next section). 
Although it is not always locally available, it should therefore be considered prior to colectomy.  
 
 
1.7.5 SURGERY  
Surgery is often the last clinical option in the management of functional constipation. The two 
commonest procedures are either subtotal colectomy with ileorectal anastomosis (STC + IRA) 
or segmental colectomy. Although data are available for both techniques from a number of 
studies, comparison between these is difficult due to different selection criteria and outcome 
measures used. This has led to wildly different success reported for colectomy in review 
articles ranging from 40% to 100%135,136. Irrespective of the surgical procedure, patient 
selection is critical to good success rates.  
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1.7.5.1 STC + IRA  
STC +IRA increases bowel frequency but there is debate as to whether this actually translates 
into an increase in quality of life.  Studies are often of a small size and are of retrospective or 
prospective design with no randomised controlled trials published to date. Following surgery 
the incidence of diarrhoea (>3 bowel movements/day) ranges from 46% -100%137-140 with 
incontinence being a significant problem in up to 50% of patients who report diarrhoea137. 
Despite this, Quality of life (QoL) assessments in patients post-operatively report an 
improvement comparable to healthy subjects139,140. STC+IRA, however, does not always 
improve abdominal pain and bloating with some studies reporting post-operative incidences 
up to 40%137,138. Furthermore, open resection is associated with a mortality rate of 1% and 
morbidity secondary to; anastomotic leak (6%), revision of the anastomosis or further 
resectional surgery (7%) and adhesional small bowel obstruction (20%)137,138. One study, with 
data different from others, demonstrated a mortality rate of 15% and 32 surgical interventions 
performed in the follow-up period on the 20 original patients. The majority of these were for 
adhesional small bowel obstruction141. The authors acknowledged that the inclusion of patients 
who had had previous abdominal surgery may bias the results but state that the high morbidity 
and mortality coupled with the poor outcomes in their 20 patients did not support the use of 
STC+IRA for the management of constipation. Laparoscopic surgery has not reduced early post-
operative complications and does not appear to lower re-operation rates for adhesional small 
bowel obstruction, but the follow up time and patient numbers are small142,143.   
 
1.7.5.2 Segmental Resection.  
Segmental resection, tailored to segmental transit time measurements, aim to reduce the 
unwanted side effects of faecal incontinence and watery diarrhoea. Kamm et al144, with just 2 
patients, demonstrated good functional outcomes after 3 years following segmental resection. 
There have been subsequent larger studies since with encouraging results. De Graaf et al145 
compared tailored left hemicolectomy with STC and IRA with mixed results. Whilst the 
segmental group had a lower incidence of constipation and abdominal discomfort, the 
incidence of diarrhoea and faecal incontinence was equal in both groups. You et al146 reported 
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in a cohort of 40 patients the efficacy of segmental resection. All patients had left or right side 
delay with normal transit at the sigmoid and rectum. At 3 months all had improvements in the 
symptoms of constipation with 93% (37/40) remaining well at 2 years. Of the 3 patients in 
whom the segmental resection was unsuccessful, STC and IRA was performed with good 
outcomes reported at 3 months. Lundin et al147 undertook segmental resection in 28 patients 
based upon the results of 111-Indium – DTPA Scintigraphy. At 50 months 82% (23/28) of 
patients were pleased with the outcome with an increase in stool frequency and a reduction in 
the number of hard stool and straining and concluded that segmental resection was 
comparable to STC and IRA for symptom relief with less severe side effects.  
Segmental resection with good patient selection appears to offer comparable symptomatic 
relief with fewer side effects compared to STC and IRA. At surgery there is the advantage of 
only needing to mobilise one flexure which is of benefit when performed laparoscopically. 
Robust randomised controlled trials with strict patient selection and measurable outcomes 
between studies are needed now to demonstrate if a clear advantage between the two 
procedures exists. 
 
 
1.7.6 NOVEL PHARMACOLOGICAL INTERVENTIONS 
Although there are many treatment options for constipation, their lack of benefit in many 
patients means new interventions are required. The use of novel pharmaceutical agents which 
target colonic receptors has been developed as the next generation of treatments for 
functional constipation. 
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1.7.6.1 The Role of Serotonin and Serotonin Agonists 
Serotonin (5-hydroxytryptamine [5-HT]), a signalling molecule that exerts its actions via seven 
main receptor subtypes (5-HT1-7), is involved in increasing GI motility, secretion and sensation. 
Approximately 95% of the body’s 5-HT is found in the GI tract, 90% of which is synthesised by 
the enterochromaffin (EC) cells and the remaining 10% by nerves in the myenteric plexus148. 5-
HT released from EC cells in response to luminal factors stimulates extrinsic (vagal or spinal) or 
intrinsic primary afferent neurons (IPANs) by binding to 5-HT receptors, principally 5-HT3,4 and 7. 
Extrinsic afferents transmit signals to the brain and are thought to convey feelings of satiety, 
nausea, pain and discomfort. IPANs, through the release of Ach and calcitonin gene related 
peptide (excitatory) and nitric oxide (inhibitory), act locally and depending on the site are 
responsible for nausea and vomiting, increased luminal secretions and peristalsis149,150. After 
release extra 5-HT is principally inactivated by the serotonin reuptake transporter (SERT) 
located on some enterocytes with the remainder, which enters the bloodstream, by circulating 
platelets. 
The role of 5-HT in the control of large bowel function is poorly understood due to the large 
numbers of receptors present in the GI tract. However, evidence has been gained from the use 
of selective agonists and antagonists on the 5-HT3 and 5-HT4 receptors. The 5-HT3 receptor is a 
ligand gated ion channel that causes a rapid and transient excitatory response when activated 
by 5-HT. The receptor is located on the intrinsic and extrinsic sensory neurones and the use of 
5-HT3 antagonists, such as ondansetron and granisetron, have been demonstrated to decrease 
nausea and vomiting in clinical practice including in highly emetogenic chemotherapy151,152. 
Ondansetron reduces the colonic transit time in healthy volunteers153 and alosetron, which is 
10 times more potent than ondansetron, has been developed for the treatment of IBS-D. In a 
clinical study by Delvaux et al154 alosetron increased the compliance of the colon to distension, 
without an associated increase in nociception. Subsequent randomised controlled trials 
reported a significant improvement in stool frequency and abdominal discomfort in suffers of 
IBS-D155,156.  Thus activation of the 5-HT3 receptor will increase GI motility, whilst antagonism 
results in a decrease in nausea and vomiting, nociception and motility. 
The 5-HT4 receptor is a G protein-coupled receptor whose activation leads to a prolonged 
excitatory response, but whose distribution is not yet clearly defined. Activation of presynaptic 
5-HT4 receptors appears not to elicit a motor response but instead to augment motor function 
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within the intestine157,158. Thus luminal stimulation releases 5-HT which activates the 5-HT4 
receptor to increase colonic motility. This physiological effect has been utilised in the 
treatment of slow transit constipation. 
Cisapride was among the first 5-HT4 receptor agonists to be developed for gastro-oesophageal 
reflux disease and gastroparesis. However, drug-drug interactions and more importantly QT 
interval prolongation and cardiac arrhythmias led to its withdrawal in 2000159.  Subsequently 
Tegaserod was approved by the FDA in 2002. Tegaserod is a selective 5-HT4 agonist which 
accelerates gastrointestinal transit160,161, stimulates intestinal secretion162, and improves 
visceral hypersensitivity163. This has been translated into clinical benefits in patients with 
functional constipation. Two, phase III RCTs comparing tegaserod (2 mg and 6 mg doses) and 
placebo demonstrated a significant increase in complete spontaneous bowel movements 
(CBSMs) in patients taking tegaserod compared to the placebo group (37-41% vs. 25-27%, 2 mg 
dose vs. Placebo, p<0.0001; 40-43% vs 25-27%, 6 mg dose vs placebo, p<0.0001). This benefit 
was maintained over the 12 week study period, but was lost in the 4 week withdrawal 
period164,165. The benefit was confirmed in a trial using male patients only166 and in studies the 
use of Tegaserod was associated with an improvement in abdominal pain and bloating. A 13 
month safety, tolerability, and efficacy study167 using patients from the work by Kamm et al165 
reported that tegaserod was safe and well-tolerated, whilst patient satisfaction with treatment 
was maintained. However, a cross-study analysis found that 13 of 11,600 patients treated with 
tegaserod had ischaemic cardiovascular events compared to one event in the placebo group168. 
The mechanism for this is not fully understood, but it is most likely related to poor selectivity of 
tegaserod for 5-HT receptors and perhaps from its affinity for 5-HT1B receptors169. 
Therefore, a more highly selective 5-HT4 receptor agonist, prucaloride, has been developed. 
Prucalopride is a highly-selective, high-affinity 5-HT4 receptor agonist which has been 
demonstrated in animal models to stimulate GI motility and transit throughout the length of 
the GI tract170,171. Prucalopride has been extensively evaluated in the management of 
functional constipation. Three large, randomised, double-blind, placebo-controlled, 12 week, 
phase III trials have assessed the efficacy of prucalopride172-174 involving almost 2000 patients, 
all of whom had severe constipation resistant to conventional treatments. All three studies 
compared placebo, prucalopride 2 mg and 4 mg doses. Each trial showed a significant 
improvement in patients who had ≥3 CSBM a week and also in those patients who had an 
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increase of 1 or more CSBM a week compared to their pre-trial baseline (Table 1.2). There 
were also significant improvement in symptom severity scores and quality of life scores as 
measured by PAC-SYM and PAC-QOL health surveys. 
Each of the trials reported no significant adverse or cardiac events with the main complaints 
being headache, abdominal pain and diarrhoea. There were no differences in the rate of these 
adverse events between the placebo group and the treatment groups. A subsequent study in 
the elderly assessed prucalopride in over 300 patients aged over 65 years of age with fewer 
than 3 SCBM / week. Again the drug was significantly more effective than placebo and more 
importantly there were no changes in laboratory, cardiovascular, or ECG variables over the 4 
week study period175. These findings were supported by a smaller study by Camilleri et al176, 
but both studies were limited by their short follow up of only 4 weeks. These results have been 
replicated in an Asian-Pacific population over a 12-week period with similar results177 and this 
beneficial effect with minimal adverse events has been shown to continue in an open follow up 
study of the participants from the three randomised controlled trials listed above178.  
Improvement in PAC-QOL scores was observed up to 18 months with 40-50% of patients not 
requiring additional laxatives during this period. The most frequent adverse events resulting in 
discontinuation were gastrointestinal (3.3%) and headache (1.0%). Assessment of cardiac 
safety was more extensively evaluated in 120 healthy volunteers in a double-blind, double-
dummy, placebo- and active-controlled trial. There was no significant change in the QT interval 
between the placebo, 2mg, and 10mg prucalopride groups, but the use of prucalopride was 
associated with a mean increase of 2-5 beats per minute. No ventricular arrhythmias were 
noted during the study period179. There has been one randomised controlled trial comparing 
prucalopride with PEG 3350+electrolytes180. Both treatments demonstrated an improvement in 
CSBMs, SBMs, stool weight, and colonic transit time compared to the run-in period, although 
these improvements were greater in the PEG group. PEG was more commonly associated with 
a loose and watery stool (Type of 5-6 on the Bristol stool chart) whilst prucalopride was 
associated with a normal stool constistency (Type 3-4) but this did not translate into lower 
patient satisfaction with a lower withdrawal rate (0 vs. 3 pts) and greater patient satisfaction in 
the PEG group. 
 
The success of prucalopride has led to the development of further 5-HT4 agonists which are 
currently at varying stages of development, the most promising of which is called velustrag. 
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  2mg 
Prucalopride 
4mg 
Prucalopride 
Placebo p-Value 
Camilleri 172 ≥ 3 CSBM / 
Wk 
30.9% 28.4% 12% Both <0.001 
Increase of 
1 or more 
CSBM / 
Wk 
47.3% 46.6% 25.8% Both <0.001 
Quigley 173 ≥ 3 CSBM / 
Wk 
24% 24% 12% Both <0.01 
Increase of 
1 or more 
CSBM / 
Wk 
43% 47% 28% Both <0.001 
Tack 174 ≥ 3 CSBM / 
Wk 
19.5% 23.6% 9.6% 2mg - <0.01 
4mg - 
<0.001 
Increase of 
1 or more 
CSBM / 
Wk 
38% 44% 20.9% Both <0.01 
 
Prucalopride is a highly selective, high affinity 5-HT4 receptor agonist which stimulates GI 
motility and transit throughout the length of the GI tract.  In each of the three large 
randomised controlled trials prucalopride significantly improved the outcomes measured 
compared to the placebo demonstrating that prucalopride was an effective treatment in 
functional constipation. 
  
Table 1.2 - The percentage of participants in each of the three trials of 
prucalopride who had ≥3 CSBM/wk and an increase of 1 or more CSBM/wk. 
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This drug is a potent agonist of 5-HT4 receptors which has efficacy in vitro and in vivo and is 
highly selective for the 5-HT4 receptor over other 5-HT receptors which may help in limiting its 
side effects181.  The drug increases the transit time in healthy volunteers in a dose-dependent 
manner182 and in a 4 week clinical trial, patients receiving 15, 30 and 50 mg doses achieved 
statistical significance in CSBM/week compared to the placebo group (P<0.0001)183. 
 
1.7.6.2 Chloride Channels and Lubiprostone 
A second novel pharmacological agent has been developed which acts through chloride 
channels. Chloride channels (CIC) are found throughout the body and are responsible for the 
transport of chloride ions across membranes184. In the gastrointestinal tract they play a critical 
role in regulating fluid transport and maintenance of both cell volume and intracellular pH 
since chloride ions are followed by the passage of sodium ions and water (Figure 1.6).  Nine 
separate CIC have been identified however only chloride channel 2 (CIC-2) is sensitive to 
lubiprostone185. CIC-2 is distributed throughout the GI tract on the apical cell membrane and is 
a transmembrane protein that is highly selective for chloride ions. Lubiprostone is a CIC 
activator which is derived from prostaglandin E1 which increases intestinal fluid secretion and 
chloride ions185. It is through this mechanism that lubiprostone, in healthy volunteers, 
decreases small bowel and colonic transit times186. Subsequent work has shown that the 
decrease in colonic transit time is not as a result of an increase in HAPCs and as such 
lubiprostone does not directly affect motility187. 
Despite the uncertainty about the precise mechanisms by which lubiprostone produces 
laxation it has shown to be efficacious in two randomised controlled trials188,189. In total, these 
two trials enrolled 479 patients (242 and 237 respectively) who were studied for 4 weeks and 
received either lubiprostone 24 mcg b.d. or placebo. Both trials reported a significantly greater 
number of SBMs/wk in the lubiprostone group and more of these patients also had a SBM 
within 24 h compared to the placebo group. These benefits were sustained over the 4 week 
period with the commonest adverse events being nausea and headache. A third, similar trial of 
170 Japanese patients, suffering with both functional constipation and IBS-C, confirmed these 
findings190. The benefits of lubiprostone were shown in both patients with functional  
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Cl- enters from the basolateral membrane across the Na-K-2Cl co-transporter. The cystic 
fibrosis transmembrane regulator (CTFR) and the CIC-2 chloride channel are situated on the 
apical membrane and allow Cl- to leave the cell. Lubiprostone activates the CIC-2 channel 
whilst the CTFR channel is activated by a rise in cGMP and is the basis of action of Linaclotide. 
  
Figure 1.6 - Model of Cl- transport in intestinal epithelial cells. 
Taken from Cuppoletti et al185. 
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constipation191 and IBS-C192 for up to 48 weeks. Both trials showed continued improvement in 
symptom score and that the drugs were safe. The commonest adverse events were diarrhoea 
(10%) and nausea (10% - 20%). Despite this the number of withdrawals due to AEs was low 
(21/520 in the IBS-C group and 33/248). There were no reported SAEs in the IBS-C group; there 
were 16 in the constipation group and no mortalities in either trial. 
 
1.7.6.3 Guanylate Cyclase C (GC-C) Activators (Linaclotide) 
The GC-C receptor is found on the apical surface of the intestinal epithelium and when it is 
activated by circulating endogenous peptides there is a resultant anion efflux into the intestinal 
lumen with associated fluid secretion193.  Linaclotide is a 14 amino acid peptide which activates 
the GC-C receptor and results in an increase in intra- and extracellular cyclic guanosine 
monophosphate (cGMP). The clinical benefits in 42 patients with functional constipation were 
an improvement in CSBMs/wk, stool consistency, straining, abdominal pain and bloating with a 
concomitant improvement in quality of life194.  The results of two randomised controlled phase 
III trials were presented by Lembo et al195. A total of 1276 patients were recruited, with 
approximately 20% of subjects who received linaclotide having three CSBM/week compared to 
3.3-6% in the placebo group.  The secondary endpoints of stool consistency, straining, 
abdominal discomfort and bloating also improved compared to the placebo group. 
Furthermore, significant improvements in the constipation-related quality of life were also 
seen.  
Additionally the rise in extracellular cGMP has been demonstrated to ameliorate visceral 
hypersensitivity in animal models by a direct action on afferent nerve endings in the gut196. This 
may have an important clinical role in the amelioration of pain associated with IBS197. 
 
1.7.6.4 The Opioid Receptor and Opioid Antagonists 
 
There are 3 opioid receptors, µ-, κ-, δ-, which are located throughout the body including in the 
gastrointestinal tract198. These belong to a family of membrane bound receptors that are linked 
to G-proteins which act as second messengers to activate potassium channels, inhibit calcium 
channels, produce membrane hyperpolarisation and reduce production of cyclic adenosine 
monophosphate199. Opioids are synthesied by the enteric neurones to act as transmitters 
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notably from myenteric neurons projecting on to the circular muscle and in neurons of 
descending enteric pathways198,200. Activation of these receptors reduces neuronal excitability 
with an overall inhibitory effect on peristaltic activity and can occur as a result of endogenous 
or exogenous opioids201. This has been demonstrated in colon models after the administration 
of both opiate agonists and antagonists which have inhibited or augmented peristaltic activity 
respectively202-204. The inhibitory mechanism on peristalsis arises from interruption of 
transmission within enteric nerve pathways where the presynaptic site of action attenuates the 
release of acetylcholine and other excitatory transmitters205. This was demonstrated in animal 
models that activation of opioid receptors also resulted in attenuation in the secretion of 
electrolytes and water206. This effect has been disputed in human colons and that the reduced 
water content of the stool is secondary to prolonged contact with the colonic mucosa.  
The overall effect of endogenous colonic opioids is to slow colonic transit and, through 
prolonged contact of the stool with mucosa and possibly the interruption of prosecretory 
enteric reflexes, facilitate the net absorption of water (Figure 1.7). The overall effect is 
constipation as seen by the exogenous administration of opiates.  
 
1.7.6.4.1 Opioid Induced Constipation (OIC) and the role of Naloxone 
OIC is a major debilitating side effect of opiate use and patients may discontinue their pain 
treatment due to constipation. In a survey it was reported that only 46% of opioid-treated 
patients achieved desired relief of OIC greater than 50% of the time207. The effects of opiates 
on gastrointestinal motility have been discussed and that their use leads to OIC. The colonic 
opiate receptors are thus a potential target for treatment in OIC. OIC can be treated in a similar 
way to functional constipation and these agents, including the more novel agents, have varying 
success. However, local antagonism of the opiate receptor in the gastrointestinal tract offers a 
more attractive option and this has been achieved through the use of opioid antagonists 
naloxone and methylnaltrexone (a quaternary ammonium derivative of naltrexone, an opioid 
antagonist similar to naloxone). 
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µ-Opioid recpetors
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δ- Opioid receptors
Cellular Targets
Enteric motor neurones
Enteric secretomotor neurones
Extrinsic primary afferent neurones
Immune Cells
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Inhibition of enteric nerve activity
Reduction of enteric nerve excitability
Pre- and postsynaptic inhibition of excitatory and inhibitory pathways
Inhibition of propulsive motor activity
Inhibition of distension-induced peristalsis
Elevation of muscle tone
Induction of non-propulsive motility patterns
Inhibition of ion and fluid secretion
Figure 1.7 – Overview of the gastrointestinal opioid system. (From 
Holzer208) 
Opioid receptors, activated by circulating opoids, produced by the enteric 
neurones, inhibit peristalsis to prolong colonic transit and facilitate the net 
absorption of water. 
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1.7.6.4.2 Naloxone and its’ effects on colonic motility  
Empirical Formula of Naloxone:  C19 H21 NO4 HCL, 2H20 
 
Naloxone hydrochloride is an established active substance whose chemical structure is shown 
below.  The pharmacological activity of naloxone on the gut has been evaluated in both in vitro 
and in vivo studies. Liu et al204 demonstrated that naloxone induced a concentration-dependent 
elevation of electricity-stimulated contraction amplitude of cathartic colon strips. The cathartic 
colon rat model attempts to replicate the cathartic colon seen after excessive use of stimulant 
laxatives and in the rat model in this study this was induced by the feeding the rats rhubarb or 
phenolphthalein for 3 months.  Each concentration of naloxone (0.05 mmol/L, 0.10 mmol/L, 
1.00 mmol/L) induced a significant elevation of the contractile response, which showed the 
contraction amplitude was significantly elevated (P<0.01) in its presence (Table 1.3). Krevsky et 
al209 had performed an in vivo study in felines and measured colonic transit using scintigraphy. 
An intramuscular dose of 0.3 mg/kg of naloxone accelerated emptying of the caecum and 
ascending colon with an increased filling of the transverse colon.  
Naloxone in healthy volunteers reverses the delays in colonic transit seen after the 
administration of opiates210,211. Importantly Netzer et al211 demonstrated that the 
administration of naloxone did not reverse the analgesic effects of morphine, whilst Hawkes et 
al210 demonstrated that naloxone alone in healthy volunteers reduced overall transit time and 
proposed it may be of benefit in the treatment of functional constipation.  
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Concentration of 
naloxone(mmoL) 
Basic contraction amplitude 
without naloxone (mm) 
Contraction amplitude with 
naloxone (mm) 
0.05 11.40±0.21 13.18±0.93 b 
0.10 11.40±0.21 15.87±0.98 ab 
1.00 11.40±0.21 19.46±1.79 bd 
  
 a - P<0.05 vs 0.05 mmol/L,  
 b - P<0.01 vs without Naloxone,  
 d - P<0.01 vs 0.05 mmol/L  
 
 
The addition of naloxone in isolated colon strips results in a significant dose-dependent 
increase in contraction amplitude compared to controls in the presence of electrical 
stimulation (4 ms duration, 10Hz and 70V). This explains the reduction in transit time 
seen with the administration of naloxone in healthy volunteers and in sufferers of 
opioid induced constipation 
 
 
  
  
Table 1.3 - Effect of naloxone on electricity-stimulated contractile response of 
cathartic colon strips (mean±SD)204. 
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Naloxone has a low systemic bioavailability (2%) due to extensive 1st pass metabolism in the 
liver. Despite this it is widely distributed in the central nervous system reversing analgesic 
effects or resulting in opioid withdrawal212. The development of a prolonged-release (PR) 
preparation has overcome these issues. PR naloxone has been combined with PR oxycodone (a 
strong, semi-synthetic opioid) with excellent results in the management of OIC. Nadstawek et 
al213 compared oxycodone PR + Placebo with Oxycodone PR + Naloxone PR (10 mg, 20 mg, and 
40 mg/day). Successful management of chronic pain was not reduced with the administration 
of naloxone PR, and this was independent of the naloxone dose. Effective analgesia was 
confirmed in a pooled prospective analysis of two randomised, double-blind, parallel-group, 
multicentre studies involving 587 patients214. The analysis also assessed bowel function 
through the Bowel Function Index (BFI) (a mean scored based on scores (0-100) for defecation, 
feeling of incomplete evacuation, and judgement of constipation with a low score indicating 
better bowel function) and laxative use. BFI scores were similar at baseline but there was a 
significant improvement in score over the 12 week period in the oxycodone/naloxone group 
and this was supported by a lower laxative intake (p<0.0001). Open-label extension studies 
demonstrated its’ long-term efficacy and tolerability over a 52 week period with a continued 
reduction in the BFI scores215. Similar effects were seen with methylnaltrexone216,217.  
The use of naloxone in the management of constipation was reported in a small case study of 
two patients by Kreek et al218. Both patients responded with an increased frequency of passage 
of faeces and also an increase in the wet and dry weight of the faeces. To date, there are no 
clinical trials designed to study the use of naloxone in functional constipation, but it has been 
used in IBS-C sufferers and although not significant, the results tended towards an 
improvement in pain, bloating, straining, and urgency to defecate219.   
 
1.7.7  PROPOSED MANAGEMENT PATHWAY FOR PATIENTS WITH INTRACTABLE 
 CONSTIPATION  
A proposed diagnostic and treatment pathway is shown in figure 1.8. Patients are investigated 
to exclude organic causes and evacuatory disorders and these should be managed 
appropriately. Once a diagnosis of functional constipation is made then the patients should be 
stared on one sachet of Movicol (polyetheleneglycol) twice a day and this titrated to achieve a 
satisfactory response. Failure of movicol should alert the clinician to consider the use of a novel 
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agent such as prucalopride. Failure at this level will require further to a tertiary centre for 
consideration of a trial of a SNS followed by surgery if unsuccessful. All treatments are guided 
by the patient’s co-morbidites and wishes. 
 
1.8 COLONIC MICROBIOTA AND THEIR ROLE IN FUNCTIONAL 
 CONSTIPATION 
The term colonic microbiota describes the microorganisms that populate both the lumen and 
the mucosa of the colon. There are approximately 3000 identified species, but this estimate 
could possibly be as high as 36000220,221, with only 11 of the known 55 bacterial divisions 
represented (see later). Two types of organism are present; autochthonous which are resident 
and allochthonous that are transient. The gastrointestinal microbiota performs a number of 
key biological functions which are beneficial for the host, some examples of which are listed 
here: 
 Biosynthesis of essential nutrients e.g. Vitamin K and B12. 
 Biotransformation of conjugated bile acids. 
 Degradation of dietary oxalates. 
 Extraction of useable calories from indigestible polysaccharides. 
 Production of butyrate (formed as an end product of fermentation and has a 
role in the metabolic welfare of colonocytes). 
 Colonisation Resistance against pathogens 
 
1.8.1 COMPOSITION OF THE COLONIC MICROBIOTA  
The GI tract is an ‘open environment’ with different populations of microbiota existing along its 
length due to rapid turnover of intestinal epithelium and mucus, different exposure to 
peristaltic activity, different environmental conditions and exposure to bacteria from the oral 
cavity. Attempts have been made to identify the composition of the microbiota and the 
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Intractable constipation fulfilling Rome III criteria
Investigate for organic cause including evalutaion for pelvic floor 
evacuatory disorder
Organic cause 
identified
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appropriate
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functional 
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Trial of biofeedback 
Improved Not Improved
Trial of Movicol (polyethyleneglycol)
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Figure 1.8 – Proposed management pathway for patients with 
intractable constipation 
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reliability of such results in part depends of the methods used in detection. Early attempts 
used ‘culture-dependent’ techniques which rely on the ability for  bacteria to be cultured 
so that they can be counted and recorded. Subsequently it has been estimated that these 
techniques may only detect 20-40 species (60-80% of species) when compared to the use 
of a DNA stain to detect the total number of bacteria present222. Reasons for the inability 
to culture all the bacteria are: 
 Obligate syntrophs (Cannot be grown in isolation). 
 Need for strict anaerobiosis (Lost during sampling and plating). 
 Lack of specific culture media. 
 Intracellular adherence may decrease the number of organism within 
faecal samples. 
Therefore, culture-independent methods have been developed which are based on 
analysis of the 16S rRNA within the ribosome of the bacterium. The 16S rRNA gene has 
conserved regions which enable the development of universal primers and variable regions 
which allow differentiation and identification of species. Techniques involved included real-
time PCR, Fluorescent in-situ Hybridisation (FISH), and Denaturing Gradient Gel 
Electrophoresis (DGGE), and 454 sequencing. FISH, DGGE, and 454 sequencing are fully 
discussed later in the methods section along with more detail on the 16S ribosome. 
Numerous major studies have used gene sequencing techniques to further the knowledge 
on the normal colonic microbiota. Of the 11 bacterial divisions represented in the colonic 
microbiota, two make up 99% of the bacterial population; Cytophaga-Flavobacterium-
Bacteroides (CFB) and Firmicutes223-225. The firmicutes comprise 50 – 65% of the detected 
phylotypes whilst the CFB division comprises a further 23-48% of the remaining 
detected223,225. Clostridia comprise the bulk of the firmicutes (95%), most of which are 
divided between sub cluster XIVa (Clostridium-Coccoides gp) and sub cluster IV 
(Clostridium-Leptum gp).  The next two most populous groups are the Mollicutes (4.5%) 
and the Bacilli (0.2%). Of the CFB division, Bacteroidetes make up 48% of the total with 
B.vulgatus (31%) and B.thetaiotaomicron (13%) appearing most dominant. From these 
culture-independent techniques it has been discovered that the abundance of 
Bifidobacterium and Lactic Acid bacteria, reported on earlier studies based on culture 
techniques, was wildly inaccurate. Langendijk et al226 compared Bifidobacterium sp counts 
from culture and from FISH from the same samples and found that whilst Bifidiobacterium 
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sp may account for up to 10% of the total culturable population, this estimate was 
incorrect by a factor of 10 with Bifidiobacterium sp only representing 0.8% +/- 0.4% of the 
total population. A similar finding was presented by Harmsen et al227 who using a 
Lactobacillus/Enterococcus probe estimated that only 0.01% of the total microbiota was 
comprised of Lactobacillus and Enterococcus sp compared to the 2% estimation from 
culture-dependent techniques. 
 
1.8.2 FACTORS AFFECTING THE COMPOSITON OF COLONIC MICROBIOTA IN 
STUDIES 
 
1.8.2.1 Site of Sampling 
Not only is the method used for sampling important but also the type of sample used when 
determining the makeup of the colonic microbiota. Most work has been done using faecal 
samples as these are easiest to collect and it is assumed that they are representative of the 
microbiota within the colon. Eckberg et al223 took mucosal biopsies from 6 regions from the 
colon at colonoscopy, and a further stool sample 1 month later from 3 individuals. 
Zoetendal et al228 took 3 biopsies and a stool sample from 10 individuals. Although 
differences in the microbiota existed between individuals in both studies, in the same 
individual the microbiota from the mucosal biopsies were similar, regardless of site, and 
differed from the microbiota of the stool sample suggesting: 
1. The faecal microbiota represents a combination of shed mucosal bacteria 
and a separate non-adherent luminal population and; 
2. A homogenous bacterial population within the mucosa along the length of 
the colon. 
The second possibility has been disputed in other studies which showed a variation 
between the microbiota identified in the caecum and the proximal sigmoid, in samples 
taken from the lumen229 and mucosa230. However, the first point is likely to be more 
significant as those organisms related to the mucosa may have a more significant impact 
on the host and an imbalance being related to GI pathology. 
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1.8.2.2 Age of subjects 
There are obvious striking changes to the microbiota of the whole of the GI tract following 
birth and also into childhood as a result of breast or formula feeding and the introduction 
of solid foods when weening. However, there are further alterations in adulthood and this 
may be due to continued changes in diet, changes in the function of the immune system, 
and increased exposure to GI tract infections. The commonest changes seen are increases 
in Enterobacteria, with decreases in Bacteroidetes and Bifidiobacteria231,232. 
 
1.8.2.3 Diet 
Although the exact impact of diet on colonic microbiota is largely unknown it is well 
established that diet plays a significant role in its composition. Subjects who are vegan and 
vegetarian have been shown to have lower counts of Bifidobacterium spp., Escherichia coli 
and Enterobacteriaceae spp. compared to omnivore controls and this difference is more 
marked in a vegan diet233. In a separate analysis Clostridium cluster XIVa was more 
prevalent in omnivores234. Neither of these studies was able to identify the actual food 
groups responsible for the changes or the impact this may have on the volunteers clinically. 
 
1.8.2.4 Role of Antibiotics 
Although antibiotics are used to treat pathogenic bacteria they will also affect the normal 
microbiota of the patient and the colonic microbiota is no exception. A five day course of 
oral amoxicillin with clavulanic acid (Augmentin) in healthy volunteers reduced both total 
bacterial (10.7 +/- 0.1 log 10 vs. 11.1 +/- 0.1 log 10, p=0.003) and bifidobacteria 
concentrations (8.1 +/- 0.5 log10 vs. 9.4 +/- 0.3 log 10, p=0.003) in stool samples compared 
to their baseline readings and that these effects persisted for over 2 months following 
completion of the course235.  In a study using mice three different antibiotics were given for 
a total of 21 days. This resulted in a reduction in Clostridium-like and Bacteroides species 
which increased but did not return to baseline values after 14 days. Despite the effects on 
bacterial communities, bacterial numbers were not affected indicating that the changes in 
a relatively small number of taxa were disproportionately favoured by antibiotics236. These 
changes in colonic microbiota with the favouring of some taxa over others may result in 
increased susceptibility to pathogenic bacteria and explain the long known clinical finding 
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that the use of antibiotics, especially cephalosporins, is associated with Clostridium difficile 
diarrhoea237,238. 
 
1.8.3 THE COLONIC MICROBIOTA IN DISEASE 
 
1.8.3.1 Obesity 
Striking changes in the microbiota are associated with obesity and these alterations revert 
to a more normal composition with weight loss. Ley et al224 studied obese individuals and 
normal controls and found that in the former there were increased numbers of firmicutes 
and decreased bacteroidetes compared to controls and that this reverted with sustained 
weight loss.  This was confirmed in mice given a high fat diet (HFD) for 8 weeks240. The 
Firmicutes to Bacteriodetes ratio increased with an increase in the growth of 
Enterobacteriaceae. Furthermore a HFD induced colonic inflammation and accelerated 
obesity and this was confirmed by Lam et al241 who demonstrated an increase in 
macrophage infiltration, TNF-α, and IL-6. It has been shown that germ-free mice are 
protected from obesity that develops from a Western diet compared to mice with gut 
microbiota242. This Western-diet causes a restructuring of the distal gut microbial 
community with increases in the numbers of mollicutes at the expense of bacteroidetes243. 
It has been proposed that an individual’s colonic microbiota can increase the capacity for 
harvesting sugars whilst modulating the host ability to process and store fats. 
 
1.8.3.2 Inflammatory Bowel Disease (IBD) 
IBD is characterised by recurrent intestinal inflammation of unknown aetiology which can 
be managed medically or surgically which involves an inappropriate and relapsing and 
remitting activation of the mucosal immune system. There are two major subtypes; 
ulcerative colitis (UC) and Crohn’s disease (CD).  UC is distributed within the mucosa of the 
colon and rectum whilst CD can occur at any site within the GI tract and involves the whole 
thickness of the bowel wall. IBD is multifactorial with the concordance rates for IBD 
between monozygotic twins being less than 50% and this is lower in CD244. Therefore a 
complex interplay between genetic environmental factors exists with one factor, the gut 
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microbiota, attracting increasing interest with the advent of next generation sequencing 
techniques. 
 
The evidence to suggest that the gut microbiota may play a role in IBD comes from the 
observation that faecal diversion may induce remission in CD and that restoration of flow 
has the opposite effect of increasing inflammation245,246. The administration of antibiotics 
in animal models of colitis have completely prevented disease247-249 and whilst the aerobic 
colony counts are unchanged, there is a dramatic decrease in the anaerobic colony 
counts247,249, which suggests a colonic dysbiosis in IBD. Furthermore, the use of antibiotics 
in clinical trials has been shown to be comparable to mesalazine and superior to placebo in 
treating the symptoms of CD250,251. 
 
Analysis of mucosal-associated and faecal bacteria have demonstrated a dysbiosis in 
patients with IBD.  As with all microbial analyses certain factors need to be taken into 
account such as the age and diet of subjects (as discussed earlier) and the secondly the site 
of the bacterial sample. There is an important point to consider with respect to the age of 
the study population. There is an age-related variation in the distribution of IBD with a 
peak at 15-30 years with smaller peaks under the age of 10 years and around 60 years of 
age. Therefore the age-related changes seen with increasing age may compound any 
changes in the microbiota seen in the different age groups with IBD compared with each 
other and with healthy controls.  The site of biopsy has been shown to affect the microbial 
composition. Whilst there are differences between lumen and mucosal composition there 
does not appear to be any regional differences between mucosal sites in the ileum and 
colon252-255.  
 
Taking these factors into account there are disturbances in the composition of the 
microbiota compared to healthy subjects. There is a reduced biodiversity with, at a phyla 
level, decreased levels of Firmicutes and Bacteroidetes and increased numbers of Gamma 
Proteobacteria and Enterobacteriaceae 225,252,255-260. Differences are also noted at higher 
taxomic levels and offer some insight into the pathophysiology of IBD. Levels of 
E.coli/Shigella are seen to increase in IBD, especially ileal CD and are more pronounced in 
mucosal samples compared to faecal samples257,258,261. The invasive nature of E.coli 
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pathovar is more abundant in ileal CD and has been shown to induce granuloma formation, 
a key characteristic of CD262.  Enterobacteriaceae induces pro-inflammatory cytokine 
pathways257 and a rise in number, particularly Escherichia coli, is associated with a younger 
age to surgery and, a higher incidence of abscess formation in those subjects with CD.  
Higher levels of serum reactivity toward microbial antigens such as Escherichia coli outer 
membrane porin C and Pseudomonas fluorescens I2 sequence result in a greater frequency 
of strictures, internal perforations, and small bowel surgery263,264. 
A second group, the genus Fusobacterium, may be involved in the pathogenesis of UC. 
F.varium numbers are increased in the colonic mucosa in patients with UC (61%) compared 
with CD (15%) and healthy controls (29%, p<0.001) where it increases the products of pro-
inflammatory pathways265,266. The instillation of butyric acid, a product of F.varium, by 
enema in mice has induced mucosal erosions similar to those seen in UC267. F.nucleatum 
has been demonstrated to stimulate rowth of colorectal cancer by activating inflammatory 
and oncogenic responses268 and this may represent a link between UC and the increased 
incidence of colon cancer seen associated with UC. 
 
Decreased levels of Faecalibacterium prausnitzii are reduced in patients with UC but also in 
unaffected relative compared with healthy controls269. In patients with ileal CD who have 
undergone resection those patients with reduced numbers of Firmicutes (Faecalibacterium 
prausnitzii and C.coccoides) have a higher incidence of endoscopic recurrence compared 
with patients who were disease free at 6 months270. A proposed mechanism to account for 
this is a decrease in butyrate production. Butyrate, a short chain fatty acid (SCFA), is the 
primary energy source for the intestinal epithelial cells and is involved in the synthesis of 
tight junction proteins which act to reinforce the colonic barrier. Also butyrate inhibits 
cytokine pathways resulting in an anti-inflammatory effect. Other SCFA-producing bacteria 
including odoribacter are reduced in UC whilst Roseburia are reduced in CD.  
 
It therefore seems logical that alterations of the microbiome may be of therapeutic 
benefit. As mentioned earlier the use of antibiotics has been shown to improve clinical 
symptoms of IBD. Antibiotics have an essential role in treating the septic complications of 
IBD e.g. intra-abdominal and perianal abscesses, inflammatory masses, fistulae, toxic 
megacolon and post-operative infections.  The role of antibiotics in the management of 
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primary is more controversial. The use of ATM (amoxicillin, tetracycline, metronidazole), an 
antibiotic combination therapy, produces an improvement in endoscopic, histological, and 
clinical scores with prolonged remission and steroid withdrawal in active UC compared to 
placebo for up to 12 months271,272 and that this likely resulted from an alteration in the 
intestinal microbiota273. Rifaximin and ciprofloxacin induce remission in the management 
of luminal and perineal CD274,275 however not all studies are promising and it appears 
antibiotic therapy is better used to maintain remission alongside conventional agents276. 
 
The use of probiotics has also been widely investigated with a mixed response in CD. Steed 
at al277 demonstrated an improvement in clinical symptoms and reduced TNF-α expression 
at 3 months but not at 6 months with a symbiotic comprising B.longum. Malchow et al278 
found that E.coli Nissle was superior to placebo in prevention of relapse after induction of 
remission with standard medical therapy. However Lactobacillus GG279 or Saccharomyces 
boulardii280 were unable to prevent relapse of disease compared to placebo. Again mixed 
results have been seen with UC. Lactobacillus combined with sulphasalazine resulted in a 
reduction of inflammation both histologically and immunologically (decrease in 
calprotectin and TNF-α) compared to sulphasalazine alone in both children and adults281,282. 
However Groeger et al were unable to demonstrate a reduction in inflammatory 
biomarkers after administration of B.infantis 35624 despite it having effects in other non-
gastrointestinal inflammatory conditions283 confirming the results of Wildt et al who could 
not demonstrate a significant remission rate compared to placebo284.  It therefore appears 
likely that the species of probiotic used plays a significant part in the therapeutic benefit 
seen. 
 
The dysbiosis seen in IBD offers an exciting insight into disease progression but also into 
the control of the disease. Further work is needed to fully understand the role the 
microbiome plays, whether the changes seen are the causative agent or merely reflect the 
luminal mileau created by the mucosal inflammation. Once this is understood restoring the 
dysbiosis may lead to a new therapeutic armamentarium to control IBD. 
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1.8.3.3 Irritable Bowel Syndrome (IBS) 
IBS is the commonest of the FGIDs, characterised by abdominal pain in association with an 
improvement in pain on defectation or a change in stool frequency or form. Diagnosis is 
based on the Rome III criteria for IBS1 (see below) and is divided into 3 categories; 
Diarrhoea predominant (IBS-D), Constipation predominant (IBS-C), and an alternating or 
mixed pattern (IBS-M). Reflecting the heterogenous nature of this condition there are a 
number of possible pathophysiological mechanisms of which a disturbance in the GI 
microbiota is one.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The change in the microbiota in IBS has been widely demonstrated (Table 1.4) although no 
consistent change has been identified. This inconsistency between studies may reflect 
different analytical techniques used or whether analysis is done for the IBS group as a 
whole, or divided into different subsets. There is also no assessment of the diet taken by 
the subjects in the studies. There are likely to be dietary differences between the two 
groups as IBS patients are known to modify their diets in an attempt to control their 
symptoms. These inconsistencies, however, may reflect the heterogenous nature of the 
condition and that IBS can alternate from one subset to another and as such have a greater 
Rome III Criteria for IBS 
Recurrent abdominal pain or discomfort** at least days/month in the last months 
associated with two or more of the following: 
 Improvement with defecation 
 Onset associated with a change in frequency of stool 
 Onset associated with a change in form (appearance) of stool 
Criterion fulfilled for the last months with symptom onset at least months prior to 
diagnosis 
** “Discomfort” means an uncomfortable sensation not described as pain. 
In pathophysiology research and clinical trials, a pain/discomfort frequency of at 
least 2 days a week during screening evaluation is recommended for subject 
eligibility 
Would not normally include patients who satisfy criteria for Functional 
Constipation 
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variability of their microbiota over time. Therefore, better designed, longitudinal trials are 
needed to accurately quantify the changes in the microbiota so that targeted treatments 
can be implemented. 
 
1.8.3.4 Functional Constipation 
Despite the incidence and associated reduction in quality of life of patients with functional 
constipation, very little is known about the colonic microbiota compared with that of IBS. 
The existing information is from culture-dependent studies and therefore must be 
interpreted with caution for the reasons discussed earlier. Celik et al291 implied that colonic 
microbiota had an important role in functional constipation after they demonstrated that 
the administration of the antibiotic, vancomycin, to sufferers of FC improved stool 
frequency, consistency, ease of defecation, and the amount of stool patients produced. 
However, they were unable to show an improvement in objective measures and since 
there was no control arm a profound placebo effect could not be excluded. Zoppi et al292 
compared 42 children, 28 patients with FC and 14 healthy controls, as part of a trial 
assessing the efficacy of calcium polycarbophil as a treatment for FC.  A secondary 
outcome of the trial assessed the colonic microbiota of the participants measured in faecal 
samples. Compared to the healthy participants, sufferers of FC demonstrated significantly 
elevated levels of clostridia (p<0.001) and bifidiobacterium (p<0.002), but following 
treatment with calcium polycarbophil showed no change in the colonic microbiota towards 
that of the normal subjects. Khalif et al293 compared the faecal microbiota in patients with 
FC before and after treatement with bisacodyl. Levels of bifidiobacteria and lactobacillus 
were significantly lower in constipated subjects with bisacodyl treatment resulting in the 
normalisation of the faecal flora. This led the authors to suggest that constipation caused 
these changes in the microbiota as opposed to a derangement in microbiota as a cause for 
FC. 
 
Further changes in the microbiota have been proposed by the increased levels of methane 
production that occurs in FC. Attaluri et al294, using methane breath testing, reported that 
sufferers of FC who had slow transit (STC) had greater numbers of methanogenic flora 
(defined as ≥ 3ppm) compared to either constipated patients with normal transit and 
normal controls. STC patients had a significantly higher methane response compared to 
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patients with normal transit and normal controls after administration of a carbohydrate 
substrate. These changes were supported in a wider population which also showed that 
subjects with diarrhoea had a significantly lower methane production compared to 
controls295. Changes in methane production may have an impact on colonic transit with 
higher levels causing an increase in transit time and hence constipation and vice versa. 
Based on these studies it is unclear, however, whether the clinical disorder is secondary to 
these changes or as a result of the disorder itself.  However animal studies have shown 
that methane attenuates the contractile amplitude of colonic longitudinal muscle strips296 
and slow transit time in small bowel297 supporting the hypothesis that an increase in 
methane producing colonic microbiota results in constipation but the explanation for the 
initial disturbance in these microbiota remains unclear. 
 
1.9 Hypothesis and Aims of this Thesis 
 
Functional constipation is a challenging condition with limited treatment options. As our 
understanding of gut physiology increases it is possible to develop new pharmacological 
treatments tailored to act on the colonic receptors and improve the symptoms of 
constipation. I propose to use naloxone hydrochloride (opiate antagonist), as a slow 
release preparation (Nalcol™) to treat functional constipation. The hypothesis is that 
Nalcol™ will antagonise the opiate receptors and decrease colonic transit by the 
mechanisms discussed above. This will result in an increase in weekly stool frequency and 
an amelioration of associated symptoms. From a subset of patients stool samples will be 
collected for microbial analysis to determine the differences in colonic microbiota between 
sufferers of functional constipation and healthy subjects using culture-independent 
analytical methods. I will investigate if these changes are corrected after successful 
treatment with Nalcol™. It is hypothesised that there will be quantifiable differences in the 
colonic microbiota and that successful treatment with Nalcol™ will normalise this. 
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 Subjects Mode of 
Analysis 
Observation Notes 
Malinen 285 IBS – 27  
(IBS-D -12, IBS-C -9, IBS-M – 6) 
 
Controls – 22 
qPCR IBS –D  
↓Bifidobacterium 
↓Lactobacillus 
IBS-C  
↑Veillonella 
↑Lactobacillus 
IBS 
↓C.coccoides 
↓B.catenulatum 
10/27 took 
regular IBS 
medication 
Kassinen 286 IBS – 24  
(IBS-D -10, IBS-C -8, IBS-M – 6) 
 
Controls – 23 
16S ribosomal 
sequencing 
with 
confirmation 
with qPCR on 
a subset 
IBS-D  
↓Biﬁdobacterium 
↓Collinsella 
IBS-C 
↓Collinsella 
IBS-M 
↑Bacteroidetes 
All Groups 
↓lactobacillus 
 
Kerckhoffs 287 41 IBS 
(IBS-D -14, IBS-C -11, IBS-M – 
16) 
Controls – 26 
FISH 
qPCR 
↓Biﬁdobacterium 
(greater ↓ in 
B.catenulatum in IBS-C 
and IBS-M) 
Controls were 
a younger 
population 
Noor260 11 IBS 
22 Control 
DGGE ↓Bacteroidetes  
Tana 288 26 IBS 
(IBS-D -8, IBS-C -11, IBS-M – 7) 
Culture 
qPCR 
↑Veillonella (qPCR) 
↑lactobacillus 
(Culture) 
No yoghurt 2 
weeks prior to 
sampling. Also 
investigated 
faecal organic 
acids and 
found link to 
symptom 
severity 
Rajilić-
Stojanović 289 
62 IBS 
(IBS-D -25, IBS-C -18, IBS-M – 
19) 
qPCR 
Phylogenetic 
microarray 
↓Bifidobacterium 
↑Firmicutes 
↓Bacteroides 
 
Chassard 290 IBS-C – 14 
Controls – 12 
FISH 
Culture 
FISH 
↓Roseburia (Firmicute) 
↓Bifidobacterium 
Culture 
↑Enterobacteriaceae 
↓lactobacillus 
↓Bifidobacterium 
 
 
All samples were faecal in origin. Kerckhoffs et al287 also took duodenal brushes. All subjects fulfilled 
the Rome criteria for IBS except for 3 subjects in the study by Kassinen et al286. 
  
Table 1.4 – Summary of the relative changes seen to the colonic microbiota in IBS compared to 
healthy controls. 
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CHAPTER 2 
 
 
A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED 
TRIAL OF NALOXONE PROLONGED RELEASE (NALCOL™) AS A 
TREATMENT FOR FUNCTIONAL CONSTIPATION 
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2.1  TRIAL METHODOLOGY 
 
2.1.1 OVERVIEW OF THE CLINICAL TRIAL 
A single-centre double-blind, randomised, placebo controlled study investigating the 
efficacy and safety of Nalcol™ given to patients with refractory constipation (Table 2.1.1 
and Figure 2.1.1). The trial consisted of three periods.  
 Period I was a two week period. Patient suitability and health were assessed to 
ensure that the inclusion criteria were met, to confirm short-term symptom 
stability, and to confirm patient compliance with diary completion. Patient 
demographics, clinical details, and pre-treatment data were collected. Consent was 
taken at the start of Period I.  
 Period II was the key treatment period and lasted 4 weeks. Nalcol™ was given to 
relieve symptoms which may vary from day-to-day and patients were randomised 
to Nalcol™ or a placebo. Clinical data over the four weeks of treatment was 
collected.  
 A final period of four weeks (Period III) allowed all patients in the trial, regardless of 
initial randomization, to evaluate Nalcol™ and provided further clinical observation 
over a longer time.  
 All patients were seen by Mr Mark Bignell (MB), the principal investigator, in a 
clinic room at the NNUH with a dedicated clinic nurse. The appointments were 
further standardisation as they all followed the protocol set out in the clinical 
record file (CRF). 
 
All patients fulfilled the Rome III criteria for functional constipation (page 11) and were 
managed at a specialist gastroenterology or colorectal clinic at the Norfolk and Norwich 
University Hospital NHS Trust (NNUH). They may have undergone radiological or 
endoscopic investigation for their constipation and their basic management, including 
dietary and lifestyle advice and modification of laxatives, had been instigated. 
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Over the ten week period there were four visits and three telephone calls and all were 
undertaken by Mr M Bignell. Period I consisted of 2 visits and allowed for screening and 
consent of patients and lasted 2 weeks. Period II and III lasted 4 weeks each. In period II 
patients were randomised to either Nalcol™ or placebo whilst in period III all patients 
received Nalcol™. 
 
Period Week Visits Treatments 
 
I 
Screening 
 
1-2 
 
2 visits at the end of week 1 and 
week 2 
 
 
None  
(Screening and assessment 
period) 
 
 
II 
RCT 
 
 
3-6 
 
Phone call at end of week 3 to 
check progress 
Visit at the end of week 6 
 
 
Randomised to  Nalcol™ or 
placebo 
 
III 
Open-
label 
 
 
7-10 
 
Phone call at the end of week 7 
to check progress 
Visit at the end of week 10 
 
All patients received  Nalcol™ 
 
Follow up phone call at 4 weeks after exiting the trial to look for delayed serious adverse 
events and adverse events. 
 
Table 2.1.1 – Outline of the three trial periods and the contact 
made with each trial participitant. 
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Period I 
Period II 
Period III 
Screening and Initial 
Assessment
2 weeks
End of Period 1 
Assessment
Randomisation
Nalcol™ 20mg b.d.
4 weeks
End of Period 2 
Assessment
Nalcol™ 20mg b.d.
4 weeks
Final Assessment 
End of Trial
Placebo
4 weeks
End of Period 2 
Assessment
Nalcol™ 20mg b.d.
4 weeks
Final Assessment 
End of Trial 
 2 Nalcol™ capsules, twice a day 
 Phone call after 1 week to check on participant 
 End of Period assessment 
 Hand over completed diary cards 
 QOL questionnaires completed 
 Repeat blood and urine tests for routine analysis 
 End Of Trial 
 Post-study check phone call in 4 weeks 
 
 2 capsules, twice a day (Nalcol™  20 mg b.d. / 
placebo) 
 Phone call after 1 week to check on participant 
 End of Period assessment 
 Hand over completed diary cards 
 QOL questionnaires completed 
 Large Bowel X-ray transit study 
 Participant invited into Period 3 
 Completion of diary cards and quality of life 
questionnaires 
 If initial assessment and diary cards are 
satisfactory and patient is willing to proceed then 
they will be entered into the trial 
Figure 2.1.1 - The 3 Periods within the Nalcol Study 
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The primary trial endpoint was a patient-derived assessment of ‘satisfactory improvement of 
symptoms’ and was assessed at the end of each period. Secondary endpoints were change in 
stool type and frequency recorded on diary cards, disease specific questionnaires, and 
objective improvements in transit times on repeat transit studies. Patients were assessed at 
the end of each period except for the transit study which was repeated once, at the end of 
period II. Only patients who had been initially investigated by means of a transit study would 
have these repeated at the end of period II.  The full clinical trial protocol is located in appendix 
1 (page 184). 
 
2.1.2 PATIENT RECRUITMENT 
2.1.2.1 Study Population 
Adults referred to the gastroenterology or colorectal clinics specialising in chronic constipation 
at the NNUH and who had persistent symptoms despite initial treatment with diet and 
laxatives were approached. The definition of constipation was according to the Rome III criteria 
for functional constipation (see below).  Attempts to exclude IBS-constipation (IBS-C) were 
made on clinical grounds based on the clinical assessment of the principal investigator. IBS-C 
was diagnosed if either abdominal pain was the most prevalent feature or if there was a history 
of alternating diarrhoea and constipation. 
 
2.1.2.2 Inclusion Criteria (all must be met) 
 Age > 18 years. 
 Male or Female. 
 Satisfy Rome III criteria for functional (slow transit) constipation. 
 No medical or surgical cause for constipation after investigation. 
 Symptoms for greater than 6 months. 
 Symptoms not relieved by diet and laxatives after 6 months. 
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2.1.2.3 Exclusion Criteria 
 Severe cardiac, renal or hepatic impairment* 
 Severe psychiatric disturbance* 
 Mental disorder preventing adequate informed consent* 
 Dilatation of the bowel (megarectum or pseudo-obstruction) 
 Concomitant medication with drugs known to cause constipation 
 Known pregnancy, suspected pregnancy, or trying to conceive* 
 Currently Breast Feeding* 
 Currently participating (or within 1 month) in any other study* 
 
• * These are standard exclusion criteria for drug trials studying novel, receptor-based 
laxatives and not specifically related to Nalcol™. 
 
  
Rome III Criteria for Functional Constipation 
1. Must include two or more of the following: 
 
a. Straining (during at least 25% of defecations) 
b. Lumpy or hard stools (on at least 25% of defecations) 
c. Sensation of incomplete defecation (on at least 25% of defecations) 
d. Sensation of anorectal obstruction/blockage (on at least 25% of 
defecations) 
e. Manual manoeuvres to facilitate defecation (on at least 25% of 
defecations) 
f. Fewer than three defecations a week 
 
2. Loose stools rarely present unless induced by laxatives 
 
3. Would not normally include patients who satisfy criteria for IBS-C 
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2.1.2.4 Recruitment 
Patients with functional constipation were recruited from three possible sources.  
I. Direct referral from consultants in gastroenterology and colorectal surgery who 
managed these patients. Most participants would be recruited from clinics which 
specialise in functional gastrointestinal disorders.  
II. Recruitment from the department of physiology at the NNUH. They have a database of 
patients who had undergone biofeedback training for constipation.  
III. Recruitment from the department of radiology at the NNUH. A search dating back ten 
years (2001 to 2011), on the electronic radiology reporting system, identified patients 
who had undergone transit studies for investigation of functional constipation.  Since 
we were recruiting patients who had failed conventional treatments for a chronic 
condition, a retrospective approach was justified.  
 
There would be some overlap of suitable cases between the three groups. The potential 
participants were sent a letter detailing the study, inviting them to take part with a follow-up 
phone call, one week after the letter, to answer any questions. A follow up phone call aimed to 
increase recruitment. Arrangements were then made to screen those interested in 
participating with a view to trial entry. The recruitment process was all conducted by MB. 
 
2.1.3 SCREENING (PERIOD I) 
The first phase of the study was a decision about whether patients were suitable for the study. 
The period lasted 2 weeks and this was an adequate time to assess disease stability. There 
were two visits during this period: 
  
I. At the initial interview eligibility was assessed against the inclusion/exclusion criteria, 
with medical and social background considered. At this point informed consent was 
sought. 
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II. At the end of Period 1 after review of the initial blood and urine tests and on successful 
completion of the diary card and questionnaires over the two week period. 
 
If for any reason the patient was considered unsuitable at the end of Period I then they were 
not randomised to Period II of the trial and were not included in the analysis. This is discussed 
fully in the results section (2.3.1.1). 
 
Screening procedures involved during visit I: 
 Explanation of all the procedures involved. 
 Recording of all current medical therapy including those used to manage constipation. 
 Current and past medical history – if necessary, referring to the patient’s medical 
notes. 
 Blood sample for routine clinical biochemistry and heamatology tests. 
 Urine for routine urinanalysis. 
 General, abdominal and digital rectal examination. 
 Blood Pressure measurement and ECG. 
 Sigmoidoscopy and stool sample if consent was obtained (to be performed ONLY if 
accepted into the trial). The stool samples were stored on ice and at the end of the 
screening clinic transferred by MB to the Institue of Food Research (IFR), Norwich for 
preparation prior to freezing. All samples were identified by the participant’s 
identification number (see methodology section for faecal analysis). 
 
2.1.3.1 Consent and Randomisation (Visit II) 
Patients seen at the start of Period I had the trial discussed and, if willing, were consented for 
the trial. At the end of the first visit they underwent routine blood tests and were instructed to 
complete the first section of the diary card. At the second screening visit two weeks later, the 
diary card was reviewed to ensure completion and assuming normal routine blood tests the 
participant was entered into the trial. The participant was entered into period II and 
randomised (1:1) to receive one of the two treatment regimes, using a computer –generated 
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randomization sequence. St Mary’s Pharmacy Unit in Cardiff was responsible for the packaging 
and randomization of the trial capsules, both Nalcol™ and Placebo. The capsules were stored 
and dispensed by the pharmacy at the NNUH, which also ensured that both the participant and 
the researchers remained blinded to the treatment. 
 
2.1.4 INTERVENTIONS 
Trial interventions were undertaken in Periods II and III. In period II patients were randomised 
to either Nalcol™ 20mg b.d. or a placebo (2 capsules b.d.). In period III all subjects were given 
Nalcol™20mg b.d. on a open label basis. 
 
2.1.5 TRIAL ENDPOINTS 
2.1.5.1 Primary Endpoint 
The primary endpoint to assess the effectiveness of Nalcol™ was a patient derived global 
assessment of satisfactory improvement of symptoms derived from Dunger-Baldauf et al298 
who used it in patients with IBS. This global assessment asked the participant the statement 
‘During the last 2 weeks I have had satisfactory improvement in my symptoms of constipation’ 
An affirmative response indicated subjective satisfactory improvement. This was assessed at 
the end of each period. 
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2.1.5.2 Secondary Endpoints 
 Change in stool frequency and stool type assessed from daily diaries. 
 Change in symptom scores from a patient-completed questionnaire (PAC-SYM). 
 Change in disease specific quality of life from a patient-completed questionnaire (PAC-
QOL). 
 Objective improvements in transit time on repeat X-ray transit studies. 
 
2.1.6 TRIAL ASSESSMENTS 
Throughout the study patients were asked to complete a diary, recording details related to 
their bowel frequency, laxative use and any adverse events. These were reviewed at the end of 
each trial period to confirm adequate completion. The timing of assessments is shown in table 
2.1.2 (Page 80) and a copy of the diary card is documented in the appendices 2 (page 248). 
 
2.1.6.1 Period I 
At the end of Period I patients completed the two validated questionnaires299,300; 
 Patient assessment of their symptoms of constipation (PAC-SYM). 
 Patient assessment of their quality of life secondary to their constipation (PAC-
QOL). 
 
The returned diary card was reviewed to check satisfactory completion and if acceptable the 
patient was randomised into the trial i.e. to start Period II.  The global assessment question was 
included on the diary card to assess the primary endpoint. At this stage it was expected that 
this would be a negative response. Patients were also asked to undergo rigid sigmoidoscopy for 
stool sampling at the end of visit I, but consent to this was not necessary for entry into the 
clinical trial. 
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2.1.6.2 Period II 
At the end of Period II these assessments were completed: 
 The diary cards were checked for satisfactory completion over the last 4 weeks 
of Period II including answering the global assessment question. Adverse 
events were noted. 
 PAC-SYM and PAC-QOL Questionnaires. 
 Compliance in taking medication was assessed against capsules returned. 
 Repeat stool sample in subset of patients. 
 Large bowel X-ray transit study in patients in those patients who had 
documented slow transit as part of their initial work up and these were used as 
a comparison. 
 
Patients were phoned after the first week of period II to ensure they understood the 
requirement of participation in the trial and to answer any questions. 
 
2.1.6.3 Period III 
At the end of the study the following procedures were completed: 
 The diary cards were checked for satisfactory completion over the last 4 weeks 
of Period III including answering the global assessment question. Adverse 
events were also noted. 
 PAC-SYM and PAC-QOL Questionnaires. 
 Compliance in taking medication was assessed against capsules returned. 
 Repeat stool sample in subset of patients. 
 Repeat blood pressure recordings. 
 Repeat blood and urine samples for follow-up haematology and biochemistry 
testing. 
 
Patients were telephoned at the end of the first week of period III, as per Period II. The timing 
of assessments are summarised in table 2.1.2. 
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2.1.7 ANALYSIS OF TRIAL DATA 
The primary analysis was a comparison of the response to treatment during Period II of the 
study (weeks 3-6) in the treatment group and those in the placebo group. Response was 
defined as those participants who give an assessment of ‘satisfactory improvement’ over the 
last two weeks of the Period II to the ‘global question’ on the diary card.  
A number of secondary analyses aimed to further assess the response to Nalcol™ treatment: 
 Comparison of stool frequency and type and of laxative use between treatment 
and placebo groups during Period II of the study.  
 Comparison of PAC-SYM and PAC-QoL scores at the end of period II. PAC-SYM will 
be used to provide an overall symptom score; but each component will also be 
analysed separately to identify changes to individual symptoms.  
 Comparison between the pre and post trial transit study as an objective marker of 
transit times. 
 Graphical representation (line or bar charts) of the temporal changes in stool 
frequency and type and analysis to assess any drop-off of effect after eight weeks 
of use of Nalcol™. i.e comparison of period II and Period III in the Nalcol™ arm. 
 A comparison of pre-treatment versus treatment symptom levels in the whole 
study population (n=120) i.e. Period 1 vs. Period 3. 
 
Note:  Usual laxatives and other lifestyle measures were taken throughout with no new 
laxatives started during the study period. Patients who developed diarrhoea were instructed to 
call MB who advised about any changes needed. In this scenario, it would be advised that 
participants reduce their ‘usual’ laxative dosage and rely on the trial capsule if they appeared 
to be working. This would be taken into account when analysing the diary cards. 
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             PHASE 
 
ASSESSMENT 
Pre-Treatment 
(Period I) 
Treatment Period 
(Period II) 
Post Treatment Period 
(Period III) 
Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Wk 8 Wk 9 Wk 10 
Global assessment  X     X    X 
Diary Card X X X X X  X X X X X 
PAC-SYM  X     X    X 
PAC-QOL  X     X    X 
 
 
The main outcome measure, the global assessment question, was recorded at the end of weeks 2, 6, and 10. The diary card 
was completed everyday and recorded stool type and frequency and also laxative usage. PAC –SYM and PAC-Qol are 
validated questionnaires used to asses constipation focusing on symptoms and quality of life respectively. 
 
 
Table 2.1.2 – The timing of assessments over the ten week trial period. 
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2.1.7.1 Statistical Analysis  
The primary outcome was analysed as a 2x2 contingency table using Fisher’s exact test. This 
was also used for the data generated from the transit studies as appropriate. Continuous 
variables from diary card data were analysed using the mean or median according to the 
distribution of the data and the appropriate statistical test (Student t-test or a Mann-Whitney 
U test), with comparisons made between baseline and treatment periods. Pre-treatment 
symptom levels and quality of life at the end of period I were compared to symptom and 
quality of life levels at the end of the study (end of period III) using the above tests, again 
according to the distribution of the data.  
 
2.1.7.2 Patient Numbers and Power of the study 
The primary endpoint was to identify responders and non-responders according to the global 
question. Recent clinical trials in this condition have shown placebo response rates ranging 
from 15-35%172,216,301,302 and as such we chose a placebo response rate of 25%. A worthwhile 
treatment response would be 32% greater than the placebo which was considered to be 
clinically significant given the resistant nature of constipation to medical management. For a 
study with a power of 95%, this increase in response could be detected at a significance level of 
0.05 if the total number included was 120 (60 in each group). This estimate was based on using 
a Binomial Test and was confirmed using Fishers Exact Test.  
 
2.1.8 ANALYSIS OF FAECAL SAMPLES 
We aimed to obtain faecal samples for analysis from a minimum of 30 participants at the end 
of each trial period. At least 200mg of fresh stool was needed but it was anticipated that a 
greater quantity would be collected. The stool was initially stored in faecal sample pots in 
polythene bags placed over ice and then transferred by MB to the IFR, Norwich (i.e. within 4 
hours of collection). Here they were divided into 5 batches of approximately 200mg and 
frozen. The methodology used to analyse the stool samples is explained later in the ‘Analysis of 
colonic microbiota methodology’ section. 
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Provision of a stool sample was NOT an absolute requirement for entry into the trial, although 
all participants were approached until there were sufficient numbers for analysis. 
 
2.1.9 PATIENT WITHDRAWAL, MONITORING, AND SAFETY 
2.1.9.1 Withdrawal from the trial 
Withdrawal from the trial was defined as any patient who failed to complete all three periods. 
Patients were withdrawn from the trial if they failed to adequately complete the diary cards or 
if they did not attend for the appointments once period II had commenced. Patients could 
voluntarily withdraw for any reason without this affecting their subsequent clinical 
management. 
On withdrawal from the study patients were asked to complete: 
 PAC-SYM and PAC-QOL questionnaires. 
 Diary cards for review to check compliance and adverse effects. 
 Routine blood and urine for analysis. 
They were also followed-up by phone four weeks after withdrawal to ensure no delayed 
adverse events had occurred. 
 
2.1.9.2 Monitoring 
The study was monitored by the trial investigators and the Norfolk and Norwich Hospital 
(sponsor) in accordance with the guidance in section 5.18 of the ICH Harmonised Guidance for 
Good Clinical Practice (www.ichgcp.net). During the trial the Medicines and Healthcare 
Products Regulatory Agency (MHRA) conducted an inspection with the only major concern 
related to timing of the consent process, which was moved to the 1st visit of Period I from the 
2nd visit. The inspection was otherwise favourable for the running of the clinical trial (see 
‘Bringing a Clinical Trial to Fruition’, section 2.2, page 85). 
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2.1.9.3 Safety Evaluation 
Potential adverse events were reported to the investigators at trial visits by the participant. 
Certain symptoms were specifically enquired about, namely; abdominal pain, diarrhoea, 
bloating, and dizziness. These were then evaluated by the investigators and the sponsor 
informed of any serious adverse events. All serious adverse events and suspected unexpected 
serious adverse events were reported in accordance with the ICH Harmonised Guidance for 
Good Clinical Practice (section 4.11, www.ichgcp.net). Full details of the safety evaluation of 
the trial are outlined in section 7 of the protocol which is located in appendix 1 (page 215). 
Both the Chief and Principal investigators had received full training in GCP. 
 
 
2.1.10 ETHICAL CONSIDERATIONS 
Written informed consent was taken by the principal investigator with a third party witness 
present. Patients were informed that they could withdraw at anytime. The use of a patient 
information sheet facilitated the process of informed consent. After receiving the information 
sheet the patients did not have a time limit to decide on whether to participate in the trial.  All 
trial data was confidential and identification within the study was by a coded number to ensure 
anonymity. The subject’s involvement in the clinical trial was made clear in the notes through 
the use of a sticky label. The trial was approved by the MHRA, Cambridgeshire Research and 
Ethics Committee 4, and the Research and Development Department at the NNUH, the latter 
also acted as sponsors. Full details of ethical considerations are listed in section 8 of the 
protocol which is located in appendix 1 (page 219). 
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2.1.11 FUNDING 
 
The trial was funded by a research fund held by Mr Michael Rhodes at the NNUH. This paid for 
labarotory consumables, the work carried out at St Mary’s Pharmacy Unit and any costs 
incurred from the NNUH for blood sampling etc. The Nalcol™and placebo were supplied by SLA 
Pharma (Watford, UK) at no cost. Mark Bignell was funded by working at the Spire Hospital, 
Norwich, and the NNUH.  
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2.2 BRINGING A CLINICAL TRIAL TO FRUITION IN THE NHS – A 
 PERSONAL  PERSPECTIVE 
 
This was the first time I had undertaken research within the NHS. There are significant 
processes involved in setting up and running a clinical trial in this setting.  This is increased 
where the trial involves an investigational medicinal product (IMP). A timeline for the Nalcol™ 
trial is shown below. 
 
2.2.1 GAINING APPROVAL 
 As with all research, approval must be sought from the local research and ethics committee 
(REC) and the hospital research and development department (R&D).  In the case of a trial 
involving an IMP approval must also be sought from the medicines and healthcare products 
regulatory agency (MHRA).  Clinical trials in the UK are regulated by The Medicines for Human 
Use (Clinical Trials) Regulations 2004 (SI 1031) as amended. These regulations 
implement Directive 2001/20/EC ('The Clinical Trials Directive'). According to the Clinical Trials 
Directive, clinical trials of medicinal products in human subjects require authorisation by the 
competent authority (MHRA in the UK) and a favourable opinion by an ethics committee. This 
authorisation is granted in the form of a clinical trial authorisation (CTA). The regulations only 
apply to trials of medicinal products. All trials involving human subjects must abide by the 
principles of good clinical practice (GCP). GCP is an international quality standard that is 
provided by International Conference on Harmonisation (ICH), an international body that 
defines standards, which governments can transpose into regulations for clinical trials involving 
human subjects. GCP guidelines are designed to protect subjects in a clinical trial and also 
provide assurance of the safety and efficacy of the research undertaken. GCP guidelines 
include standards on how clinical trials should be conducted; define the roles and 
responsibilities of clinical trial sponsors, clinical research investigators, and monitors, and how 
to act upon adverse events. 
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Applications must be made to all these bodies and in January 2009 a new web based 
application system, IRAS (Integrated research application system), was introduced.  As its’ 
name suggest, IRAS allows for one application form to be  filled and once completed the 
programme produces the required fields to be amalgamated for each regulatory body to avoid 
duplication. Prior to completing the application form it is important to take the time to fully 
develop the protocol and anticipate any possible amendments that maybe needed once the 
trial is running before the application is approved. The benefit of this is that any amendment 
made after approval often need to be submitted to all three regulatory agencies before it can 
be implemented. The turnaround time for this is up to 35 days and can add significant delays to 
the progress of the trial. To aid in this it is important to have liaised with all parties involved in 
the running of the trial at the outset. Aspects of this advice were not heeded at the start of this 
trial. The research team felt whilst designing the protocol that the Norfolk and Norwich 
University hospital (NNUH) should act as sponsor since it would recruit NHS patients at a NHS 
institution. The R&D department were approached before ethics and MHRA approval was 
sought but, due to a lack of experience in their department with acting as a sponsor, they felt 
that the trial should be sponsored by the UEA and Mr Michael Rhodes. The sponsor is the 
individual or institution that takes responsibility for the initiation, management and financing 
(or arranging the financing) of the study. The sponsor must satisfy itself that the study meets 
the relevant GCP standards and ensure that arrangements are put in place for management, 
monitoring and reporting. The sponsor is often involved in the indemnification of the trial. This 
trial recruited NHS patients and the NHS indemnity scheme therefore applied. Furthermore 
SLA pharma provided further indemnity. It was only after submitting to R&D, having gained 
approval from the REC was it felt that this trial should be sponsored by the NNUH requiring a 
substantial amendment to REC before the trial had even started. This highlights the importance 
of good communication from the outset and is something that is gained from running IMP 
trials which neither I nor the NNUH R&D department had. 
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2.2.2 RUNNING A CLINICAL TRIAL 
Running a clinical trial is not simply recruiting patients and recording the data generated. Any 
clinical trial requires a trial master file (TMF) to be created and maintained, the contents of 
which are listed in the appendices. Any documentation pertaining to the trial is filed in the 
TMF. Should any amendment to the trial need to be made then an application to both REC and 
the MHRA needs to be submitted and this needs to be recorded in the amendment log, as well 
as the documentation being filed in the TMF. Maintaining the TMF is an important part of 
running a trial. This acts as an audit trail to ensure that the trial is run in accordance with the 
principles of GCP and forms the basis of monitoring visits. Monitoring visits are usually 
conducted monthly by the sponsor and the TMF forms the basis of the visit. Any action that 
needs to be undertaken after a monitoring visit is recorded in a report which must be 
completed by the time of the next monitoring visit The work generated from these visits 
depends on the complexity of the trial but also on the experience of the research team. Those 
who are less experienced are more likely to be unaware of all the documentation that needs to 
be archived. The TMF for this trial consisted of five A4 ring binders. Alongside the monitoring 
visits it is important to have regular meetings with the sponsor (+/- R&D), chief investigator 
and other closely involved departments, in this case pharmacy. The minutes of these meetings 
are recorded. 
 
2.2.2.1 Inspection by MHRA 
Any clinical trial where approval by the MHRA was sought is liable to inspection by the MHRA 
as is any institution involved in the running or sponsoring of the clinical trials. In January 2011 
the NNUH was inspected by the MHRA who randomly selected three trials to be examined in 
detail, with this trial being selected. The preparation required for the visit by the investigators 
and the R&D department was extensive since a poor review could result in the trial being 
suspended or at worst the NNUH having to suspend all clinical trials if a serious breach was 
identified. To prepare for the inspection the TMF was fully reviewed and a number of issues 
were found and dealt with.  Attendance at a ‘GCP and how to survive a MHRA inspection visit’ 
was compulsory to help in the preparations. The inspection was conducted over three days 
with an interview with the inspectors for the principal investigators of the three trials selected 
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on the final day. The interview dealt with issues that had arisen over the course of the 
inspection and in my opinion was a stressful experience. Fortunately the report from the 
MHRA was positive and the inspection report was favourable. 
 
2.2.3 CLOSURE OF A CLINICAL TRIAL 
Closure of a clinical trial is relatively straight forward. All the documentation including the 
clinical record files and database need to be archived and reports sent to each of the 
regulatory bodies. It is also courteous to inform the family doctor of the participants that the 
trial had ceased and any further follow-up or procedures which need to be undertaken. 
 
2.2.4 LESSONS LEARNT 
At the start of the trial I had very limited experience of clinical research and looking back over 
the last two years there are a two areas that I would do differently. Firstly the importance of 
good protocol design and the involvement of the sponsor and other parties involved in running 
the trial is key. This allows the trial to run smoothly without the delays encountered that 
accompany any amendment made. Secondly it is apparent that it is unrealistic for a clinical trial 
to be run without the involvement of the clinical research and trials unit based at the hospital. 
At a minimum, advice can be sought but I think the use of a dedicated research nurse is 
essential to aid not only in participant interventions but to also ensure that the administration 
is also kept up-to-date. 
Running a clinical trial has been a worthwhile experience and given me skills that I will continue 
to use on my return to clinical medicine. I will continue to be involved in clinical research and 
the experience gained in this trial will stand me in good stead to ensure that further trials are 
run efficiently and in accordance with the standards of GCP. 
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2.2.5 TIMELINE OF CLINICAL TRIAL – Year 1 - 2009 
  
  
JANUARY 
FEBRUARY 
MARCH 
APRIL 
MAY 
JUNE 
JULY 
AUGUST 
SEPTEMBER 
OCTOBER 
NOVEMBER 
DECEMBER 
Initial Protocol Written 
Approached R&D regarding 
NNUH acting as sponsor. 
Advised either UEA or Mr 
Rhodes (MR). UEA unwilling 
to sponsor since trial on 
NHS patients.  MR agrees to 
act as sponsor. 
Also informed R&D NOT 
involved until REC approval! 
Application to 
MHRA, Ethics and 
R&D (NNUH) 
prepared 
Submit to REC 
Application made to R&D 
who felt it may be 
appropriate to act as 
sponsor – Referred to R&D 
committee for discussion 
NNUH R&D agree to act as 
sponsor 
Submit to MHRA and R&D 
STARTED FULL TIME 
RESEARCH 
REC APPROVAL 
Amendment to REC: 
Change Sponsor 
Radiation Assessment 
(Overlooked by REC at 1st 
submission) 
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TIMELINE OF CLINICAL TRIAL – Year 2 - 2010 
  
  
DECEMBER 
NOVEMBER 
SEPTEMBER 
FEBRUARY 
OCTOBER 
AUGUST 
JULY 
JUNE 
MAY 
APRIL 
MARCH 
JANUARY 
MHRA  APPROVAL 
R&D (NNUH) APPROVAL 
RECRUITMENT STARTED 
TRIAL HALTED 
ASH cloud in Iceland 
delayed shipment of drugs 
Amendment to MHRA 
Change to drug labelling 
due to change of address 
for site responsible for 
packaging 
TRIAL RECOMMENCED 
Meet with Matt Williams 
and R&D at James Paget 
Hospital to discuss role as a 
recruitment site 
Application to MHRA to 
extend shelf life of drug 
Amendment for: 
2nd recruitment site – JPH 
Change of CI to Andrew 
Hart (AH) 
Open label phase of trial 
(Period IV) 
Realised I may not recruit 
the proposed study 
numbers therefore decision 
to approach local hospitals 
to act as a recruitment site 
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TIMELINE OF CLINICAL TRIAL – Year 3 - 2011 
  
 
 
  
JANUARY 
FEBRUARY 
MARCH 
APRIL 
MAY 
JUNE 
JULY 
AUGUST 
SEPTEMBER 
OCTOBER 
NOVEMBER 
DECEMBER 
MHRA INSPECTION VISIT 
Amendment: 
Timing of consent 
Removal of tissue biopsy 
from consent form (in 
response to MHRA visit) 
Amendment: 
Matt Williams to recruit 
patients at JPUH. R&D at 
JPUH would not allow MB 
to contact patients due to 
data protection (different 
trust) 
Amendment: 
Change PI to Lucasz Kruppa 
(LK) due to slow 
recruitment and MB leaving 
to start as SpR in Wessex. 
MB had taken two years 
away from clinical training 
to undertake a MD and was 
unable to complete the 
clinical trail in this time. TRIAL CLOSED 
Decision made to close 
trial. LK unable to allocate 
enough time to recruit and 
run trial to acceptable 
standard 
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2.3 RESULTS OF THE NALCOL™ CLINICAL STUDY 
The results are presented according to the three trial periods; Period I (Screening), Period II 
(Nalcol™ vs. Placebo), and Period III (Open Label). 
 
2.3.1 PERIOD I (SCREENING FOR ELIGIBILITY PERIOD) 
This was an initial two week period designed to assess, demographics, baseline symptoms and 
clinical characteristics, and eligibility for the clinical study. 
 
2.3.1.1 Patient Recruitment 
During the study 42 females and no males attended for screening.  One patient completed the 
initial interview but was ineligible for entry as symptom control on her current treatment had 
improved over the preceding few weeks. She was therefore excluded from subsequent analysis 
leaving 41 participants who were enrolled and randomised. The 41 patients had a median age 
of 45 yrs (range 23-76 years) with symptoms for a median of 20 years (Range, 3-55; IQR, 12-
30). The demographic and clinical investigations and treatments are described in Table 2.3.1. 
Twenty were randomised to the active treatment phase and twenty-one to the placebo phase 
(Figure 2.3.1). It was the aim of the study to recruit 120 subjects (60 in each group) and this 
was not achieved. 
Transit studies were part of the initial workup in 34 patients (83%) of which 27 (66%) had 
documented slow transit. There were 18 patients (44%) who had undergone biofeedback with 
either no initial response or no continued response. Thirty-two patients (78%) were taking 
laxatives without satisfactory symptom resolution.  
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  Active (n=20) Placebo (n=21) P value 
 
Median Age (Yrs) 
(range, IQR) 
 
 47 
(25 – 76, 39 – 53) 
42 
(23 – 67, 38 – 55) 
0.66 
Sex (F) 
 
 20 21 n/a 
Median Duration 
of symptoms 
(yrs)  
(range, IQR) 
 
 20 
(3 – 45, 9 – 27) 
23 
(3 – 55, 13 – 30) 
0.28 
Previous 
Investigations  
Transit Study 15 (75%) 19 (90%) 0.24 
 Barium Enema 
 
12 (60%) 8 (38%) 0.22 
 Colonoscopy 
 
10 (50%) 8 (38%) 0.54 
 
 
Biofeedback 9 (45%) 9 (43%) 0.76 
Current 
treatment 
None 
 
3 (15%) 5 (24%) 0.70 
 Laxatives 
 
17 (85%) 15 (71%) 0.45 
 
 
Rectal Irrigation 0 1 (5%) 1.00 
Concomitant 
opiate Use 
 
 4 (20%) 2 (10%) 0.41 
 
The 41 patients had a median age of 45 yrs (range 23-76 years) with symptoms for a median of 
20 years (Range, 3-55; IQR, 12-30). Transit studies were part of the initial workup in 34 patients 
(83%) of which 27 (66%) had documented slow transit. There were 18 patients (44%) who had 
undergone biofeedback with either no initial response or no continued response. Thirty-two 
patients (78%) were taking laxatives without satisfactory symptom resolution. There were no 
significant differences between either treatment arm 
 
  Table 2.3.1 – Characteristics of patients screened into clinical trial (Period I) 
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42 patients attended for screening and these were all female. One patient was ineligible 
therefore 41 patients were entered into the trial. One patient was lost to follow up in period II 
and two were lost in period III. There were six withdrawals in period III. In Period II the number 
of patients completing each arm was similar (Nalcol – 20/20, Placebo 20/21). 
  
Attended for 
Screening
42 Patients
Recruited into trial
41 Patients
Active
20 Patients
Active
20 Patients (100%)
Completed Period 
III
16 patients (80%)
Lost to Follow-
up
1 patient
Withdrwan
3 patients
Placebo
21 Patients
Active
20 patients (95%)
Completed Period 
III
16 patients (76%)
Withdrawn
3 Patients
Lost to Follow-
up
1 Patient
Lost to follow-
up
1 Patient
1 patient ineligible after 
screening  as controlled 
with current medication
PERIOD I 
(Recruitment) 
2 weeks 
PERIOD II 
(RCT) 
4 weeks 
PERIOD III 
(OPEN 
LABEL) 
4 weeks 
RANDOMISATION 
FIGURE 2.3.1 – PROGRESSION OF PARTICIPANTS THROUGH THE STUDY 
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2.3.2 PERIOD II – NALCOL™ VS. PLACEBO  
During period II patients were randomised and received either oral Nalcol™ (20mg, b.d.) or 
Placebo for 4 weeks. There were 20 participants randomised to the active medication in Period 
II whilst the remaining 21 took the placebo with one patient lost-to-follow up in the placebo 
arm. The patient who was lost to follow up was a 23yr old woman who had had symptoms for 
7 years. She had documented slow transit and had no response from biofeedback 
 
2.3.2.1 Adverse Events and Reasons For Withdrawal 
The reported adverse events throughout period II are listed in Table 2.3.2.  There were 32 
adverse events in 23 patients (56%).  In the placebo group, 11 adverse events occurred in 9 
patients (43%) compared to 21 events in 14 patients (70%) in the active group (p=0.21). The 
commonest adverse events were abdominal pain/cramps and bloating. There was no 
difference in the number of patients with abdominal pain (8/20 (40%) Vs 7/21 (33%), p=0.75) 
between treatment arms, however there were significantly more patients in the Nalcol™ group 
who complained of bloating than in the placebo group (8/20 (40%) Vs 1/21 (5%), p=0.009). 
There were no withdrawals, in either arm, in Period II. 
 
2.3.2.2 Response to the Global Improvement Question (Table 2.3.3) 
This was the primary outcome of the trial.  In both groups all responses were ‘No’ to the global 
question - ‘Did you have a satisfactory improvement in your symptoms over the last 2 weeks?’ 
at the end of the screening period (Period I). There was no difference between the two groups 
at the end of period II in response to the global question (Nalcol™ vs. Placebo; 20% vs. 24%, 
p=1.00).  Further sub analysis of those patients who had had a transit study as part of their 
initial work-up revealed no statistical difference in the number of affirmative responses 
between those who had documented slow transit and those with normal transit (1/12 (8%) vs. 
3/8 (38%), p=0.26). 
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 Period II Period III 
 Abdominal 
Pain 
Dizziness Bloating Other Abdominal 
Pain 
Dizziness Bloating Other 
Active 
(n=20) 
8 (40%) 0 8 (40%) Anxiety 
Flatus x2 
Diarrhoea 
x2 
9 (45%) 1 (5%) 9 (45%) Flatus x2 
Migraine 
Anxiety 
Placebo 
(n=21) 
7 (33%) 1 (5%) 1 (5%) Rectal 
Bleed 
Migraine 
4 (19%) 0 5 (24%) Headache 
Palpitations 
 
 In period II there were 32 adverse events in 23 patients.  In the placebo group 11 adverse events occurred in 9 patients  
 compared to 21 events in 14 patients in the active group. In period III (open label) there were 34 adverse events in 20  
 patients. 
 
 Table 2.3.2 – Adverse events reported throughout the study period for all patients 
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
97 
 
2.3.2.3 Interpretation Of The Symptom Diary Cards (Tables 2.3.4 and 2.3.5 and Figure 2.3.2) 
Completed diary cards were available for 37 of the 41 (90%) participants with two participants 
in each group failing to return diary cards at the end of the 10 week trial (end of period III).  At 
completion of Period II there were no differences in the median stool type (Nalcol™ vs. 
Placebo; 3 vs. 3, p=0.91) or the median stool frequency (Nalcol™ vs. Placebo; 1 vs. 1, p=0.69) 
between the two groups. There was also no difference in the scores for each group compared 
to the baseline scores at the end of period I.  When the patients who had stool types 5-7 were 
excluded (diarrhoea secondary to laxative use or rectal irrigation, n=7; placebo=5) there was a 
non-significant improvement in the median stool type from 2.5 to 2 at the end of period II 
(p=0.60) in the active group and from 2.5 to 2 in the placebo group (p=0.60) however there 
was no significant difference between the two treatment arms at the end of period II (P=0.92). 
There was no difference in the median stool frequency between periods I and II in either the 
active or placebo group (p=0.96 and 0.75 respectively). Of the 41 patients enrolled eight 
patients (20%) were not using laxatives to manage their constipation (four in each group). 
There was no difference at the end of period II between the two groups in the amount of 
laxative used compared to the end of Period I (Figure 2.3.2). 
 
2.3.2.4 Results Of The Repeat Transit Studies (End Of Period II) 
Repeat transit studies were requested on all patients who had previously had documented 
slow transit (n=27, 66%). This was performed at the end of period II, with any change to normal 
transit providing an objective marker of improvement. Only 33% (4/12) of patients randomised 
to Nalcol™ attended for these and 47% (7/15) in the placebo group (p=0.70) (Table 2.3.6). One 
patient in the placebo group forgot to attend for her transit study at the end of period II and 
instead attended at the end of period III (patient is shown in italics). No patients had a 
reduction in their transit time at the end of period II, irrespective of treatment arm, and in 
spite of 2 patients having a clinical response in the placebo group. 
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 Period II Period III 
Active (n=20) 4 (20%) 7 (35%) 
Placebo (n=21) 5 (24%) 9 (43%) 
 
 
 
Stool 
frequency / 
day 
Week 2 
Period I 
Week 6 
Period II 
Week 10 
Period III 
Active 1 
(0 – 4) 
1 
(0 – 2) 
1 
(0 – 2) 
Placebo 1 
(0 – 3) 
1 
(0 – 2) 
1 
(0 – 2) 
 
 
 
Stool type Week 2 
Period I 
Week 6 
Period II 
Week 10 
Period III 
Active 2 
(1 – 5) 
2.5 
(1 – 6) 
3 
(1 – 7) 
Placebo 3 
(1 – 7) 
2.5 
(1 – 5) 
3 
(1 – 5) 
 
 
 
Completed diary cards were available for 37 of the 41 participants. None of 
the parameters listed in the tables above were significant 
Table 2.3.3 – Number of affirmative responses to the global question 
at the end of Period II and III (Primary Outcome) 
Table 2.3.4 - Median stool frequency /day (range) at the end of each 
trial period for both groups 
Table 2.3.5 - Median stool type at the end of each trial period for both 
groups as determined by the Bristol Stool Chart (range) 
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Of the 41 patients enrolled eight patients (20%) were not using laxatives to manage their constipation (four in each group). There 
was no difference at the end of period II between the two groups in the amount of laxative used compared to the end of Period I 
 
0
1
2
3
4
5
6
7
8
9
10
Not On
Laxatives
No Change Increased Reduced Stopped Withdrawn,
Lost-to-Follow
up, Failed to
Return Diary
Card
Number of Participants
Active
Placebo
Figure 2.3.2 - Bar graph to show 
changes in laxative use at the end 
of period II compared to end of 
period I 
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Active  Placebo  
Patients who had transit 
study as part of initial work-
up 
15 (75%) 
(n=20) 
19 (90%) 
(n=21) 
Number of patients with 
documented slow transit 
12 (80%) 
(n=15) 
15 (79%) 
(n=19) 
Number of patients who had 
a repeat transit study 
4 (20%) 
(n=15) 
7 (37%) 
(n=19) 
Number of patients with slow 
transit at end of period II 
4 6  
 
 
Number of patients with an 
affirmative response to the 
global question (1o outcome) 
at the end of period II 
0 3 
 
1 patient had developed 
normal transit with a clinical 
response in both periods II and 
III 
 
Repeat transit studies were requested on all patients who had previously had documented slow 
transit (n=27, 66%). This was performed at the end of period II, with any change to normal 
transit providing an objective marker of improvement. Only 33% (4/12) of patients randomised 
to Nalcol™ attended for these and 47% (7/15) in the placebo group (p=0.70) (Table 2.3.6). One 
patient in the placebo group forgot to attend for her transit study at the end of period II and 
instead attended at the end of period III (patient is shown in italics). No patients had a reduction 
in their transit time at the end of period II, irrespective of treatment arm, and in spite of 2 
patients having a clinical response in the placebo group. 
  
Table 2.3.6 – Patients who had a repeat transit study at the end of period II 
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2.3.2.5 Analysis Of The Disease-Specific Questionnaires (PAC-SYM And PAC-QOL) 
In total 34 of the 41 participants (83%) completed questionnaires for each of the study periods, 
16 (80%) in the active group and 18 (86%) in the placebo group (p=0.70).  
 
2.3.2.5.1 Patient Assessment of Constipation – Symptoms (PAC-SYM) 
The PAC-SYM consists of 12 questions that are assigned to 3 subsets: 
 Abdominal Symptoms  (4 questions) 
 Rectal Symptoms   (3 questions)  
 Stool Symptoms   (5 questions) 
The responses were recorded on a 5-point likert scale ranging from 0 ‘absent’ to 4 ‘very severe’ 
and recalled symptoms over the preceding two weeks. A low score indicates a low symptom 
severity and vice versa. The median symptom scores for period II are show in table 2.3.7 and 
figure 2.3.3. There was no significant difference between the scores for the groups at the end of 
periods I and II, except for the rectal symptoms in Period II.  Here the score was lower in the 
placebo group; 3 Vs 0.5 (p=0.01). However, this value was of borderline significance at the end 
of Period I; Placebo vs. Nalcol™, 3 Vs 1 (p=0.06) 
Comparing the two groups longitudinally over the study period the symptom scores were not 
significantly different at the end of period II compared to period I in either group.  
The mean difference in the scores for each component of the PAC-SYM (Abdominal, Rectal, 
Stool) was -0.06, 0, and 0.13 respectively in the active group compared to -0.22, -0.89, and -0.56 
in the placebo group (figure 2.3.4). There were no significant differences between the scores in 
the active and placebo groups (p=0.89, 0.69, and 0.58 respectively). At the end of period II there 
had been a slight improvement in the abdominal symptoms of the active group all scores 
improved in the placebo group, however, the difference in scores between the active and 
placebo group were not significant. 
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 Period I Period II Period III 
 
Abdominal Symptom Scores 
Active  8 
(0-15) 
8 
(0-16) 
5 
(0-14) 
Placebo 7 
(0-16) 
7 
(0-14) 
4 
(0-15) 
Rectal Symptom Scores 
Active 3 
(0-9) 
3 
(0-10) 
2 
(0-10) 
Placebo 1 
(0-11) 
0.5 
(0-7) 
0 
(0-7) 
Stool Symptoms Scores 
Active 8 
(2-16) 
9 
(0-17) 
7 
(1-19) 
Placebo 7.5 
(0-19) 
6.5 
(1-18) 
4.5 
(0-18) 
 
 The PAC-SYM consists of 12 questions that are assigned to 3 subsets. The 
responses were recorded on a 5-point likert scale ranging from 0 ‘absent’ to 4 
‘very severe’ and recalled symptoms over the preceding two weeks.   
A higher numerical score represents a high symptom severity (subjectively).The 
only significance difference (*) was between the rectal symptom scores for the 
end of  period II (3 vs 0.5, p=0.01). 
 
 
* 
Table 2.3.7 – Table to show the median scores (range) for each component 
of the PAC-SYM for both active and placebo groups at the end of each 
study period. 
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 Abdominal Symptoms 
 
 Rectal Symptoms 
 
 Stool Symptoms  
 
The only significance difference was between the rectal symptom scores for the end of period II, 
indicated by the arrow (3 vs 0.5, p=0.01). The cause for this is unclear and unexpected but 
suggests that the placebo group may have had patients whose FC consisted of an element of 
pelvic floor dysfunction. 
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Figure 2.3.3 - Line plots to show the median score for each component of the PAC-SYM for 
each treatment arm over the study periods 
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The PAC-SYM consists of 12 questions that are assigned to 3 subsets. The 
responses were recorded on a 5-point likert scale ranging from 0 ‘absent’ to 4 
‘very severe’ and recalled symptoms over the preceding two weeks.  There was 
no significant difference between the scores in the active and placebo groups 
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Figure 2.3.4 - Bar Graph to show the mean differences in scores for each 
component of the PAC-SYM for active and placebo groups at the end of 
Periods I and II. 
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2.3.5.5.2 Patient Assessment of Constipation – Quality of Life (PAC-QOL) 
The PAC-QOL consists of 28 questions that are assigned to 4 areas: 
 Physical Discomfort   (4 questions) 
 Psychosocial Discomfort   (8 questions) 
 Worries and Concerns   (11 questions) 
 Satisfaction with QoL  (5 questions) 
The responses were recorded on a 5-point likert scale ranging from 0 ‘none of the time / not at 
all’ to 4 ‘all of the time / extremely’ and recalled symptoms over the preceding two weeks. A low 
score indicates a low symptom severity and vice versa, except for satisfaction where a low score 
reflects poor satisfaction. The median symptom scores for each three periods are show in the 
table 2.3.8 and figure 2.3.5.  
At the end of period II the QoL was not-significantly better in the placebo group compared to 
the Nalcol™ group when assessed for ‘physical discomfort’ and ‘worries and concerns’ with no 
difference in the ‘psychosocial’ component and a worse score for ‘patient satisfaction with 
symptoms’.  
At the end of period II, in those participants who took Nalcol™, all scores except for ‘satisfaction’ 
had improved, but not significantly. In the placebo group there was no change in the ‘physical’ 
component with a worsening in the ‘psychosocial’ component and an improvement in ‘worries 
and concerns’. Again ‘satisfaction’ scores had worsened, but these were not significant. 
The mean difference in the scores for each component of the PAC-SYM (Physical Discomfort, 
Psychosocial Discomfort, Worries and Concerns, Satisfaction with QoL) was -1, -2.56, -2.56, and 
0.13 respectively for the active group compared to -0.72, -1.28, -3, 0.94 respectively in the 
placebo group (figure 2.3.6). At the end of period II there had been improvements in all 
categories except for satisfaction for both the placebo and active groups.  However this 
difference in scores between the active and placebo group were not significant (p=0.84, 0.51, 
0.89, and 0.54 respectively). 
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 The PAC-QOL consists of 28 questions that are assigned to 4 areas: The 
responses were recorded on a 5-point likert scale ranging from 0 ‘none of the 
time / not at all’ to 4 ‘all of the time / extremely’ and recalled symptoms over 
the preceding two weeks. A low score indicates a low symptom severity and vice 
versa, except for satisfaction where a low score reflects poor satisfaction. The 
only significance difference was for ‘satisfaction with quality of life’ in those who 
were randomised to the placebo arm at the end of period III (4 weeks of 
Nalcol™, open label) compared to period I (7 vs. 4, p=0.01). 
 
 
 Period I Period II Period III 
 
Physical  
Active 12 
(0-15) 
11 
(1-17) 
8 
(0-15) 
Placebo 8 
(0-15) 
8 
(0-13) 
4.5 
(1-14) 
Psychosocial 
Active 13 
(0-27) 
8 
(0-28) 
6.5 
(0-22) 
Placebo 5.5 
(0-24) 
8 
(0-20) 
3.5 
(0-20) 
Worries and Concerns 
Active 23.5 
(1-37) 
20.5 
(3-41) 
15.5 
(0-41) 
Placebo 19.5 
(6-44) 
14.5 
(3-27) 
13 
(4-29) 
Satisfaction 
Active 4.5 
(2-14) 
5 
(3-9) 
6.5 
(3-16) 
Placebo 4* 
(1-13) 
6 
(2-13) 
7* 
(3-16) 
Table 2.3.8 – The median scores (range) for each component of the PAC-
QOL for both active and placebo groups at the end of each study period. 
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Figure 2.3.5 - Line charts to show the changes in the median score for each component of 
the PAC-QOL for each treatment arm during the study period 
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 Satisfaction 
 
 
The PAC-QOL consists of 28 questions that are assigned to 4 areas: The responses were recorded 
on a 5-point likert scale ranging from 0 ‘none of the time / not at all’ to 4 ‘all of the time / 
extremely’ and recalled symptoms over the preceding two weeks. A low score indicates a low 
symptom severity and vice versa, except for satisfaction where a low score reflects poor 
satisfaction. The only significant difference was for satisfaction with quality of life in those who 
were randomised to the placebo arm at the end of period III (4 weeks of Nalcol™, Open label) 
compared to Period I as indicated by the arrows (7 Vs 4, p=0.01). 
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Figure 2.3.5 (Cont’d) - Line charts to show the changes in the median score for each 
component of the PAC-QOL for each treatment arm during the study period 
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The PAC-QOL consists of 28 questions that are assigned to 4 areas: The 
responses were recorded on a 5-point likert scale ranging from 0 ‘none of the 
time / not at all’ to 4 ‘all of the time / extremely’ and recalled symptoms over 
the preceding two weeks. A low score indicates a low symptom severity and 
vice versa, except for satisfaction where a low score reflects poor satisfaction. 
There was no significant difference in the scores between the active and 
placebo groups. 
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Figure 2.3.6 - Bar Graph to show the mean difference in scores for each 
component of the PAC-QOL for active and placebo groups at the end of 
Periods I and II 
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2.3.3 Period III – Open label Period 
This was a 4 week open label period where all participants were prescribed Nalcol™ i.e. patients 
who took Nalcol™ in period II continued Nalcol™ (8 weeks in total) and those who took the 
placebo in period III started Nalcol™. The purpose of this phase was to monitor for adverse 
events over an eight period and also allow the opportunity for all participants to take the trial 
medication. There were 20 patients in each arm at the start of period III. In each arm there was 
1 patient lost-to-follow up and three patients who withdrew. Therefore 32 patients (78%) 
finished the trial in total (16 in each arm) (Figure 2.3.1, page 94). 
 
2.3.3.1 Adverse Events And Reasons For Withdrawal 
The reported clinical adverse events during period III are listed in Table 2.3.2 (page 96). In period 
III (open label) there were 34 adverse events in 20 patients. The commonest events were again 
abdominal pain/cramps and bloating (79% n=27). There was no significant difference at the end 
of period III in the abdominal pain (9/20 vs. 4/21; p=0.10) or bloating (9/20 vs. 5/21; p=0.18) in 
those who had taken Nalcol™ for eight weeks compared to four weeks. This was despite a 
reduction in abdominal pain and an increase in bloating in those who started Nalcol™ 
(previously placebo). There was no difference in abdominal pain, dizziness, or bloating between 
period II and period III. Six patients withdrew from the study and these all occurred during 
period III.  The reasons for which were:  
Patient 1  Anxiety and Bloating 
Patient 2  Pain and Bloating 
Patient 3  Headaches 
Patient 4  Headaches 
Patient 5  Palpitations 
Patient 6  Abdominal Pain 
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None of the patients who withdrew had any improvement in their symptoms at the time of 
withdrawal.  All three patients who had been on the placebo in period II withdrew in week 9, i.e. 
after 2 full weeks of Nalcol™ treatment. Of the patients who had been prescribed Nalcol™ in 
period II, one withdrew in week 8 (after taking Nalcol for a further week), one in week 9 and the 
final patient in week 10.  
 
2.3.3.2 Response To The Global Question (Table 2.3.3, page 98)  
Both groups reported an increase in the number of affirmative responses at the end of period III 
(35% vs. 43%, p=0.75) to the global question - ‘Did you have a satisfactory improvement in your 
symptoms over the last 2 weeks?’, but this difference was not significant. Between periods II 
and III there was an increase in affirmative response in the Nalcol™ arm of 15% (20% to 35%, 
p=0.48) compared to an increase of 19% (24% to 43%, p=0.33) in the placebo arm. 
 
2.3.3.3 Interpretation Of The Diary Cards (Tables 2.3.4 And 2.3.5, page 98) 
There was no improvement in the stool frequency or stool type at the end of period III 
compared to either the end of Period I or Period II. 
 
2.3.3.4 Analysis Of The Disease-Specific Questionnaires 
In total 34 of the 41 participants (83%) completed questionnaires for each of the study periods, 
16 (80%) in the active group and 18 (86%) in the placebo group (p=0.70).  
 
2.3.3.4.1 Patient Assessment of Constipation – Symptoms (PAC-SYM) 
All three subsets which assessed the symptoms of constipation had improved by the end of 
period III compared to their initial scores at the end of period I and this almost reached 
borderline significance for abdominal symptoms (Nalcol™ arm, p=0.11; Placebo arm, p=0.10). 
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There was no difference in the scores at the end of period III between the active and placebo 
group (Table 2.3.7, page 102 and figure 2.3.3, page 103). 
 
2.3.3.4.2 Patient Assessment of Constipation – Quality of Life (PAC-QOL) 
At the end of period III, the QoL was better in the placebo group compared to the active group 
when assessed except for patient satisfaction with symptoms although these differences were 
not significant. The QoL scores at the end of period III for each component were not significantly 
better than the scores at the end of period I and period II except for ‘satisfaction’.   This 
component worsened throughout the whole trial in both arms and this was significant in the 
placebo group at the end of period III (p=0.01) (Table 2.3.8, page 106 and figure 2.3.5, page 107-
108). 
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2.4 DISCUSSION OF CLINICAL TRIAL 
2.4.1 SUMMMARY OF FINDINGS 
The hypothesis of this clinical trial was that Nalcol™ would improve the symptoms of functional 
constipation compared to the placebo over a four week period. The results do not support the 
hypothesis since there was no improvement as judged by the primary and secondary outcome 
measures. In period II, in response to the primary outcome (the global patient satisfaction 
question), 20% of participants who took Nalcol™ felt that they had satisfactory improvement in 
their symptoms over the preceding two weeks compared to 24% in the placebo group (p=1.00). 
Furthermore, there was no difference in the stool type or frequency at the end of period II 
between the two groups or longitudinally when period I was compared with period II. This lack 
of difference was supported by the PAC-SYM and the PAC-QOL scores at the end of period II. 
The only significant difference in period II was for ‘rectal symptoms’ which were significantly 
better in the placebo arm compared to the Nalcol™ arm (3 vs. 0.5,p=0.01). There was no 
significant difference in the other component scores of the PAC-SYM or PAC-QOL between the 
two treatment arms at the end of period II and whilst the scores for both questionnaires 
improved at the end of period III compared to period I this was not significant. This suggests that 
any benefits perceived by the individuals are likely to be the result of a placebo effect.  This 
finding is supported by the repeat transit studies which showed no improvement in transit time 
at the end of period II, regardless of treatment response, except for 1 patient who was in the 
placebo group. However, this data is limited by the small number of participants who completed 
a repeat transit study. Therefore in summary no clinical benefits of Nalcol™ could be 
demonstrated in functional constipation. 
Despite Nalcol™ appearing to have no therapeutic benefit it was associated with an increased 
frequency of bloating in period II compared to the placebo arm (8/20 vs. 1/21, p=0.01). In the 
placebo arm the frequency of bloating increased in period III when Nalcol™ was started 
suggesting it was related to the trial medication.  It is however, difficult to determine if 
abdominal pain and bloating are related to the trial medication or just reflect symptoms 
associated with functional constipation.  Irrespective of the aetiology, two patients withdrew as 
a result of abdominal pain and bloating and a third from abdominal pain alone and this would 
certainly be a limitation of a medication which in this trial had little or no proven benefit. Except 
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for dizziness, the other adverse events were not predictable from the two previous studies that 
have used Nalcol™210,219 but have been seen in a report combining the data from two RCTs using 
20-80mg / day of naloxone PR in combination with oxycodone in the treatment of chronic, non-
malignant pain214. They reported a frequency of diarrhoea of 5% and headaches of 4% compared 
to 4% and 4% respectively in this study. They did not report any incidence of cardiac adverse 
events but these are a well recognised, rare complication of the use of prolonged release 
naloxone303.  
There were no withdrawals during period II with one patient lost-to-follow-up and only during 
the open-label period, period III, did any withdrawals happen. It is interesting that patients who 
had been taking Nalcol™ in period II should develop symptoms after taking the drug for 4 weeks 
without incident. Possibly four weeks is not long enough to evaluate the full effects of Nalcol™ 
and has implications for further trial design. In healthy volunteers effects from Nalcol™ were 
noted over a 9 day period202 and in the report by Löwenstein et al214 benefits from naloxone 
were noted within 4 weeks even though the trial ran for 12 weeks. However Hawkes et al219 
used Nalcol™ for 8 weeks in patients with IBS and did not achieve a significant improvement in 
symptoms but a ‘satisfactory improvement in symptoms’ was noted at 4 weeks in 4/14 
increasing to 6/14 in the Nalcol™ group compared to 3/12 and 3/11 in the placebo group (p=1 
and p=0.68). However, this study was open to all patients with IBS-C and IBS-M and not 
specifically those with IBS-C and this may have impacted on the response rates. 
 
2.4.2 STRENGTHS AND LIMITATIONS OF THE STUDY 
The biggest strength of the trial was that it was randomised, double-blinded, and placebo-
controlled. Treatment trials for any FGID have been shown to be associated with a placebo 
response rates up to 85% depending on the FGID investigated304,305 and this highlights the 
importance of blinding both the participants and investigators. The trial was well designed in 
that a two week screening period allowed disease stability to be assessed and the 4 week trial 
period (Period II) is of an accepted duration306 to assess short-term efficacy in FGID. This trial 
also included a further 4 week open label period meaning that some patients will have taken 
Nalcol™for 8 weeks. The evidence supporting the use of a 4 week trial period has been discussed 
in the preceding paragraph in more detail. The use of a global symptom question as a primary 
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outcome measure of satisfactory symptom relief has been used in IBS307,308. This outcome 
measure was used in this trial for its ease, simplicity, and lack of specificity. Constipation consists 
of a heterogenous collection of symptoms where patients place differing importance on each 
symptom. Therefore using a global question relating to symptomatic improvement is 
appropriate for the group as a whole. The secondary outcomes were able to target specific 
symptoms such as frequency of defecation or abdominal pain and the use of validated, disease-
specific questionnaires further enhanced the strength of the trial design with analysis of both 
primary and secondary outcomes done on an intention-to-treat basis. 
There are however several potential limitations to the study. The first and foremost was the 
lower than expected recruitment into the trial. Over 200 patients were identified as potentially 
suitable for the trial but approximated 50% of these were symptom free or unable to be 
contacted, a limitation of using retrospective databases. Of those contacted only 40% were 
interested in taking part in the study. The participants were not reimbursed for their time and 
enrolment in the study required 4 visitors to the NNUH which serves a wide geographic area and 
this may have been a reason for the low uptake. Only a few patients were recruited 
prospectively from specialist clinics. To improve recruitment in further work it would be 
appropriate to pay for travel expenses but more importantly to involve other centres in patient 
recruitment, either as patient recruitment centres or as a multi-centred trial. A multi-centre trial 
would reduce the distance patients need to travel but at the expense of increasing the 
administrative side of the clinical trial. It was attempted in this trial to use the James Paget 
University Hospital (JPUH) as a recruitment site in August 2010 when it was realised that 
recruitment would fall short in a single-centre trial. Approval from local ethics and the MHRA 
was obtained but the R&D department of the JPUH could not allow the principal investigator 
access to clinical notes without patient approval first. Therefore, a gastroenterologist at the 
JPUH was happy to contact potential participants but was unsuccessful due to a lack of 
administration time.  The power calculation to detect a 35% response required the enrolment of 
120 patients, but only a third of this target was achieved. Therefore any possible benefit from 
Nalcol™ may not have been seen. However the statistical analysis showed no difference 
between the Nalcol™ and placebo arms with a p-value that was not close to significance 
(p=1.00). So whilst it cannot be proved that Nalcol™ is ineffective in the treatment of functional 
constipation it is felt that if a benefit exists it is probably very small with the number of patients 
in our work only able to detect  a very large benefit. Two pilot studies using linaclotide 
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(guanylate cyclase-C receptor agonist) as a treatment for functional constipation and IBS-C 
recruited 42 patients194 and 36 patients309 respectively with significant results in favour of the 
trial drug.  This has also been seen for the pilot studies of prucalopride (5HT4 agonist)310 and 
lubiprostone (Chloride channel 2 agonist)311 which recruited 53 and 129 patients respectively. 
The lubiprostone trial recruited 33 patients into the placebo arm and 30, 32, and 34 patients 
into 3 different lubiprostone doses (24mcg, 48mcg, and 72mcg). This built upon work from 
healthy volunteers recruiting 30 and 26 volunteers which demonstrated that 24mcg was an 
effective dose to increase bowel movements in healthy volunteers186,312. This lends weight to 
our suggestion that if a real difference did exist between the Nalcol™ and the placebo arms, 
then this should be noted in a trial such as ours recruiting 42 subjects.  
Heterogenous patient selection may further limit this work. All patients fulfilled the Rome III 
criteria, but there was great variability in the pre-trial investigations. Imaging of the colon by 
barium enema or colonoscopy was achieved in 68% (n=28) of patients thus excluding 
mechanical causes for obstruction. Of the remaining 13 patients, the mean age was 39 Yrs (+/- 
9.6 Yrs), only 3 had no investigation at all with the remaining 10 patients having either a transit 
study or biofeedback. In total thirty-four patients (83%) underwent transit studies but only 66% 
of patients (27/41) had documented slow transit and further to this no patient had undergone 
formal investigation for pelvic evacuatory disorder (PED) which is a cause of slow transit 
demonstrated on shape studies. This lack of heterogeneity combined withthe poor recruitment 
is likely to further underpower the study supporting the hypothesis that only a large benefit 
would be detected in this work. Even then it would be difficult to draw valid conclusions.  Ideally 
if the trial was repeated all patients, as part of screening, would undergo a transit study and a 
defecating proctogram to characterise the nature of the constipation and exclude patients with 
PED.  Those patients with slow transit could then undergo repeat transit study as in this study to 
act as an objective secondary outcome but since normal transit demonstrated on the initial 
transit study would not exclude patients from the trial it would need careful consideration 
whether the increase in radiation exposure is justified. The use of a defecating proctogram as 
part of the initial screening investigations however, would need careful consideration. The 
proctogram would be a point of embarrassment for most patients and would most likely reduce 
patient recruitment further in what has already been shown in our work to be difficult. The 
enrolment of patients with IBS-C is another potential limitation. IBS is defined by the presence of 
abdominal pain with or without bowel dysfunction. Any patient who suffered predominately 
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with abdominal pain, irrespective of the presence of constipation, or any patient who had an 
alternating bowel habit prior to laxative use was excluded from the trial and therefore the 
number of IBS-C patients enrolled was likely to be low. The enrolment of IBS-C subjects cannot 
be totally avoided due to the overlap in symptoms with functional constipation, however the 
use of lubiprostone in IBS-C has been shown to improve the symptoms of constipation similar to 
that in functional constipation188,313, suggesting that recruitment of these patients may not 
affect the end result. 
The use of a binary response (Yes/No) to the primary outcome is also a limitation. Given that 
‘satisfaction in symptom relief’ is highly subjective and dependant on what the subject feels is 
satisfactory it is likely that only large benefits will be noted and subtle improvements will be 
underreported. A continuous assessment scale, such as the visual analogue score, would have 
been better as this will still assess satisfaction with bowel function but detect a response that 
would not produce a ‘yes’ in a binary outcome assessment.  
The final limitation of the study was the decision to keep the participants on their usual laxative 
regimen. This decision was based on the limited clinical information available and to aid in 
recruitment. As detailed in the introduction (section 1.7.6.4.1, page 50) the data available for 
the use of naloxone in opiate induced constipation is well documented but there is limited data 
on its use in functional constipation. The use of naloxone in healthy volunteers reduced gut 
transit time from 53.1 to 42.1h (p=0.005)210, whilst its use in IBS-C showed an improvement in 
symptomatic relief, pain, bloating, straining, and urgency to defecate but this was not 
significant219. Since the population recruited for this trial had used laxatives extensively without 
full benefit it was deemed appropriate to see if Nalcol™ could augment their usual laxative 
regimen and if possible replace it. It was also thought that this would be more appealing to the 
participants and increase enrolment. 
However, the concomitant use of laxatives has two flaws. First it is impossible to confirm that 
the subjects did not alter their usual laxative regieme to gain symptom relief and failed to record 
this accurately on the diary card or that lifestyle changes were made that could have impacted 
on the results. Secondly interpretation of the patient data more difficult, specifically the stool 
frequency and stool type over the study period and also the laxative use which was obtained 
from data from the diary cards. Patient use of laxatives could make it harder to detect any 
significant benefit of Nalcol™. In this study 20% (8/41) of the participants had stool type 5 or 
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above (diarrhoea) as a result of their laxative use. Involvement of these patients in stool analysis 
would skew stool type towards the normal range of 3-4. The median stool frequency/day is 
compounded by laxative use but also by the nature of constipation itself. A subset of patients 
with constipation has stool types I and II, but have to defecate multiple times a day to achieve a 
satisfactory response. This would skew the frequency towards ‘1’ (i.e. normal) but belie the 
extent of the symptoms. Therefore these factors may hide any response to Nalcol™ when using 
the outcome measures of stool type and frequency. Finally stool type is a highly subjective 
outcome with high intra- and inter-observer variance. 
The use of CSBM as in indicator of response is therefore a better outcome measure than stool 
frequency and type. A CSBM is defined as a spontaneous bowel movement (SBM) with a 
complete sense of evacuation and the use of this nullifies the increased frequency associated 
with type I and II stool and the impact that type 5-7 stool has. ≥3 CSBM/wk or an increase in 1 
CSBM/wk have been used as outcome measures in the large, multi-centred trials already 
quoted172-174 and is therefore an accepted outcome measure. Its use here would have allowed 
for easier analysis of treatment effect whilst allowing for comparison between trials. The use of 
the primary outcome measure used in this trial has been justified here and if the trial was 
repeated it would remain as the primary outcome measure with the CSBM replacing stool 
frequency and type as a secondary outcome. They could be used in conjunction as the global 
question is simple and assesses the patient as a whole whilst the CSBM assesses just one facet of 
the symptomatology of constipation. 
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2.4.3 EXPLANATIONS FOR LACK OF EFFICACY 
Why did Nalcol™ not have any therapeutic benefit over a placebo in this particular patient 
group? There are four possible explanations: 
I. The length of time Nalcol™ was prescribed for was insufficient 
II. Nalcol™ had a small effect and was not seen in the small sample size of this trial 
III. Incorrect dosage used 
IV. Nalcol™ does not affect colonic motility in vivo as expected in functional 
constipation 
Explanations I and II have been discussed earlier, however points III and IV warrant further 
discussion. 
 
2.4.3.1 Incorrect Dosage 
The dosage chosen was greater than the dosage used in the previous trials of Nalcol™, 20mg b.d 
compared with 10 mg b.d210,219. This increase was chosen due to the severity of the constipation 
and the possibility existing that the dose may be too great, with the resultant diarrhoea an 
indication of this. Using a dose that may be potentially too great allows the trial dose  to be 
reduced to an effective and tolerable dose whereas too low a dose would result in the scenario 
of ‘too low a dose’ vs. ‘Nalcol™ not having a physiological effect in vitro in functional 
constipation’ should no response be seen. The use of naloxone prolonged release (naloxone PR) 
has been extensively studied in combination with oxycodone in the management of OIC. 
Meissner et al217 reported the bowel function index (BFI) score decreased as the naloxone PR 
dose increased and that 40mg/day of naloxone PR brought about a significant result compared 
to placebo (27.9 vs. 43.3, p=0.0004) earlier than 20mg/day, which brought about significant 
improvements by the end of the trial (27.9 vs. 34.2 vs. 43.3, 40mg vs. 20mg vs. Placebo). 
10mg/day of naloxone PR however did not bring about any significant reduction in the BFI 
scores compared to placebo. This effect of naloxone PR was also reported by Nadstawek et al213 
who again found that treatment efficacy improved with increasing dose of naloxone PR.  43.5 % 
of patients in the placebo group described efficacy as ‘good’ or ‘very good’ compared to 50%, 
67.4%, and 72.5% in the 10mg, 20mg, and 40mg/day naloxone PR dose groups respectively. It 
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therefore seems likely that a dose of 40mg/day, as chosen for this study, should be adequate to 
elicit a response and would be used again if the trial was to be repeated. 
 
2.4.3.2 Nalcol™ does not affect colonic motility in vivo as expected in functional constipation 
If the dose of Nalcol™ was adequate then why did the patients not respond in a positive 
manner? The answer may lay in the role that endogenous opioids play in controlling colonic 
motility. The effects of opiates on colonic motility have been studied in vivo and in vitro and 
have often used opiate anatogonists to confirm responses. Van Neuten314 in 1977 demonstrated 
that the administration of met-enkephalin produced a dose-dependent inhibition of rhythmic 
peristaltic activity induced by increasing the distending pressure. This inhibitory effect of 
peristaltic activity by opiates is on opioid receptors. When morphine is administered to µ-
receptor knock-out mice there is no effect on transit time compared to heterozygous or wild-
type mice where the expected increase in transit time is seen315. This has been confirmed by the 
use of selective µ, κ, and δ receptor agonists. Shahbazian et al316 demonstrated that µ- and κ-
opioid receptor agonists dampened peristaltic performance whilst Liu et al317 confirmed that µ 
and κ agonists decreased contractile amplitude. The ability of naloxone to antagonise µ and κ 
agonists and to promote peristaltic activity when used alone supports the role of opiates and 
opioid receptors in the role of decreasing peristaltic activity. Whilst this explains why opioid 
analgesic such as morphine induce constipation and why naloxone can act as a therapeutic 
agent in OIC it does not explain the role of endogenous opiates in normal gut function. 
Endogenous opiates suppress both excitatory and inhibitory neuronal pathways to GI muscle 
producing either muscle relaxation or spasm respectively.  Suppression of excitatory pathways 
reduces neuronal excitability and neurotransmitter release at both the pre and post-synaptic 
sites with a resultant decrease in the levels of acetylcholine (ACh) and substance-P producing a 
blockade of distension-induced peristalsis.  Ach and naloxone were able to reinitiate peristaltic 
activity in isolated guinea pig ileum but that this effect was inhibited by pre-treatment with 
normorphine201. It was subsequently shown that normorphine caused depression of the 
excitatory post synaptic potential (EPSP) by increasing potassium conductance following 
activation of µ receptors and that this effect was bocked by administration of naloxone318. 
Suppression of inhibitory pathways results in decreased levels of nitric oxide (NO), vasoactive 
intestinal peptide (VIP), and adenosine 5’-triphosphate (ATP) with an elevation of muscle tone 
and non-propulsive motility patterns as a consequence. This overall suppressive function of 
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opiates was demonstrated by Kadlec and Horacek319 who stressed guinea pig ileum by the use of 
longitudinal stretch and luminal distension for 2 minutes. This resulted in an inhibition of 
peristalsis that outlasted the length of the stimulus and which was abolished or shortened when 
the experiment was repeated in the presence of naloxone.  The role of endogenous opiates in 
suppressing peristalsis was demonstrated using guinea pig ileum and measuring met-enkephalin 
levels at rest and during peristaltic activity320. When guinea pig ileum was maintained with an 
intraluminal pressure of 0cm of H2O met-enkephalin was released into the bathing fluid. As the 
luminal pressure was increased, peristalsis was induced, and met-enkephalin levels reduced. 
However, following prolonged distension, the peristaltic activity became intermittent and the 
levels of met-enkephalin rose compared to the ileum that continued to peristalse. It had been 
shown several years earlier that the addition of naloxone to intermittently peristalsing ileum as 
a result of prolonged distension resulted in an increase in peristaltic activity leading the authors 
to conclude that naloxone reversed fatigued ileum321. What is more likely is that endogenous 
opioids are protective in periods of prolonged stress by abolishing peristaltic activity and 
increasing muscle tone and non-propulsive muscle activity.  
Therefore, it would seem logical that the addition of local acting naloxone would block the 
endogenous opiates and allow colonic peristalsis to continue unabated and thus be beneficial in 
functional constipation. However, naloxone failed to initiate contractions of guinea pig ileum in 
the absence of a distension stimulus201 and had no effect on EPSP amplitude when used alone 
but prevented depression of the EPSP as a result of treatment with opioid agonists318. In the 
same year Schang et al322 demonstrated that in healthy volunteers who had been given only 
naloxone, non significant changes in colonic myoelectric activity were recorded compared to the 
controls. In those volunteers given morphine there was an increase in rhythmic stationary bursts 
and a decrease in propagating bursts which was reversed when naloxone was given.  It has 
subsequently been shown that oral naloxone (40-80mg daily in two or three divided doses) in an 
open study failed to reduce the whole gut transit time in 4 patients with chronic constipation323.  
The endogenous opioid system, therefore, may act as a ‘brake’, protecting the GI tract from 
inappropriate or adverse conditions. Although the pathophysiology of functional constipation is 
poorly understood (section 1.5, page 23) it is accepted that there is a decrease in peristaltic 
activity resulting in an increased transit time. Blockade of the opioid system, as in this study, is 
ineffective as the GI tract is not under inappropriate or adverse conditions and hence the opioid 
system is not active. If it is imagined that a car represents the GI tract and the engine represents 
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colonic activity, removal of the handbrake (the opioid system) will allow the car to pull forward. 
In the case of constipation, however, it is possible that the engine does not work and therefore 
removal of the handbrake is insufficient to allow the car to go forward. From this we can 
hypothesise that the opioid system is not involved in the pathophysiology of functional 
constipation.  That said it is still possible that naloxone may play a role in the management of 
functional constipation if combined with an agent, such as prucalopride, which increases colonic 
motility, i.e. gets the engine running. 
 
2.4.4 SUMMARY 
 
The trial found no effect of Nalcol™ in clinical practice. The reasons for this may be due to 
underpowering of the study, incorrect dosage and short duration, or a lack of appreciation of 
the physiological mechanisms of colonic motor control. This work suggests that future studies 
should be conducted with the aim of determining the effective dose and duration, if any, of 
Nalcol™ in a larger sample group and to investigate the role of endogenous opiates in chronic 
constipation. 
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CHAPTER 3 
 
 
COMPARISON OF COLONIC MICROBIOTA IN SUFFERERS OF 
FUNCTIONAL CONSTIPATION AND HEALTHY CONTROLS 
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3.1 SUMMARY OF THE LABAROTORY METHODOLOGY USED 
3.1.1 CULTURE INDEPENDENT ANALYSIS AND THE 16S RIBOSOME 
The classical method for determining the quantitative composition in a faecal sample is 
microbial culture. This is a labour intensive process which involves dilution of the faecal sample 
and then plating on a specific medium. Taking into account the dilution bacterial populations 
can be determined if the number of colonies is calculated. This method has two major flaws. 
Firstly the reliability of the bacterial count relies on the ability of the culture medium to allow 
the growth of the bacterial species. If the species is poorly cultured then an underestimation of 
the proportion that the particular species makes up in the total microbiota will occur. Secondly 
it well known that not all ’specific’ media are totally specific with the result that some bacterial 
species may be counted more than once. Therefore, DNA based culture independent analysis 
has been developed and these methods have been applied to the faecal samples from 
participants in the Nalcol trial with the primary aim of determining if any difference exists 
between healthy subjects and those suffering with constipation. A secondary objective was to 
determine if any changes in the microbiota were noted should the trial medication prove to be 
effective. 
 
3.1.1 16S Ribosomal RNA 
Ribosomes play a key role in the synthesis of protein in any cell. Bacterial ribosomes consist of a 
50S and a 30S subunit (Figure 3.1.1) and these subunits consist of RNA and proteins. The 30S 
subunit contains the 16S rRNA subunit which, in bacteria, is a molecule containing 1500 
nucleotides. The significance of the 16S rRNA subunit is that it has different degrees of variability 
between species and this variability can be harnessed to identify specific bacterial groups and 
species.  
A number of such 16S based molecular profiling methods have been developed in the last ten 
years. The selection of the methods will depend on the specificity and the depth of phylogenic  
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    30S Subunit        21 proteins 
Figure 3.1.1 - Components of a bacterial ribosome.  
Ribosomes play a key role in the synthesis of protein in any cell. Bacterial ribosomes 
consist of a 50S and a 30S subunit (Figure 3.1.1) and these subunits consist of RNA 
and proteins. The 30S subunit contains the 16S rRNA subunit which, in bacteria, is a 
molecule containing 1500 nucleotides. The significance of the 16S rRNA subunit is 
that it has different degrees of variability between species and this variability can be 
harnessed to identify specific bacterial groups and species.  
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information that is required. In this thesis I have employed the following three forms of analysis 
which will be described later in the section: 
1. Polymerase Chain Reaction – Denaturating Gel Gradient Electrophoresis (PCR-DGGE) 
2. Fluorescence in Situ Hybridisation (FISH) 
3. 454 pyrosequencing 
 
3.1.2 POLYMERASE CHAIN REACTION – DENATURING GRADIENT GEL  
 ELECTROPHORESIS  (PCR – DGGE) 
PCR was developed by Kary Mulis et al324 and allows sequences of DNA or even whole DNA 
strands to be replicated and billions of copies to be made in vitro and this is the first step in PCR-
DGGE.  DGGE is an electrophoresis gel based methods originally developed by Muyzer325 and the 
principle behind DGGE is that single stranded or partially denatured DNA migrates more slowly 
than double-stranded DNA during electrophoresis. The application of a constant heat and an 
increasing gradient in the denaturing agents in the polyacrylamide gel (Formamide (0-40%) and 
Urea 0-7mM) results in the DNA molecules unwinding. The DNA molecules move through the 
pores of the polyacrylamide gel to the positive electrode and each separate DNA molecule, due 
to differing DNA sequences, unwind at a specific point along the gel gradient. This is the point at 
which the DNA strand is said to have ‘melted’, it stops from further migration and appears as a 
band on the gel after staining. The differences in the different melting points of the DNA strands 
depend on the base sequences which unwind at different concentrations and this slows the 
migration over time. G-C pairs which have 3 hydrogen bonds are more stable than A-T pairings 
which have 2 hydrogen bonds. This means that PCR amplicons which have different sequences 
will migrate different distances along the gel and this can allow different bacterial species to be 
separated and detected.  An important component of the PCR step is the GC Clamp. One of the 
PCR primers contains an extended sequence of multiple G bases. The GC clamp formed during 
PCR has a high melting domain and prevents the DNA strand from completely dissociating 
during the electrophoresis. 
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3.1.3 FLUORESCENCE IN SITU HYBRIDISATION (FISH)  
DNA probes have been developed which consist of 18-22 nucleotides that hybridise to specific 
regions of the 16S rRNA molecule. These probes are fluorescently labelled and are directed at 
different phylogenetic levels and allow identification of bacterial species within the gut 
microbiota. These can then be viewed under a microscope using green light and from this an 
estimate of the total number in the faecal microbiota for that subject can be calculated. 
 
3.1.4 PYROSEQUENCING 
Pyrosequencing is a technique whereby DNA sequences are determined by the generation of 
pyrophosphate which produces detectable light following an enzymatic cascade using luciferase 
(Figure 3.1.2)326. The process in its current form was developed by Margulies et al327 and follows 
four main steps which are illustrated in Figures 3.1.2 and 3.1.3: 
 Generation of a single stranded template DNA Library 
 Emulsion-Based PCR clonal amplification of the library 
 Data generation via pyrosequencing 
 Data analysis 
 
3.1.4.1 Generation of a single stranded template DNA Library 
The whole genome or target DNA is first prepared.  The double helix is fragmented into 400-600 
base pair fragments (not necessary for small non-coding RNA or PCR amplicons) which are then 
ligated to adapters and then separated into single strands. The adaptors are used for 
purification, amplification, and sequencing steps and the single-stranded fragments with 
attached adaptors comprise the library used in the downstream processes. 
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3.1.4.2 Emulsion-Based PCR clonal amplification of the library 
Each single-stranded DNA fragment from the library is then bound to an individual capture bead 
which, under certain condition, allows only one DNA fragment to bind to it. The bead-DNA 
complexes are then emulsified and the water-in-oil emulsion is subjected to emulsion PCR to 
produced approximately 10 million identical copies that are immobilised onto each bead. 
 
3.1.4.3 Data Generation via pyrosequencing 
The bead-DNA complexes are placed onto the wells of a fibre-optic slide. The diameter of the 
wells is designed so that only one bead-DNA complex will fit into each well. Beads containing the 
enzymes required for the pyrosequencing are also added to each of the well. Once loaded into 
the sequencer the slide is washed sequentially with the four nucleotide bases which are 
incorporated onto the DNA strands and in doing so convert the pyrophosphate generated into 
light which is detected. The bases are passed in the same order a number of times to allow 
construction of the complementary DNA strand. 
The light signal is detected by a charge-coupled device (CCD) camera with the intensity of the 
light generated varying with the number of complimentary nucleotide bases added i.e. three 
consecutive A’s (A-A-A) has three times the light intensity as a single A nucleotide. At the start of 
sequenceing the machine is calibrated with a TCAG sequence. 
 
3.1.4.4 Data analysis 
The combination of signal intensities allows the DNA sequences to be determined in each well. 
Bioinformatic software can be used to reconstruct the DNA templates which are then mapped 
against reference sequences. 
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Pyrosequencing is a technique whereby DNA sequences are determined by the generation of 
pyrophosphate which produces detectable light following an enzymatic cascade using luciferase. 
The template strand is represented in red, the annealed primer is shown in black and the DNA 
polymerase is shown as the green oval. Incorporation of the complementary base (the blue "G") 
generates inorganic pyrophosphate (PPi), which is converted to ATP by the sulfurylase (blue 
arrow). Luciferase (red arrow) uses the ATP to convert luciferin to oxyluciferin, producing light. 
Taken from Rothberg and Leamon328. 
 
 
  
Figure 3.1.2 – Diagram of the pyrosequencing process 
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 (a) Genomic DNA is isolated, fragmented, ligated to adapters and separated into single 
 strands.  
 (b) Fragments are bound to beads under conditions that favour one fragment per bead, 
 the beads are isolated and compartmentalized in the droplets of a PCR-reaction-
 mixture-in-oil emulsion and PCR amplification occurs within each droplet, resulting in 
 beads each carrying ten million copies of a unique DNA template.  
 (c) The emulsion is broken, the DNA strands are denatured, and beads carrying single-
 stranded DNA templates are enriched (not shown) and deposited into wells of a  fibre-
 optic slide.  
 (d) Smaller beads carrying immobilized enzymes required for a solid phase  
 pyrophosphate  sequencing reaction are deposited into each well.  
 (e) Scanning electron micrograph of a portion of a fibre-optic slide, showing fibre-optic 
 cladding and wells before bead deposition.  
 (f) The 454 sequencing instrument consists of the following major subsystems: a fluidic 
 assembly (object i), a flow cell that includes the well-containing fibre-optic slide (object 
 ii), a CCD camera-based imaging assembly with its own fibre-optic bundle used to image 
 the fibre-optic slide (part of object iii), and a computer that provides the necessary user 
 interface and instrument control (part of object iii).  
 
Figure 3.1.3 – Overview of the 454 Pyrosequencing Technology 
(Taken from Rothberg and Leamon328). 
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3.2 LABORATORY METHODOLOGY 
The Nalcol™ clinical study was given ethical approval by the Cambridgeshire REC 4, the MHRA, 
the R&D department at the NNUH and the IFR. Full details are found in the Methodology 
section of the clinical trial (Chapter 2, Section 1, page 69). The trial protocol is also fully 
detailed in appendix 1 (page 189) but is summarised here.  Patients enrolled into the 
microbiota analysis were taking part in a single-centre double-blind, randomised, placebo 
controlled study investigating the efficacy and safety of Nalcol™ given to patients with 
refractory constipation. The trial consisted of three periods (Figure 3.2.1 and Table 3.2.1);  
 Period I was a two week period. Patient suitability and health were assessed to ensure 
that the inclusion criteria were met, to confirm short-term symptom stability, and to 
confirm patient compliance with diary completion. Patient demographics, clinical 
details, and pre-treatment data were collected. Consent was taken at the start of 
Period I.  
 
 Period II was the key treatment period and lasted 4 weeks. Nalcol™ was given to 
relieve symptoms which may vary from day-to-day and patients were randomised to 
Nalcol™ or a placebo. Clinical data over the four weeks of treatment was collected.  
 
 A final period of four weeks (Period III) allowed all patients in the trial, regardless of 
initial randomization, to evaluate Nalcol™ and provided further clinical observation 
over a longer time.  
 
All patients fulfilled the Rome III criteria for functional constipation (page 11) and were 
managed at a specialist gastroenterology or colorectal clinic at the Norfolk and Norwich 
University Hospital NHS Trust (NNUH). They may have undergone radiological or endoscopic 
investigation for their constipation and their basic management, including dietary and lifestyle 
advice and modification of laxatives, had been instigated.  
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Period I 
Period II 
Period III 
Screening and Initial 
Assessment
2 weeks
End of Period 1 
Assessment
Randomisation
Nalcol™ 20mg b.d.
4 weeks
End of Period 2 
Assessment
Nalcol™ 20mg b.d.
4 weeks
Final Assessment 
End of Trial
Placebo
4 weeks
End of Period 2 
Assessment
Nalcol™ 20mg b.d.
4 weeks
Final Assessment 
End of Trial 
 2 Nalco™l capsules, twice a day 
 Phone call after 1 week to check on participant 
 End of Period assessment 
 Hand over completed diary cards 
 QOL questionnaires completed 
 Repeat blood and urine tests for routine analysis 
 End Of Trial 
 Post-study check phone call in 4 weeks 
 
 2 capsules, twice a day (Nalcol™ 20 mg b.d. / 
placebo) 
 Phone call after 1 week to check on participant 
 End of Period assessment 
 Hand over completed diary cards 
 QOL questionnaires completed 
 Large Bowel X-ray transit study 
 Participant invited into Period 3 
 Completion of diary cards and quality of life 
questionnaires 
 If initial assessment and diary cards are 
satisfactory and patient is willing to proceed then 
they will be entered into the trial 
Figure 3.2.1 - The 3 Periods within the Nalcol™ Study 
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             PHASE 
 
ASSESSMENT 
Pre-Treatment 
(Period I) 
Treatment Period 
(Period II) 
Post Treatment Period 
(Period III) 
Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Wk 8 Wk 9 Wk 10 
Global assessment  X     X    X 
Diary Card X X X X X  X X X X X 
PAC-SYM  X     X    X 
PAC-QOL  X     X    X 
 
 The main outcome measure, the global assessment question, was recorded at the end of weeks 2, 6, and 10. The diary card 
was completed everyday and recorded stool type and frequency and also laxative usage. PAC –SYM and PAC-Qol are 
validated questionnaires used to asses constipation focusing on symptoms and quality of life respectively. 
 
 
Table 3.2.1 – The timing of assessments over the ten week trial period. 
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3.2.1 COLLECTION AND STORAGE OF FAECAL SAMPLES 
Samples were taken at the end of each trial period. The samples from period I would be 
compared against healthy controls to determine if a difference existed between the colonic 
microbiota of healthy and constipated individuals. The samples at the end of period I also 
acted as a baseline for which changes in period II and III could be compared against. 
Consent was obtained from participants of the Nalcol™ trial for faecal sampling. In the left 
lateral position faecal material was taken from the patient through the use of a rigid 
sigmoidoscope. Samples were placed into a faecal sample specimen container and 
immediately labelled and placed onto ice. At the end of the clinic, the samples were 
transferred to the IFR from the NNUH. The maximum time a sample was kept on ice before 
freezing was 180 minutes. At the IFR the faecal samples were aliquoted into 200 mg 
samples, placed into 2 ml eppendorf tubes and stored in a -80oC freezer until further 
processing. 
 
3.2.2 EXTRACTION OF DNA FROM FAECAL SAMPLES 
DNA was extracted from one 200 mg aliquot using the QIAamp DNA Stool Mini Kit 
(Qiagen®, UK.). The full protocol is listed in appendix 3 section but the methodology is 
summarised here with the adjustments that were made to the protocol.  
The frozen sample was taken and 10x vol/wt of Buffer ASL was added (200µl). The sample 
was then homogenised using a hand-held homogeniser for approximately one minute. The 
sample was then placed in a water bath at 90oC and then vortexed for a further 30 seconds. 
After centrifugation for 1 minute at 14000 x g 1.2 ml of supernatant was transferred to a 
new 2 ml snap-lock tube and 1 tablet of InhibitEX was added. This was centrifuged for 6 
minutes, the supernatant then removed and centrifuged for a further 3 minutes at 14000 x 
g. 15 µl of proteinase K was added to 200 µl of supernatant and then 200 µl of Buffer AL 
was added before incubating at 70oC for 10 minutes. Following this 200µl of 96-100% 
ethanol was added before placing in a QIAamp spin column and centrifuged at 14000 x g 
for 1 minute. The spin column was then washed with 500 µl of washing buffer AW 1 and 
then by 500 µl of washing buffer AW2. 100 µl of elution buffer AE was then used to elute 
the DNA which was then stored at -80oC or in the fridge at 4oC depending on the time 
interval for downstream processing. 
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3.2.3 PCR AMPLIFICATION 
PCR amplification for DGGE analysis was based on the method described by Tourlomousis 
et al (2010)329. PCR amplification was undertaken using as the template the DNA extracted 
from the faecal samples as previously described. The variable V4 region of the 16S rRNA 
gene was amplified by using the primers U968-GC-f (5’-CGC-CCG-GGG-CGC-GCC-CCG-GGC-
GGG-GCG-GGG-GCA-CGG-GGG-GAA-CGC-GAA-GAA-CCT-TAC-3’) and U1401-r (5’-CGG-TGT-
GTA-CAA-GAC-CC-3’)(primers were supplied from Eurofins MWG Operon, Ebersberg, 
Germany). 
PCR amplification was performed with the following mixture: 
 HotMaster Taq DNA Polymerase (5-Prime, Nottingham, UK), (5U/µl) 0.2µl 
 dNTP Mix 100mM, Concentration 25mM (Bioline, London, UK)  0.4µl 
 Hotmaster Taq Buffer with magnesium, 10X    5µl 
 (5-Prime, Nottingham, UK) 
 Forward Primer  (20 mM)      1µl 
 Reverse Primer (20 mM)      1µl 
 BSA (Sigma, UK) (1% w/v)      1µl 
 Ultrapure water       40.4µl 
 Extracted DNA (50-100ng)      1µl 
 
 TOTAL Volume        50µl 
 
The use of BSA as a PCR enhancer had already been described in this laboratory329 and was 
added since PCR amplification was suboptimal without its addition.   
The mixture was amplified using a Tprofessional standard gradient thermocycler 
(Biometra®) with the following program: 
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 94oC 5 minutes 
 94oC 30 seconds 
 50oC 20 seconds  35 cycles 
 72oC 40 seconds 
 72oC 7 minutes 
The presence of PCR products was confirmed through electrophoresis using a standard 
0.7% (wt/vol) agarose gel and visualised using a dark reader after staining with Ethidium 
Bromide. The products were then cleaned using the E.Z.N.A.® Cycle-Pure Spin kit (Omega 
Bio-tek, USA) and their concentration was measured via spectophotometry (ND1000, 
Nanodrop Technologies, Wilmington, USA). 
 
3.2.4 DGGE METHODOLOGY 
DGGE was carried out using the Bio-Rad D-Code system (Bio-Rad, Hemel Hempsted, UK) 
and the full protocol is described in appendix 4. The acrylamide gels were created using 
appropriate volumes of 0%, 40%, and 60% acrylamide solution (Severn Biotech ltd., UK). 
200 ng of each PCR product along with 5 µl of loading buffer were loaded into the wells of 
the gel and DGGE was then undertaken using 1xTAE and run at 50V for 16 hours. Gels were 
stained in SYBR Green for 45 minutes then washed in 300 ml of dH2O for 15 minutes. 
Images were obtained after scanning via Pharos FX molecular imager (Bio-Rad, Hemel 
Hempsted, UK) 
Each gel was loaded with a marker at the beginning and end and with one to two markers 
in between depending on the number of samples loaded. The marker was created from the 
PCR product of a healthy sample was felt to have a wide spread of bands when a pilot 
DGGE was run. The use of this marker was critical for final analysis of the DGGE gels. 
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3.2.4.1 Analysis of DGGE Gel images 
DGGE Lanes were analysed using Total Lab 120 V2006 (Phoretix 1D Advanced Software, 
NonLinear Dynamics, Newcastle, UK) and subjected to a number of steps which were 
applied to all gels. Firstly lanes were automatically detected and then manually corrected.  
Background was then subtracted and bands automatically detected. Three parameters 
were adjustable for band detection: 
 Minimum slope   how pronounced the band should be from its  
     surrounding area 
 Noise Reduction  degree to which small peaks are ignored 
 Percentage maximum peak parameter which discards peaks of under a certain 
     size in relation to the highest peak on the gel 
In all analyses the parameters above were set at ‘100’, ‘5’ and ‘5’ respectively. After 
automatic detection the lanes were checked to confirm correct detection of bands with any 
artefacts detected by the software deleted. The next step was Retardation Factor (Rf) 
calibration. This is a measurement of the position of a band along the length of the lane. 
Horizontal lines were added and ‘locked’ across bands from each of the marker lanes and 
given arbitrary values ranging from 0 to 1. Once this was completed bands in the non-
marker lanes were matched to the marker lanes.  
Output from TL120 comprised of Rf values of all detected bands, their intensities, and their 
corresponding positions (measured in pixels) in the original profiles. The data along with 
the original profiles was then transferred to Matlab R2008a (The Mathworks, Inc., 
Cambridge, MA) for further analysis. The use of Matlab was developed by this laboratory in 
conjunction with the Bioinformatics and Statistics Partnership at the IFR329. In brief the data 
was first aligned and then normalised.  Alignment was carried out to a set of 10 reference 
bands and common to all of the reference lanes of the 3 gels. The alignment method used 
was the same as in earlier DGGE work carried out at the IFR329. After this the data were 
normalised by setting the minimum of each lane to 0; and for subsequent statistical 
analyses, by setting the integrated area under the curve (lane) to unity. Supervised 
modelling and univariate analyses were then undertaken to look for differences between 
the samples. 
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3.2.5 FISH ANALYSIS 
Faecal samples were subjected to FISH using the protocol detailed in appendix 5. The 
samples were prepared and then stored at -18oC in a PBS/ethanol mixture until needed. 
When needed samples were defrosted and hybridised with the appropriate volume of 
hybridisation buffer and probe (see table in FISH protocol). Samples were then washed by 
adding the hybridised sample to washing buffer and DAPI. These were then filtered on 
0.2µm paper and fixed with slow fade before a glass slide was applied. Slides were stored 
at 4oC in the dark to minimise fading. Using a Nikon electron microscope with a Fluor 100 
lens the bacteria were located with green light (UV light for DAPI) and the cells counted 
manually. 15 random fields from each slide were counted and each sample was prepared 
and counted twice. 
 
3.2.6 454 PYROSEQUENCING 
DNA was extracted from the faecal samples using QIAamp DNA extraction protocol and 
then cleaned up using an ENZAcycle pure spin protocol as outlined below. The extracted 
DNA was quantified and approximately 100ug of the DNA was sent to Veterinary 
Laboratiory agency for 454 pyrosequencing. The method for the pyrosequencing is fully 
explained in the paper by Ellis et al330. The DNA was amplified with universal primers for 
the V4 and V5 regions of the 16S rRNA gene. The primers used permitted amplification of 
both bacterial and archaeal ribosomal gene regions, whilst providing the best possible 
taxonomic resolution based on published information. Amplification was performed with 
FastStart HiFi Polymerase (Roche Diagnostics Ltd, UK) and the amplicons were purified 
using Ampure XP magnetic beads (Beckman Coulter). The concentration of each sample 
was measured using the fluorescence-based Picogreen assay (Invitrogen). Concentrations 
were normalized before pooling samples in batches of up to 16, each of which would be 
subsequently identified by its unique MID. Pooled samples were then subjected to 
unidirectional sequencing from the forward primer on the 454 GS FLX Titanium platform 
according to the manufacturer’s instructions (Roche Diagnostics Ltd, UK). The sequencing 
data received from VLA were analysed at IFR using Qiime software331 with help of Dr Adrian 
Tett.  
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3.3 COMPARATIVE ANALYSIS OF THE COMPOSITON OF THE FAECAL 
 MICROBIOTA IN  PATIENTS WITH CHRONIC CONSTIPATION 
 AND IN HEALTHY SUBJECTS 
 
3.3.1 PATIENTS 
There were 42 patients enrolled into the clinical trial comparing the effect of Nalcol™ to 
placebo in the management of functional constipation and 20 of these patients gave at 
least one stool sample via rigid sigmoidoscopy as described in the trial methodology 
(Section 2.1.3, page 74). The patient characteristics are summarised in table 3.3.1. The 
number of samples donated and the patient outcomes in the clinical trial at the end of 
period II (Nalcol™ vs. Placebo) are also reported. All the subjects were female with a 
median age of 46.5 years (Range; 23-67 years, IQR; 36.5-55.5 years). At the time of 
sampling, in period I, 25% of subjects (5/20) were not taking laxatives with 1 patient (5%) 
using rectal irrigation. All other patients were taking laxatives as listed in table 3.3.1. The 
subject who used rectal irrigation did so after faecal sampling as required. At the end of 
period II only 15 patients (75%) were able to provide a further stool sample; of the eight 
patients randomised to take Nalcol™ during period II only one of these failed to provide a 
stool sample at the end of the period compared to four patients in the placebo group 
(p=0.60). This number reduced further at the end of period III with only eight of the original 
20 patients providing a sample, three patients who took Nalcol™ in period II and five 
patients who took placebo during period III. There were three responses to the Nalcol™ 
and no responses in the placebo group (Nalcol - 3/7, Placebo – 0/8, p=0.077) in those who 
provided a sample at the end of period II.  
The healthy controls were all female, were from the local region, and had no history of 
gastrointestinal disease or laxative use. 
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Subject 
number 
 
 
Age Laxative Use Active/ 
Placebo 
Outcome at 
end of 
Period II 
Stool sample at the end of ......  
(5 x 200 mg aliquots unless stated) 
Period I Period II Period III 
NAL001 55 Picolax Placebo Response X (4) - - 
NAL002 61 Lactulose 
and Senna 
Active No Response X X X 
NAL003 40 Senna Placebo No Response X (2) X X (3) 
NAL004 48 Picolax Active No Response X X - 
NAL005 62 Movicol and 
Magnesium 
Hydroxide 
Placebo No Response X (2) X (4) X 
NAL008 39 Diary card 
not returned 
Active No Response X X - 
NAL010 52 Nil Placebo No Response X X X 
NAL013 50 Nil Active No Response X (4) X - 
NAL015 57 Bisacodyl Placebo No Response X - X 
NAL016 25 Laxido Active Response X X X 
NAL017 23 Laxido and 
Dulcolax 
Placebo No Response X X (4) X 
NAL019 39 Movicol Placebo No Response X X - 
NAL021 67 Rectal 
Irrigation 
Placebo No Response X X (1) - 
NAL023 45 Movicol Active Response X (3) X - 
NAL026 31 Lactulose Active Response X X X 
NAL028 32 Movicol Placebo No Response X (2) X - 
NAL029 38 Nil Placebo No Response X X - 
NAL031 49 Nil Active No Response X - - 
NAL032 58 Lactulose Placebo No Response X - - 
NAL033 32 Nil Placebo Response X (4) - - 
 
  Table 3.3.1 - Patient characteristics of those participants who underwent stool sampling 
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3.3.2 ANALYSIS OF MICROBIOTA COMPOSITION USING DGGE  
DGGE analysis was undertaken using 20 healthy controls and samples from all 20 
constipated subjects (taken in period I). The gels can be seen in figure 3.3.1. No profile was 
produced for one of the healthy controls despite all other samples on that gel running 
without incident. After lane alignment was performed, supervised modelling was used to 
look for evidence of difference between the groups. A cross-validated, discriminate, Partial-
Least-Squares method was used (Figure 3.3.2). This is a multivariate pattern recognition 
method that uses the whole profile of the sample and the relative band intensity 
information is retained (as opposed to converting to presence-absence data). Using this 
method it was shown that a difference existed between the two groups with a cross-
validated success rate of 77% (p<0.01, y-scrambling permutation test, 10 000 
permutations, a test used to determine if variables in two groups are from the same 
distribution). Looking specifically at the bands (Figure 3.3.3) it was shown that one band 
was most associated with the ‘patient group (constipated)’ as indicated by the red arrow.  
This band was weak in most of the healthy controls and was the only band to show a 
significant difference between groups in a univariate test (Kruskal-Wallis, figure 3.3.4). 
Analysis of the bands using presence/absence plots (not shown) showed no significant 
difference, even at different intensity thresholds. This was the same for similarity methods 
using presence/absence data and band position. Therefore statistical difference was only 
seen between the two groups when band intensity information was preserved and pattern 
recognition modelling was used. 
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
142 
 
 
 
  
ORIGINAL GEL IMAGES (Slightly corrected for distortion) 
Gel 1 Gel 2 Gel 3 
LANE DATA AFTER REGISTRATION AND NORMALIZATION 
Lane Number Lane Number Lane Number 
Red arrows 
show the 
reference 
band 
Pixel 
Scale 
Pixel 
Scale 
 
 
Alignment check on the 
12 reference lanes 
Figure 3.3.1 - Alignment and normalization of data generated from PCR-DGGE of healthy and constipated faecal samples 
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   Controls   
   Patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  The cross validated success rate in classification = 77% 
  
Figure 3.3.2 – Cross-validated PLS scores (normalised 
dataset) of DGGE-PCR Data.  
The control group consisted of 19 healthy female subjects vs. 
20 subjects with constipation. One lane in the healthy group 
failed to run correctly and was excluded 
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0 
Weight 
vector 
 
 
-ve  
Indicates bands 
associated more 
with the 
‘healthy’ group 
+ve  
Indicates bands 
associated more with 
the ‘constipated’ 
group 
The band most associated with 
the ‘constipated’ group is 
indicated with the red arrows 
(at index ~650). This band is 
very weak in most of the 
healthy subjects. It is also the 
only band to show a significant 
(p<0.01) difference between 
groups in a univariate test 
(Kruskal-Wallis, see figure 4). 
Figure 3.3.3 – Comparison of band intensity 
between the two groups following PCR-DGGE 
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A Kruskal-Wallis test looking for differences between groups was applied separately to each 
row in the profile matrices. The only band to show even an uncorrected p-value less than 0.01 
was that at index 644 
 
  
Normalised 
Intensity 
Figure 3.3.4 – Box-Plot for data at index 644 as 
described in Figure 3.3.3 
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3.3.3 ANALYSIS OF MICROBIOTA COMPOSITION USING FISH 
Samples from eight healthy volunteers were compared with samples from eight subjects with 
constipation who had given samples for each of the trial periods. Three of the eight trial 
participants had taken Nalcol™ and two of these had a positive response in both periods. Six 
patients took the placebo with no response at the end of period II with only one participant 
having a response after four weeks of Nalcol™ at the end of period III. 
The mean count for each of the bacterial probes was standardised since different volumes of 
probes were used and then converted to a logarithmic scale with the results presented as 
‘log10 cell/g faeces’. The value for each probe was then converted to a ratio:  
    log10 cells/g of faeces for the target probe  
   log10 cells/g of faeces of DAPI 
This allowed comparison between subjects and time periods and the values are shown in table 
3.3.2. 
 
3.3.3.1 Healthy Controls vs. Constipated subjects (Period I – Screening) 
Constipated subjects had a lower ratio of bifidobacteria compared to healthy subjects (0.67 vs. 
0.88, p=0.03) with five of the constipated subjects having bacterial counts below the threshold 
for detection. These were given a mean count of 0.07 per sample (one bacteria detected over 
15 counts) to allow for analysis. If these patients are excluded the ratio changes to 0.93 
compared to 0.88 in the healthy group (p=0.26). There was no statistical difference in the 
counts for the other probes used between the two groups (Bac, p=0.29; Lab, p=0.21; Clos 
p=0.30). This is summarised in table 3.3.2 and figure 3.3.5. 
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  BIF 164 BAC 303 LAB 158 EREC 482 
 
Healthy 
Controls 
(n=8) 
 0.88  
(+/- 0.04) 
0.92 
(+/- 0.02) 
0.82 
(+/- 0.02) 
0.86  
(+/- 0.11) 
Constipated 
Subjects 
(n=8) 
Period I 0.67  
(+/- 0.23) 
0.93 
(+/- 0.02) 
0.81 
(+/- 0.02) 
0.9 
(+/- 0.03) 
Period II 0.70 
(+/- 0.15) 
0.93 
(+/- 0.01) 
0.81 
(+/- 0.09) 
0.91 
(+/- 0.04) 
Period III 0.75 
(+/- 0.16) 
0.94 
(+/- 0.01) 
0.81 
(+/- 0.04) 
0.91 
(+/- 0.01) 
 
DAPI - Total DNA, BIF 164 - Bifidobacterium spp., BAC 303 - Bacteroides spp.,  
LAB 158 - Lactobacillus / enterococcus, Erec 482 - C.coccoides-Eubacterium rectale gp.  
 
  Table 3.3.2 – ratio of probe/DAPI (+/-s.d.) for each period following FISH analysis 
comparing healthy samples (n=8) against sufferers of functional constipation 
enrolled in the Nalcol™ drug trial (n=8). 
Constipated subjects had a lower ratio of bifidobacteria compared to healthy 
subjects (0.67 vs. 0.88, p=0.03) with five of the constipated subjects having 
bacterial counts below the threshold for detection. There were no significant 
changes to any of the counts over the three study periods. 
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Figure 3.3.5 - Ratio of probe/DAPI for each period following FISH analysis comparing 
healthy samples against sufferers of functional constipation enrolled in the Nalcol™ drug 
trial. 
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3.3.3.2 Controls vs. Nalcol vs. Placebo (Period II) 
This was a four week period where patients were randomised to either Nalcol™ or Placebo in a 
double blind fashion. To assess if the trial drug had any impact on the microbiota of the 
subjects, a comparison was made between healthy controls, subjects who took Nalcol™ for 
four weeks, and those who were randomised to take the placebo (Figure 3.3.6 and Table 3.3.3). 
The three patients who had taken Nalcol, two of whom had a response, had a bifidobacteria 
ratio closer to that of the healthy subjects (0.82 vs. 0.88, p=0.62) compared to those on the 
placebo (0.61 vs. 0.88, p>0.0001). However these bifidobacteria ratios were not significantly 
different to the baseline ratios taken from the samples given at the end of Period I (Nalcol, 0.79 
vs. 0.81, p=0.88, Placebo, 0.57 vs. 0.61, p=0.65). There was no significant difference in the 
ratios for the other probes at the end of period II. 
 
3.3.3.3 Controls vs. Nalcol™ (Period III) 
This was an open label period where all subjects had taken Nalcol for at least 4 weeks at the 
end of period III. There were no significant changes in the bifidobacteria / DAPI ratios at 
baseline compared to the end of period III. There was no significant change in the other probes 
analysed (Figure 3.3.7) 
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Figure 3.3.6 - ratio of probe/DAPI following FISH analysis comparing healthy 
samples against subjects who had taken Nalcol™ for 4 weeks and those who 
took placebo (Period II) 
The three patients who had taken Nalcol, two of whom had a response, had a 
bifidobacteria ratio closer to that of the healthy subjects (0.82 vs. 0.88, p=0.62) 
compared to those on the placebo (0.61 vs. 0.88, p>0.0001). However these 
bifidobacteria ratios were not significantly different to the baseline ratios taken 
from the samples given at the end of Period I (Nalcol, 0.79 vs. 0.81, p=0.88, 
Placebo, 0.57 vs. 0.61, p=0.65). There was no significant difference in the ratios 
for the other probes at the end of period II. 
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 BIF 164 BAC 303 LAB 158 EREC 482 
 
Healthy Controls 
 
 
0.88  
(+/- 0.04) 
0.92 
(+/- 0.02) 
0.82 
(+/- 0.02) 
0.86  
(+/- 0.11) 
Baseline count for patients 
who took Nalcol in period II  
 
0.79  
(+/- 0.27) 
0.92 
(+/- 0.01) 
0.80 
(+/- 0.02) 
0.88 
(+/- 0.02) 
Baseline count for patients 
who took Placebo in period II  
 
0.57 
(+/- 0.19) 
0.93 
(+/- 0.02) 
0.82 
(+/- 0.02) 
0.91 
(+/- 0.03) 
Randomised to Nalcol in 
Period II 
 
0.81 
(+/- 0.18) 
0.92 
(+/- 0.01) 
0.86 
(+/- 0.01) 
0.91 
(+/- 0.05) 
Randomised to Placebo in 
Period II 
0.61 
(+/- 0.01) 
0.93 
(+/- 0.02) 
0.79 
(+/- 0.12) 
0.92 
(+/- 0.03) 
 
 
  
Table 3.3.3 - ratio of probe/DAPI (+/- s.d.) following FISH analysis comparing 
healthy samples against subjects who had taken Nalcol for 4 weeks and those 
who took placebo during Period II 
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Figure 3.3.7 – ratio of probe/DAPI following FISH analysis comparing healthy samples against 
periods I and III of the Nalcol™ drug trial 
This was an open label period where all subjects had taken Nalcol for at least 4 weeks at the 
end of period III. There were no significant changes in the bifidobacteria / DAPI ratios at 
baseline compared to the end of period III. There was no significant change in the other 
probes analysed. 
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3.3.4 ANALYSIS OF MICROBIOTA COMPOSITION USING 454 PYROSEQUENCING 
In total 48 samples were sent for 16S rDNA sequencing which included 16 healthy samples, 16 
constipated subjects taken at the end of Period I, eight samples taken at the end of period II 
and eight at the end period III.  Rarefaction curves were plotted to determine sample richness 
and adequacy of sampling in the population (figure 3.3.8) and the data was denoised in an 
attempt to reduce sequencing errors. After analysis of the curves it was decided to use a 
rarefaction level of 1846. This excluded five samples from the constipated group sampled at 
the end of period I and two samples from the healthy group. 
At the phylum level there was a significant decrease in the proportion of Firmicutes (25% vs. 
45%, p=0.004) and a significant increase in the proportion of Bacteroidetes (66% vs. 41%, 
p=0.002) in the constipated group compared to healthy individuals (Table 3.3.4, Figure 3.3.9). 
There were no other differences seen between the two groups at the phylum level. The 
Bacteroidetes and Firmicutes made up 91% of the phyla detected in the constipated subjects 
and 86% of those in the healthy population (p=0.38). The difference in the constipated subjects 
in the Firmicutes phylum was secondary to a significant reduction in the clostridia class (25% 
vs. 45%, p=0.004) whilst the difference seen in the bacteroidetes phylum was due to a 
significant increase in the bacteroidia class compared to healthy volunteers (66% vs. 41%, 
p=0.002). Other differences were noted between the ML615J-28, mollicutes, and Erysipelotrichi 
classes of the tenericutes phylum in the two groups but these were either not significant or 
were of a low abundance (Table 3.3.5).  
At the order level the bacteroidales (phylum – bacteroidetes) is significantly greater in the 
constipated subjects compared to the healthy individuals (66% vs. 41%, p=0.002) with the 
decreases seen in the firmicute phylum in constipated subjects are due to a reduction in the 
clostridiales order (24% vs 45%, p=0.003). Again other differences between the two groups 
were noted but were either not significant or of low abundance (Table 3.3.6). Analysis at the 
family level demonstrated that both porphyromonadaceae (3.5% vs. 1.6%, p =0.007) and 
rikenellaceae (22% vs. 9%, p=0.010) were responsible for the increase in the bacteroidetes 
phylum (Table 3.3.7, Figure 3.3.10). The decrease in the clostridia (continued on page 163......)  
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Rarefaction curves were plotted to determine sample richness and adequacy of sampling in the population. After analysis of the curves it was 
decided to use a rarefaction level of 1846. This excluded five samples from the constipated group sampled at the end of period I and two 
samples from the healthy group 
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Figure 3.3.8 - Rarefaction Curves of the denoised 
data following 454 sequencing 
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 *p<0.005. The increase in the Bacteroidetes phylum and the decrease in Firmicutes  
 phylum in constipated subjects were significant (p=0.002 and 0.004 respectively). 
  
Phyla  Mean percentage of 
bacteria in faecal samples 
of constipated subjects  
(+/- s.d)  N=11  
Mean percentage of 
bacteria in faecal 
samples of healthy 
subjects (+/- s.d)  N=14   
P value 
Other 0.2 (+/- 0.3) 0.8 (+/- 1.5) 0.18 
Actinobacteria 0.3 (+/- 0.8) 0.2 (+/- 0.2) 0.56 
Bacteroidetes* 65.9 (+/-17.5) 40.9 (+/- 18.0) 0.002 
Cyanobacteria 0.1 (+/- 0.2) 0.1 (+/- 0.2) 0.71 
Firmicutes* 24.6 (+/- 12.9) 45.1 (+/- 18.6) 0.004 
Fusobacteria 0.0 (+/- 0.00) 0.0 (+/- 0.0) 0.34 
Lentisphaerae 0.0 (+/- 0.00) 0.1 (+/- 0.0) 0.11 
Proteobacteria 2.8 (+/- 3.6) 3.1 (+/- 4.6) 0.83 
Synergistetes 0.0(+/- 0.00) 0.0 (+/- 0.0) 0.34 
Tenericutes 6.2 (+/- 7.7) 9.7 (+/- 7.3) 0.25 
Verrucomicrobia 0.0 (+/- 0.00) 0.0 (+/- 0.0) 0.87 
Table 3.3.4 – Comparison of the percentage of bacteria (%) at the phylum level in 
healthy and constipated subjects who underwent pyrosequencing.  
Samples from 16 healthy individuals and 16 constipated individuals were sent for 
16S rDNA sequencing taken at the end of Period I but after exclusion based on 
the rarefaction curve five samples were excluded from the constipated group 
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 The increase in the Bacteroidetes phylum and the decrease in Firmicutes phylum in  
 constipated subjects were significant (p=0.002 and 0.004 respectively). 
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Figure 3.3.9 - Comparison of the percentage of bacteria (%) at the phylum level in healthy 
and constipated subjects who underwent pyrosequencing. 
Samples from 16 healthy individuals and 16 constipated individuals were sent for 16S rDNA 
sequencing taken at the end of Period I but after exclusion based on the rarefaction curve 
five samples were excluded from the constipated group (n=11) and two from the healthy 
population (n=14)   
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Phyla Class 
Mean percentage 
of bacteria in 
faecal samples of 
constipated 
subjects (+/- s.d)  
N=11 
Mean percentage 
of bacteria in 
faecal samples of 
healthy subjects 
(+/- s.d)  N=14   
p-value 
1 Other Other 0.2 (+/- 0.3) 0.8 (+/- 0.015) 0.18 
2 Actinobacteria Actinobacteria 0.3 (+/- 0.8) 0.2 (+/- 0.002) 0.56 
3 Bacteroidetes* Bacteroidia  65.9 (+/- 17.5) 40.9 (+/- 0.180) 0.002 
4 Cyanobacteria 4C0d-2 0.1 (+/- 0.2) 0.1 (+/- 0.002) 0.62 
5 Cyanobacteria Chloroplast 0.0 (+/- 0.0) 0.0 (+/- 0.000) 0.34 
6 Firmicutes Bacilli 0.1 (+/- 0.1) 0.1 (+/- 0.001) 0.65 
7 Firmicutes* Clostridia  24.5 (+/- 12.9) 45.0 (+/- 0.185) 0.004 
8 Fusobacteria Fusobacteria 0.0 (+/- 0.0) 0.0 (+/- 0.000) 0.34 
9 Lentisphaerae Lentisphaerae 0.0 (+/- 0.0) 0.1 (+/- 0.002) 0.11 
10 Proteobacteria Alphaproteobacteria 1.5 (+/- 3.1) 1.3 (+/- 0.029) 0.90 
11 Proteobacteria Betaproteobacteria 1.0 (+/- 0.9) 1.5 (+/- 0.019) 0.38 
12 Proteobacteria Gammaproteobacteria 0.2 (+/- 0.5) 0.2 (+/- 0.005) 0.99 
13 Synergistetes Synergistia 0.0 (+/- 0.0) 0.0 (+/- 0.000) 0.34 
14 Tenericutes Other 0.0 (+/- 0.0) 0.0 (+/- 0.000) 0.34 
15 Tenericutes Erysipelotrichi 2.7 (+/- 4.6) 1.0 (+/- 0.010) 0.25 
16 Tenericutes* ML615J-28  0.0 (+/- 0.1) 0.4 (+/- 0.007) 0.037 
17 Tenericutes Mollicutes 3.5 (+/- 6.3) 8.3 (+/- 0.065) 0.07 
18 Verrucomicrobia Verrucomicrobiae 0.0 (+/- 0.0) 0.0 (+/- 0.000) 0.87 
* p< 0.05. The difference in the constipated subjects in the firmicute phylum was secondary to 
a significant reduction in the clostridia class (25% vs. 45%, p=0.004) whilst the difference seen 
in the bacteroides phylum was due to a significant increase in the bacteroidetes class compared 
to healthy volunteers (66% vs. 41%, p=0.002). 
  Table 3.3.5 - Comparison of the percentage of bacteria (%) at the class level in healthy and 
constipated subjects who underwent pyrosequencing  
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Phyla Class Order 
Mean percentage of bacteria 
in faecal samples of 
constipated subjects (+/- s.d)  
N=11   
Mean percentage of 
bacteria in faecal samples 
of healthy subjects (+/- 
s.d)  N=14   
P value 
1 Other Other Other 0.2 (+/- 0.3) 0.8 (+/- 1.5) 0.18 
2 Actinobacteria Actinobacteria Actinomycetales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.49 
3 Actinobacteria Actinobacteria Coriobacteriales 0.3 (+/- 0.8) 0.2 (+/- 0.2) 0.59 
4 Bacteroidetes* Bacteroidia Bacteroidales 65.9 (+/- 1.75) 40.9 (+/- 18) 0.002 
5 Cyanobacteria 4C0d-2 YS2 0.1 (+/- 0.2) 0.1 (+/- 0.2) 0.62 
6 Cyanobacteria Chloroplast Streptophyta 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
7 Firmicutes Bacilli Bacillales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.06 
8 Firmicutes Bacilli Lactobacillales 0.1 (+/- 0.0) 0.1 (+/- 0.1) 0.77 
9 Firmicutes Bacilli Turicibacterales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
10 Firmicutes Clostridia Other 0.0 (+/- 0.1) 0.0 (+/- 0.1) 0.56 
11 Firmicutes* Clostridia  Clostridiales 24.5 (+/- 12.9) 45.0 (+/- 18.5) 0.003 
12 Fusobacteria Fusobacteria Fusobacteriales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
13 Lentisphaerae Lentisphaerae Victivallales 0.0 (+/- 0.0) 0.1 (+/- 0.2) 0.11 
14 Proteobacteria Alphaproteobacteria ----- 1.5 (+/- 3.1) 1.3 (+/- 2.9) 0.90 
15 Proteobacteria Betaproteobacteria Burkholderiales 1.0 (+/- 0.9) 1.5 (+/- 1.9) 0.38 
16 Proteobacteria Gammaproteobacteria Enterobacteriales 0.2 (+/- 0.5) 0.0 (+/- 0.0) 0.17 
17 Proteobacteria Gammaproteobacteria Pasteurellales 0.0 (+/- 0.0) 0.2 (+/- 0.5) 0.12 
18 Proteobacteria Gammaproteobacteria Pseudomonadales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
19 Synergistetes Synergistia Synergistales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
20 Tenericutes Other Other 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
21 Tenericutes Erysipelotrichi Erysipelotrichales 2.7 (+/- 4.6) 1.0 (+/- 1.0) 0.25 
22 Tenericutes* ML615J-28  ----- 0.0 (+/- 0.1) 0.4 (+/- 0.7) 0.037 
23 Tenericutes Mollicutes Anaeroplasmatales 0.0 (+/- 0.0) 0.0 (+/- 0.1) 0.54 
24 Tenericutes Mollicutes RF39 ----- 3.5 (+/- 6.3) 8.3 (+/- 6.5) 0.08 
25 Verrucomicrobia Verrucomicrobiae Verrucomicrobiales 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.87 
 
Table 3.3.6   Comparison of the percentage of bacteria at the order level in healthy and constipated subjects who 
  underwent pyrosequencing. * p>0.05. Significant differences were seen in the bacteroidales order 
  (66% vs. 41%, p=0.002) and the Clostridales order (25% vs. 45%, p=0.003). 
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Phyla Class Order Family 
Mean percentage of 
bacteria in faecal samples 
of constipated subjects (+/- 
s.d)  N=11   
Mean percentage of 
bacteria in faecal 
samples of healthy 
subjects (+/- s.d)  N=14   
P value 
1 Other Other Other Other 0.2 (+/- 0.3) 0.8 (+/- 1.5) 0.18 
2 Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.76 
3 Actinobacteria Actinobacteria Actinomycetales Corynebacteriaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
4 Actinobacteria Actinobacteria Coriobacteriales ---- 0.3 (+/- 0.8) 0.1 (+/- 0.2) 0.47 
5 Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae 0.0 (+/- 0.0) 0.1 (+/- 0.1) 0.09 
6 Bacteroidetes Bacteroidia Bacteroidales Other 0.7 (+/- 1.0) 0.5 (+/- 0.6) 0.53 
7 Bacteroidetes* Bacteroidia Bacteroidales ----- 3.3 (+/- 3.3) 6.6 (+/- 5.3) 0.07 
8 Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae 36.3 (+/- 22.3) 20.2 (+/- 13.7) 0.05 
9 Bacteroidetes* Bacteroidia Bacteroidales Porphyromonadaceae 3.5 (+/- 1.8) 1.6 (+/- 1.3) 0.007 
10 Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae 0.1 (+/- 0.1) 2.9 (+/- 6.4) 0.13 
11 Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae 21.9 (+/- 12.7) 9.2 (+/- 7.3) 0.010 
12 Cyanobacteria 4C0d-2 YS2 ----- 0.1 (+/- 0.2) 0.1 (+/- 0.2) 0.62 
13 Cyanobacteria Chloroplast Streptophyta ----- 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
14 Firmicutes Bacilli Bacillales Other 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.06 
15 Firmicutes Bacilli Lactobacillales Lactobacillaceae 0.0 (+/- 0.0) 0.0 (+/- 0.1) 0.79 
16 Firmicutes Bacilli Lactobacillales Leuconostocaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
17 Firmicutes Bacilli Lactobacillales Streptococcaceae 0.0 (+/- 0.0) 0.0 (+/- 0.1) 0.74 
18 Firmicutes Bacilli Turicibacterales Turicibacteraceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
19 Firmicutes Clostridia Other Other 0.0 (+/- 0.1) 0.0 (+/- 0.1) 0.56 
20 Firmicutes Clostridia  Clostridiales Other 0.5 (+/-0.8) 0.7 (+/- 1.1) 0.60 
21 Firmicutes Clostridia  Clostridiales ----- 3.3 (+/- 3.8) 5.0 (+/- 6.0) 0.40 
Table 3.3.7 – Comparison of the percentage of bacteria at the family level in healthy and constipated subjects (Divided into three parts on pages 159 – 161). 
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Phyla Class Order Family 
Mean percentage of 
bacteria in faecal samples of 
constipated subjects (+/- s.d)  
N=11   
Mean percentage of 
bacteria in faecal 
samples of healthy 
subjects (+/- s.d)  N=14   
p value 
22 Firmicutes Clostridia  Clostridiales Catabacteriaceae 0.4 (+/- 0.5) 1.1 (+/- 1.5) 0.11 
23 Firmicutes Clostridia  Clostridiales Clostridiaceae 0.1 (+/- 0.4) 0.2 (+/- 0.3) 0.50 
24 Firmicutes Clostridia  Clostridiales Clostridiales Family XI. Incertae Sedis 0.0 (+/- 0.1) 0.0 (+/- 0.0) 0.47 
25 Firmicutes Clostridia  Clostridiales Clostridiales Family XIII. Incertae Sedis 0.0 (+/- 0.1) 0.1 (+/- 0.2)  0.06 
26 Firmicutes Clostridia  Clostridiales Dehalobacteriaceae 0.0 (+/- 0.0) 0.0 (+/- 0.1) 0.09 
27 Firmicutes Clostridia  Clostridiales Eubacteriaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.43 
28 Firmicutes Clostridia  Clostridiales Lachnospiraceae 8.5 (+/- 6.7) 12.0 (+/- 6.9) 0.23 
29 Firmicutes Clostridia  Clostridiales Peptococcaceae 0.0 (+/- 0.1) 0.0 (+/- 0.0) 0.90 
30 Firmicutes Clostridia  Clostridiales Peptostreptococcaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.22 
31 Firmicutes Clostridia  Clostridiales Ruminococcaceae 11.0 (+/- 5.1) 14.4 (+/- 5.5) 0.12 
32 Firmicutes* Clostridia  Clostridiales Veillonellaceae 0.6 (+/- 0.9) 11.4 (+/- 14.7) 0.016 
33 Fusobacteria Fusobacteria Fusobacteriales Fusobacteriaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
34 Lentisphaerae Lentisphaerae Victivallales Other 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
35 Lentisphaerae Lentisphaerae Victivallales Victivallaceae 0.0 (+/- 0.0) 0.1 (+/- 0.2) 0.10 
36 Proteobacteria Alphaproteobacteria ----- ----- 1.5 (+/- 3.1) 1.3 (+/- 2.9) 0.90 
37 Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae 1.0 (+/- 0.9) 1.5 (+/- 1.9) 0.40 
38 Proteobacteria Betaproteobacteria Burkholderiales Oxalobacteraceae 0.0 (+/- 0.0) 0.1 (+/- 0.1) 0.15 
39 Proteobacteria Gammaproteobacteria Enterobacteriales Enterobacteriaceae 0.2 (+/- 0.5) 0.0 (+/- 0.0) 0.17 
40 Proteobacteria Gammaproteobacteria Pasteurellales Pasteurellaceae 0.0 (+/- 0.0) 0.2 (+/- 0.5) 0.12 
41 Proteobacteria Gammaproteobacteria Pseudomonadales Pseudomonadaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
42 Synergistetes Synergistia Synergistales Dethiosulfovibrionaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.34 
43 Tenericutes Other Other Other 0.0 (+/- 0.0) 0.0 +/- (0.0) 0.34 
Continuation of table 3.3.7 
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* - p < 0.05. In the bacteroidetes phylum, Porphyromonadaceae and Rikenellaceae were significantly increased in constipated subjects. In the clostridia 
phylum, Veillonellaceae was significantly reduced in constipated subjects compared to healthy subjects. 
  
 
Phyla Class Order Family 
Mean percentage of 
bacteria in faecal samples of 
constipated subjects (+/- s.d)  
N=11   
Mean percentage of 
bacteria in faecal 
samples of healthy 
subjects (+/- s.d)  N=14   
p value 
44 Tenericutes Erysipelotrichi Erysipelotrichales Erysipelotrichaceae 2.7 (+/- 4.6) 1.0 (+/- 1.0) 0.25 
45 Tenericutes Erysipelotrichi Erysipelotrichales vadinHA31 0.0 (+/- 0.0) 0.0 (+/- 0.1) 0.24 
46 Tenericutes* ML615J-28  ----- ----- 0.0 (+/- 0.1) 0.4 (+/- 0.7) 0.037 
47 Tenericutes Mollicutes Anaeroplasmatales Anaeroplasmataceae 0.0 (+/- 0.0) 0.0 (+/- 0.1) 0.54 
48 Tenericutes Mollicutes RF39 ----- ----- 3.5 (+/- 6.3) 8.3 (+/- 6.5) 0.08 
49 Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Verrucomicrobiaceae 0.0 (+/- 0.0) 0.0 (+/- 0.0) 0.87 
 
Continuation of table 3.3.7 
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Figure 3.3.10 – Comparison of the mean percentage of the bacteroidetes phylum in 
constipated and healthy subjects when viewed at the family level who underwent 
pyrosequencing. 
In the bacteroidetes phylum, Porphyromonadaceae (3.5% vs. 1.6%, p=0.007) and 
Rikenellaceae  (2.2% vs. 9.2%,  p=0.01) were significantly increased in constipated 
subjects.  
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class in constipated subjects was as a results of an almost 20x decrease in veillonellaceae (0.6% 
vs. 11%, p=0.016), however all family members of the clostridia class are either lower or equal 
in constipated subjects compared to the healthy population (Table 3.3.7, Figure 3.3.11). Again 
there were no significant differences except in the tenericutes phyla but these were of low 
abundance.  
There were several genera that were significantly reduced or increased in the constipated 
group compared to the healthy group. In the bacteroidetes phylum of constipated subjects 
there were significant increases in the Odoribacter (% vs. 0.55%, p=0.02), Parabacteroides 
(2.21% vs. 1.10%, p=0.04), and Alistipes (20.05% vs. 8.16%, p=0.01) genera. In the Firmicutes 
phylum there were significant decreases in the Oscillospira (0.52% vs. 1.33%, p=0.007) and 
Dialister (0.44% vs. 11.14%, p=0.02) genera. Other changes in the microbiotra at a genus level 
are shown in table 3.3.8. 
 Analysis was undertaken on the samples provided from the constipated subjects who gave a 
sample at the end of each period (n=8). The baseline samples did not differ in these 8 subjects 
from the constipated group as a whole (n=11) and as such there was no difference other than 
that already described above when compared to healthy subjects. There was also no change in 
the composition of the microbiota of the subjects over the 10 week trial period, despite the 
use of Nalcol for in all subjects for four weeks during period III. The data for these analyses is 
not shown. 
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Figure 3.3.11 - Comparison of 
the mean percentage of the 
clostridia class in constipated 
and healthy subjects after 
pyrosequencing  when 
viewed at the family level  
In the clostridia phylum, 
Veillonellaceae (0.6% vs. 
11.4%, p= 0.016) was 
significantly reduced in 
constipated subjects 
compared to healthy subjects. 
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Phyla Class Order Family Genus Mean percentage 
of bacteria in 
faecal samples of 
constipated 
subjects  (+/- s.d)  
N=11  
Mean percentage 
of bacteria in 
faecal samples of 
healthy subjects 
(+/- s.d)  N=14   
P Value 
Other Other Other Other Other 0.16 (+/- 0.32) 0.73 (+/- 1.41) 0.16 
Actinobacteria Actinobacteria Actinomycetales Actinomycetaceae Actinomyces 0.00 (+/- 0.02) 0.01 (+/- 0.02) 0.70 
Actinobacteria Actinobacteria Actinomycetales Corynebacteriaceae Corynebacterium 0.01 (+/- 0.05) 0.00 (+/- 0.00) 0.34 
Actinobacteria Actinobacteria Coriobacteriales ----- ----- 0.32 (+/- 0.81) 0.13 (+/- 0.17) 0.47 
Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae Adlercreutzia 0.02 (+/- 0.04) 0.06 (+/- 0.13) 0.30 
Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae Collinsella 0.00 (+/- 0.00) 0.00 (+/- 0.01) 0.34 
Actinobacteria Actinobacteria Coriobacteriales Coriobacteriaceae Eggerthella 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
Bacteroidetes Bacteroidia Bacteroidales Other Other 0.02 (+/- 0.06) 0.05 (+/- 0.10) 0.32 
Bacteroidetes Bacteroidia Bacteroidales ----- ----- 4.06 (+/- 4.09) 7.00 (+/- 5.54) 0.14 
Bacteroidetes Bacteroidia Bacteroidales Bacteroidaceae Bacteroides 36.35 (+/- 22.75) 20.08 (+/- 13.56) 0.05 
Bacteroidetes* Bacteroidia Bacteroidales Porphyromonadaceae  Odoribacter 1.38 (+/- 0.93) 0.55 (+/- 0.49) 0.02 
Bacteroidetes* Bacteroidia Bacteroidales Porphyromonadaceae Parabacteroides  2.21 (+/- 1.44) 1.10 (+/- 0.96) 0.04 
Bacteroidetes Bacteroidia Bacteroidales Porphyromonadaceae Porphyromonas 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae ----- 0.00 (+/- 0.00) 0.41 (+/- 1.55) 0.34 
Bacteroidetes Bacteroidia Bacteroidales Prevotellaceae Prevotella 0.07 (+/- 0.07) 2.62 (+/- 6.76) 0.18 
Bacteroidetes Bacteroidia Bacteroidales Rikenellaceae ----- 1.53 (+/- 1.51) 1.10 (+/- 1.33) 0.46 
Bacteroidetes* Bacteroidia Bacteroidales Rikenellaceae Alistipes  20.05 (+/- 12.47) 8.16 (+/- 6.76) 0.01 
Table 3.3.8 – Comparison of the percentage of bacteria at the genus level in healthy and constipated subjects (Divided into five parts on pages 
165 – 169). 
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Phyla Class Order Family Genus Mean percentage 
of bacteria in 
faecal samples of 
constipated 
subjects  (+/- s.d)  
N=11  
Mean percentage 
of bacteria in 
faecal samples of 
healthy subjects 
(+/- s.d)  N=14   
P Value 
Cyanobacteria 4C0d-2 YS2 ------ ----- 0.04 (+/- 0.13) 0.10 (+/- 0.21) 0.38 
Cyanobacteria Chloroplast Streptophyta ------ ----- 0.01 (+/- 0.03) 0.01 (+/- 0.02) 0.85 
Euryarchaeota Methanobacteria Methanobacteriales Methanobacteriaceae Methanobrevibacter 0.05 (+/- 0.02) 0.05 (+/- 0.01) 0.87 
Firmicutes* Bacilli Bacillales Bacillaceae Bacillus 0.00 (+/- 0.00) 0.04 (+/- 0.06) 0.04 
Firmicutes Bacilli Turicibacterales Turicibacteraceae Other 0.01 (+/- 0.03) 0.00 (+/- 0.00) 0.19 
Firmicutes Clostridia Other Other Other 0.03 (+/- 0.07) 0.01 (+/- 0.04) 0.45 
Firmicutes Clostridia Clostridiales Other Other 0.49 (+/- 0.76) 0.49 (+/- 1.11) 1.00 
Firmicutes Clostridia Clostridiales ------ ----- 3.21 (+/- 3.79) 4.84 (+/- 5.86) 0.41 
Firmicutes Clostridia Clostridiales Catabacteriaceae ----- 0.40 (+/- 0.53) 1.10 (+/- 1.43) 0.11 
Firmicutes Clostridia Clostridiales Clostridiaceae Clostridium 0.13 (+/- 0.30) 0.28 (+/- 0.50) 0.36 
Firmicutes Clostridia Clostridiales ClostridialesFamilyXI.Incertae 
Sedis 
----- 0.03 (+/- 0.07) 0.02 (+/- 0.05) 0.66 
Firmicutes Clostridia Clostridiales ClostridialesFamilyXI.Incertae 
Sedis 
Peptoniphilus 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
Firmicutes Clostridia Clostridiales ClostridialesFamilyXIII.Incertae 
Sedis 
Other 0.00 (+/- 0.00) 0.09 (+/- 0.20) 0.10 
Firmicutes Clostridia Clostridiales ClostridialesFamilyXIII.Incertae 
Sedis 
----- 0.02 (+/- 0.04) 0.06 (+/- 0.08) 0.09 
Firmicutes Clostridia Clostridiales ClostridialesFamilyXIII.Incertae 
Sedis 
Eubacterium 0.04 (+/- 0.06) 0.03 (+/- 0.05) 0.70 
Firmicutes Clostridia Clostridiales Dehalobacteriaceae Dehalobacterium 0.00 (+/- 0.02) 0.02 (+/- 0.05) 0.19 
Firmicutes Clostridia Clostridiales Eubacteriaceae Anaerofustis 0.00 (+/- 0.00) 0.01 (+/- 0.03) 0.19 
Firmicutes Clostridia Clostridiales Eubacteriaceae Eubacterium 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
  
Continuation of Table 3.3.8 
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Phyla Class Order Family Genus Mean percentage 
of bacteria in 
faecal samples of 
constipated 
subjects  (+/- s.d)  
N=11  
Mean percentage 
of bacteria in 
faecal samples of 
healthy subjects 
(+/- s.d)  N=14   
P Value 
Firmicutes Clostridia Clostridiales Lachnospiraceae Other 0.59 (+/- 0.67) 0.82 (+/- 1.24) 0.56 
Firmicutes Clostridia Clostridiales Lachnospiraceae ----- 0.64 (+/- 0.91) 1.87 (+/- 2.27) 0.08 
Firmicutes Clostridia Clostridiales Lachnospiraceae Blautia 0.75 (+/- 0.99) 0.26 (+/- 0.31) 0.14 
Firmicutes Clostridia Clostridiales Lachnospiraceae Clostridium 1.99 (+/- 1.3) 2.57 (+/- 01.62) 0.33 
Firmicutes Clostridia Clostridiales Lachnospiraceae Coprococcus 0.43 (+/- 0.53) 0.46 (+/- 0.35) 0.91 
Firmicutes Clostridia Clostridiales Lachnospiraceae Eubacterium 0.37 (+/- 0.52) 0.29 (+/- 0.27) 0.66 
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnobacterium 0.03 (+/- 0.11) 0.23 (+/- 0.5) 0.19 
Firmicutes Clostridia Clostridiales Lachnospiraceae Lachnospira 1.39 (+/- 2.05) 2.61 (+/- 3.02) 0.24 
Firmicutes Clostridia Clostridiales Lachnospiraceae Roseburia 1.91 (+/- 1.83) 2.43 (+/- 2.54) 0.56 
Firmicutes Clostridia Clostridiales Lachnospiraceae Ruminococcus 0.48 (+/- 0.84) 0.16 (+/- 0.18) 0.24 
Firmicutes Clostridia Clostridiales Peptococcaceae ----- 0.04 (+/- 0.07) 0.04 (+/- 0.06) 0.91 
Firmicutes Clostridia Clostridiales Ruminococcaceae Other 0.95 (+/- 0.50) 1.41 (+/- 1.26) 0.23 
Firmicutes Clostridia Clostridiales Ruminococcaceae ----- 2.50 (+/- 1.37) 4.24 (+/- 3.44) 0.10 
Firmicutes Clostridia Clostridiales Ruminococcaceae Acetivibrio 0.00 (+/- 0.00) 0.06 (+/- 0.17) 0.23 
Firmicutes Clostridia Clostridiales Ruminococcaceae Anaerotruncus 0.06 (+/- 0.08) 0.04 (+/- 0.04) 0.48 
Firmicutes Clostridia Clostridiales Ruminococcaceae Clostridium 0.50 (+/- 0.60) 0.25 (+/- 0.27) 0.22 
Firmicutes Clostridia Clostridiales Ruminococcaceae Eubacterium 0.29 (+/- 0.63) 0.06 (+/- 0.10) 0.27 
Firmicutes Clostridia Clostridiales Ruminococcaceae Faecalibacterium 3.72 (+/- 2.81) 3.36 (+/- 3.37) 0.78 
Firmicutes* Clostridia Clostridiales Ruminococcaceae  Oscillospira 0.52 (+/- 0.62) 1.33 (+/- 0.76) 0.007 
Firmicutes Clostridia Clostridiales Ruminococcaceae Ruminococcus 1.02 (+/- 1.83) 1.20 (+/- 1.78) 0.80 
Firmicutes Clostridia Clostridiales Ruminococcaceae Subdoligranulum 1.54 (+/- 2.06) 2.64 (+/- 3.91) 0.37 
 
Continuation of Table 3.3.8 
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Phyla Class Order Family Genus Mean percentage 
of bacteria in faecal 
samples of 
constipated 
subjects  (+/- s.d)  
N=11  
Mean percentage 
of bacteria in 
faecal samples of 
healthy subjects 
(+/- s.d)  N=14   
P Value 
Firmicutes Clostridia Clostridiales Veillonellaceae ------ 0.09 (+/- 0.29) 0.15 (+/- 0.46) 0.70 
Firmicutes* Clostridia Clostridiales Veillonellaceae Dialister  0.44 (+/- 0.85) 11.14 (+/- 14.69) 0.02 
Firmicutes Clostridia Clostridiales Veillonellaceae Veillonella 0.02 (+/- 0.04) 0.09 (+/- 0.14) 0.10 
Fusobacteria Fusobacteria Fusobacteriales Fusobacteriaceae Fusobacterium 0.01 (+/- 0.02) 0.00 (+/- 0.00) 0.17 
Lentisphaerae Lentisphaerae Victivallales Victivallaceae ----- 0.00 (+/- 0.020 0.07 (+/- 0.14) 0.12 
Proteobacteria Alphaproteobacteria ----- ----- ----- 1.48 (+/- 2.97) 1.36 (+/- 2.88) 0.92 
Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae ----- 0.49 (+/- 0.79) 0.36 (+/- 0.41) 0.62 
Proteobacteria Betaproteobacteria Burkholderiales Alcaligenaceae Sutterella 0.55 (+/- 0.86) 1.11 (+/- 1.72) 0.30 
Proteobacteria Betaproteobacteria Burkholderiales Oxalobacteraceae Oxalobacter 0.03 (+/- 0.10) 0.06 (+/- 0.12) 0.54 
Proteobacteria Deltaproteobacteria Desulfovibrionales Desulfovibrionaceae Bilophila 0.00 (+/- 0.02) 0.00 (+/- 0.01) 0.87 
Proteobacteria Gammaproteobacteri
a 
Enterobacteriales Enterobacteriaceae Other 0.17 (+/- 0.55) 0.00 (+/- 0.00) 0.34 
Proteobacteria Gammaproteobacteri
a 
Enterobacteriales Enterobacteriaceae Escherichia 0.07 (+/- 0.10) 0.02 (+/- 0.03) 0.14 
Proteobacteria Gammaproteobacteri
a 
Pasteurellales Pasteurellaceae Haemophilus 0.01 (+/- 0.03) 0.23 (+/- 0.49) 0.13 
Proteobacteria Gammaproteobacteri
a 
Pseudomonadales Pseudomonadaceae Pseudomonas 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
Proteobacteria Gammaproteobacteri
a 
Xanthomonadales Xanthomonadaceae Xanthomonas 0.00 (+/- 0.00) 0.00 (+/- 0.01) 0.34 
Synergistetes Synergistia Synergistales Dethiosulfovibrionaceae Pyramidobacter 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
Tenericutes* Other Other Other Other 0.00 (+/- 0.00) 0.02 (+/- 0.03) 0.04 
Tenericutes Erysipelotrich Erysipelotrichales Erysipelotrichaceae ----- 1.65 (+/- 4.11) 0.52 (+/- 1.01) 0.40 
Tenericutes Erysipelotrich Erysipelotrichales Erysipelotrichaceae Clostridium 1.00 (+/- 0.68) 0.46 (+/- 0.65) 0.06 
Continuation of Table 3.3.8 
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Phyla Class Order Family Genus Mean percentage 
of bacteria in 
faecal samples of 
constipated 
subjects  (+/- s.d)  
N=11  
Mean percentage 
of bacteria in 
faecal samples of 
healthy subjects 
(+/- s.d)  N=14   
P Value 
Tenericutes Erysipelotrich Erysipelotrichales Erysipelotrichaceae Coprobacillus 0.01 (+/- 0.02) 0.00 (+/- 0.00) 0.17 
Tenericutes Erysipelotrich Erysipelotrichales Erysipelotrichaceae Holdemania 0.06 (+/- 0.06) 0.02 (+/- 0.03) 0.06 
Tenericutes Erysipelotrich Erysipelotrichales vadinHA31 RFN20 0.00 (+/- 0.00) 0.02 (+/- 0.06) 0.19 
Tenericutes* ML615J-28 ----- ----- ----- 0.03 (+/- 0.11) 0.50 (+/- 0.79) 0.05 
Tenericutes Mollicutes Anaeroplasmatales Anaeroplasmataceae ----- 0.00 (+/- 0.00) 0.04 (+/- 0.16) 0.34 
Tenericutes Mollicutes RF39 ----- ----- 3.43 (+/- 6.22) 8.30 (+/- 6.49) 0.07 
Verrucomicrobia Verrucomicrobiae Verrucomicrobiales Verrucomicrobiaceae Akkermansia 0.00 (+/- 0.02) 0.00 (+/- 0.00) 0.34 
 
*  p>0.05. In the bacteroidetes phylum there were significant differences in the Odoribacter (1.38% vs. 0.55%, p=0.02), Parabacteroides (2.21% 
vs. 1.10%, p=0.04), and Alistipes (20.05% vs. 8.16%, p=0.01) genera. In the Firmicutes phyla there were significant differences in the Oscillospira 
(0.52% vs. 1.33%, p=0.007) and Dialister (0.44% vs. 11.14%, p=0.02) genera. 
Continuation of Table 3.3.8 
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3.4  DISCUSSION OF THE COMPARATIVE ANALYSIS OF THE COMPOSITION OF THE 
 FAECAL MICROBIOTA IN PATIENTS WITH CHRONIC CONSTIPATION AND IN 
 HEALTHY SUBJECTS 
  
3.4.1 SUMMARY OF RESULTS 
The analysis of the samples provided has shown that differences exist between the microbiota 
of healthy and constipated subjects. DGGE has shown that this difference exists in the 
abundance of different organisms but not in a complete absence of one particular organism. 
This was confirmed by supervised modelling carried out on the 454 sequencing data. FISH and 
454 Sequencing has highlighted the differences that exist at various taxonomic levels. FISH 
revealed that constipated subjects have a lower number of bifidobacterium spp. compared to 
healthy subjects with no significant difference in C.coccoides-Eubacterium rectale sp., 
Lactobacillus sp., Enterococcus sp. or Bacteroides spp. 454 sequencing revealed that 
constipated subjects had a significantly lower proportion of the Firmicutes phylum, specifically 
the veillonellaceae family (Clostridia order), and a significant  increase in the bacteroidetes 
phylum, specifically the porphyromonadaceae and rikenellaceae families. There were no 
significant changes in the microbiota of the constipated subjects over the ten week trial period 
on 454 sequencing or FISH analysis.  This demonstrates that the microbiota was stable over the 
trial period and implies that Nalcol™ had no impact on this balance. It may be hypothesised 
that Nalcol™ was not used selectively by some organisms as a substrate or that Nalcol™ had no 
effect on colonic motility and thus further supports the results of the clinical trial.  
 
3.4.2 STRENGTHS AND LIMITATIONS OF THE METHODOLOGY 
The strengths and limitations of methodology are divided into those relating to study design 
and those related to the specific techniques. 
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3.4.2.1 Study Design 
The patients with functional constipation all fulfilled the Rome III criteria (page 11) and had 
undergone investigation to confirm the diagnosis. They represented a closely homogenous 
disease group. Whilst there may be some features consistent with IBS-C in the group this has 
been minimised through the strict screening criteria set out within the clinical trial. The healthy 
controls had all donated samples previously at the IFR, were female, and over the age of 18 
years. All healthy subjects were free of GI disease. The median age of the healthy control group 
is not known and if there was a significant age difference between the two groups this may 
confound the microbiota analysis.  Although age-related changes occur in the microbiota these 
are more striking with advanced age (age > 60 years) and therefore the impact may be less 
significant if the median ages are less than 60 years332,333. The use of antibiotics in the healthy 
group and the individual diet of both groups have also not been controlled for. No patient with 
functional constipation who donated a sample took antibiotics either 4 weeks before the trial 
commenced or during the trial period but this is not certain in the healthy volunteers. With 
respect to the individual diets, all subjects were from the Norfolk area and likely consumed 
produce from the local area or from similar food outlets and whilst there may be some 
individual differences it is unlikely that significant differences exist between the groups which 
have an impact on the microbial analysis. 
Recruitment of case-matched controls would remove the confounding factor of age and 
control for antibiotic use. Control of diet would be more difficult. As discussed in the 
introduction (section 1.8.2.3, page 59), diet modification is a simple measure to improve the 
symptoms of functional constipation which all patients are aware of. Stipulating a change in 
their diets as a prerequisite for stool sampling would be met with resistance and result in a 
reduction of volunteers and therefore not be feasible. Furthermore, controlling for these 
factors is only likely to have an impact on individuals and at the lower orders of the taxonomic 
classification (genus and species). Comparison of the groups and interpretation of the results at 
the phylum and class level are therefore valid. 
The use of laxatives may also impact on the results although to what extent is unclear. 
Increases in bifidobacteria and Eubacterium / Clostridium – coccoides groups have been seen 
following the administration of lactulose in rats and healthy human subjects334,335 whilst 
administration of PEG to rats is associated with a significant decrease in the contribution of 
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Firmicutes (p=0.01) and an increased contribution of Verrucomicrobia  (p=0.01) to the faecal 
flora following analysis with pyrosequencing techniques336. The results from this work however 
showed a reduction in the contribution of bifidobacterium to the colonic microbiota and only 3 
subjects were taking lactulose and therefore its impact is unlikely to be significant. The use of 
PEG may be of more importance. PEG was taken by a 1/3 of subjects (n=6) and this may have 
contributed to the reduction in the proportion of Firmicutes seen in the constipated subjects 
compared to the healthy subjects. When the patients who took PEG were removed from the 
phyla analysis there was still a significant reduction in the number of Firmicutes (24% vs. 45%, 
p=0.004) demonstrating that the reduction in numbers cannot be explained by the use of PEG 
alone. 
 
3.4.2.2 Techniques used to analyse the colonic microbiota 
There are inherent limitations to the techniques used and each has their advantages over the 
next.  
  
3.4.2.2.1 Extraction of DNA from Stool Samples 
All the techniques are limited by the ability to isolate the DNA from the stool sample. The 
extraction of DNA for downstream PCR was carried out with the QIAamp® DNA Stool Mini Kit 
(Qiagen™). This kit has been shown to as effective as the bead-beating method described by 
Stahl et al337 when the product was used for PCR-DGGE analysis338 and in a comparison of five 
methods  for extracting bacterial DNA (including 4 commercial DNA extraction kits) it was the 
most effective extraction method339. It is less effective than commercial kits that incorporated 
a bead-containing lysis matrix340 and therefore use of a hand-held homogeniser aimed to 
compensate for this. In preparation for FISH analysis the use of the hand-held homogeniser 
was also used to further enhance the breakup of the stool samples and dissolution into the PBS 
solution 
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3.4.2.2.2 Inherent Bias in PCR Amplification 
PCR amplification can be a major source of bias.  The quality and the amount of the DNA 
template used, whether is high341 or low342 can adversely affect the PCR product.  The number 
of cycles involved in the PCR reaction is also important with a high number of cycles 
responsible for a loss in the original ratios of the initial concentrations of the template DNA343. 
Low cycle numbers with the lowest annealing temperature possible to allow a reaction that is 
specific and where unspecified products are not observed should also be used344. Optimisation 
of the primer concentrations, annealing temperature, number of amplification cycles and the 
quality of the DNA template will result in a reduction in the number of side products, chimeras, 
heteroduplexes, and single-stranded DNA molecules which will bias further downstream 
analysis341,345,346. Despite optimisation of the above factors there may still be selective 
amplification of DNA with a low-G+C content. High-G+C genes dissociate into single-stranded 
molecules with lower efficacy than low-G+C templates therefore low-G+C templates may be 
over-represented in the population343. This may be remedied by the addition of acetamide to 
the PCR mix to reduce the melting point of the template hybrids and therefore allow high-G+C 
genes to compete more effectively341,347. The methodology for the PCR reaction had been used 
previously in similar work carried out at the laboratory in the IFR with good outcomes. Whilst 
the factors could have been optimised it was not done so for two reasons. Firstly there were 
time constraints that limited the development of a new PCR method and secondly the results 
of the DGGE analysis were qualitative and not quantitative. Any error or bias introduced by the 
PCR reaction would either dilute or exaggerate the differences between the two groups and 
this would be done in an homogenous way such that the overall difference would still be 
apparent. This is also applicable for the downstream analysis performed with pyrosequencing 
such that whilst the differences will be preserved the actual components of each microbiota 
may be influenced. 
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3.4.2.2.3 Strengths and Limitations of DGGE 
DGGE allows rapid analysis of multiple samples and estimations of diversity. It allows the 
monitoring of shifts in communities over time and the fragments excised can be cloned and 
sequence for identification325,348,349. It is able to detect a constituent that represents only 1% of 
the total population325. Using the intensity of the bands it is also able to detect the relative 
abundance of the constituents of the population. For these reasons it was suitable to look for a 
difference in the diversity between the two groups and to allow for analysis of the microbiota 
over the trial period. 
DGGE is not without its limitations however. The technique is difficult to learn and it can be 
difficult to replicate results between gels, furthermore the band position does not provide 
reproducible taxonomic identification. DGGE is also susceptible to the biases inherent in PCR as 
described earlier. These may result in an over estimation of bacterial diversity. Bacterial 
species may display microheterogeneity, i.e. have multiple copies of the 16S rRNA gene. This 
will be represented on DGGE by multiple bands and biasing the true diversity of the 
sample350,351. Also it has been demonstrated that heterologous sequences may migrate the 
same distance i.e. bands at the same position are not necessarily phylogenetically related352,353. 
With these limitations in mind interpretation of the DGGE analysis needs to be taken with 
some care. Whilst the gels have shown a small but statistical difference it is possible that this is 
due to the biases mentioned above or due to the wide variability seen in the colonic microbiota 
of humans. However the samples were randomly distributed amongst the 3 gels and it would 
be expected that any biases would apply to all sequences evenly. In addition the results of the 
pyrosequencing have also shown a clear difference and it can therefore be assumed with a 
degree of confidence that a difference does exist in the composition of the microbiota 
between healthy and constipated subjects based on DGGE analysis. 
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3.4.2.2.4 Strengths and Limitations of FISH 
FISH is a simple technique that can detect single species in an ecosystem and quantify their 
number within it. It can also be used to follow changes in the target organism over time. Its 
reliance on probes however limits its use. The human gut has a complex microbiota which is 
difficult to study and its diversity limits analysis at a species level using FISH due to a lack of 
probes. Diversity can therefore only be reliably measured at a higher taxonomic levels, and 
even then the diversity of the probes is still limited354,355. Furthermore probes are not always 
specific. To detect the bacteria of the CFB phylum, Manz et al356 designed four probes which 
could only discriminate at a group or genus level and with one probe binding to both the 
Bacteroides and Preveotella genera within the bacteroides group. This is also seen with the 
Eubacterium and Clostridium genera which are intertwined and thus genus-specific probes 
cannot be designed. Bacteria need to be present at levels of greater than 106 / ml357 and this, 
along with the lack of available probes, means that only 2/3rd of normal flora can be detected 
using FISH358. 
The methodology of FISH can also limit the reliability of the results for a given probe and these 
are the hybridisation of the probe and the subsequent detection of the hybridised bacteria. For 
the bacteria to be detected the probe needs to hybridise successfully to the 16S rRNA and this 
can be a problem in the cell wall of gram-positive bacteria. The concentration of formamide 
used in the hybridisation step and the concentration of NaCl in the wash solution in the post 
hybridisation step can significantly influence performance359. This, the authors felt, partly 
explained the difference in detection of bacteria in aquatic ecosystems with the EUB338 
oligonucleotide probe from 1% - 100% in the 105 studies they reviewed.  Whilst it has been 
demonstrated that variation exists between sample-to-sample measurements due to uneven 
fluoresence and that variation even exists between cell measurements on different fields on 
the same slide360 this was not a factor in the differences described by Bouvier et al359. The 
differences in FISH protocols amongst the studies in the literature make comparison between 
studies difficult and the results from this work are no different. However the results of this 
study do allow comparison between healthy and constipated subjects and comparison of the 
samples from the constipated subjects over the three periods of the clinical trial. Since the 
same methodology was used for all the samples any bias inherent in the methodology would 
apply equally to all the groups and therefore any difference seen is true.  
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3.4.2.2.5 Technical considerations of pyrosequencing 
Pyrosequencing is a high throughput analysis that allows multiple samples to be sequenced 
simultaneously, generating hundreds of thousands of sequence reads of up to 500 bases which 
can describe the microbiota of the sample down to species level in a short time frame. This 
allows in depth analysis of the sample that the previous methods are unable to perform. Read 
lengths are limited by the number of flow cycles. The 454/Roche GS FLX Titanium platform 
used here is limited to 200 flow cycles which produces average read lengths of 400 bases. The 
limitation in read lengths is due to the limitations imposed by the efficiency of the polymerases 
and luciferases. The simultaneous generation of large numbers of sequence reads from 
multiple samples can be obtained for a relatively low cost compared to other sequencing 
techniques and this cost continues to fall. The advantage of this high number of sequence 
reads is that it allows greater investigation into the sample diversity. This investigation of 
diversity is dependent on the depth of sequencing (number of sequences per sample) and the 
breadth of samples (number of samples sequenced).  A greater depth of sampling will permit 
better coverage of the sample and allow identification of rare species whilst a greater breadth 
of sampling allows more samples to be examined and gives greater statistical confidence on 
the results obtained. However, it is unclear to what depth samples need to be sequenced to 
accurately determine microbial diversity. The abundance of the microbial population is 
comprised of a few species with the majority of the species present in low numbers361 and as a 
result deep sequencing with up to 400 000 sequences is needed to determine diversity or 
differences in an individual sample or closely related community362-364. However if gross 
differences are required or analysis at the higher taxonomic levels then sequencing to a depth 
of 100 – 1000 reads will be sufficient216,217,364,365 but this will negate the effect of the rarer 
species in what are collectively known as the ‘rare biosphere’366. 
The concept of the ‘rare biosphere’ is one that warrants further discussion and the ability to 
sequence at depths is why pyrosequencing is the best tool for the investigation of population 
diversity. Sorgin et al366 demonstrated that the microbial diversity in sea water (through 
pyrosequencing of the V6 hypervariable region) was dominated by a small number of different 
populations and that thousands of low abundance populations accounted for the majority of 
the diversity seen. This rare biosphere, they argued, was largely unexplored and needed 
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further investigation to determine their relationship with the more dominant flora. However it 
is unclear to what extent this ‘rare biosphere’ represents a previously unknown population or 
rare phylotypes as opposed to sequencing errors inherent in the sequencing process.  
Sequencing errors lead to an over estimation of the actual diversity and this was demonstrated 
by Kunin et al367 who used Escherichia coli MG1655 alone as a reference template thereby 
ensuring that all sequence reads from the pyrosequencing should be allocated to the 
Escherichia coli MG1655 phylotype. The downstream analysis correctly assigned 99.97% of the 
sequence data but 3 operational taxonomic units (OTUs) were incorrectly assigned to members 
of the Bacteroidetes, Proteobacteria, and Firmicutes phyla. 
Pyrosequencing is therefore potentially limited by inherent errors in the methodology which 
are broadly categorised into errors introduced by the PCR step and errors introduced by the 
pyrosequencing itself. Factors in the PCR step involve PCR polymerases, chimera formation, 
experimental contamination, and ‘mixed beads’.  The PCR polymerases typically have error 
rates of one substitution per 105 – 106 bases368 and the rate of chimera formation, where 
incomplete PCR products serve as primers to amplify related fragments, is thought to range 
from 5 – 45%369. However there are a number of chimera-checking software programs that 
form part of the downstream processing that are aimed to remove these before final 
analysis369-371. Experimental contamination of the PCR mixture was thought to be responsible 
for the errors introduced in the study by Kunin et al367 and supports the work of Tanner et al372 
which demonstrated that PCR undertaken with no DNA templates still produced rDNA which 
was thought to be secondary to contamination of the reagents used. Following PCR, single 
templates are combined with the emulsion mixture before being deposited in separate wells 
on the picotiter plate. A fraction of these beads will, however, contain multiple copies of the 
PCR templates and the result will be a sequence that does not reflect a true molecule. It is 
again possible to filter these reads out in downstream processing. 
The majority of errors, approximately 40%, introduced during pyrosequencing are due to 
inaccurate reads of homopolymers373-375. Homopolymers are lengths of sequence comprised of 
only one base and there can be ambiguity of the length due to difficulty in resolving the 
intensity of the luminescence produced. This is more likely for large polymers (7 or more 
bases)327. Errors also occur if there are excess or insufficient nucleotides for each flow and are 
collectively known as CAFIE (CArry Forward Incomplete Extension). Carry forward errors occur 
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when flushing between two flows is not sufficient and leftover nucleotides remain within the 
well. These can then bind to the template with luminescence, but for a different nucleotide. 
Incomplete extension occurs when there are insufficient nucleotides within a flow to complete 
the sequence causing a misread. It is estimated that the error rate following pyrosequencing 
approximates at 0.5% comprising insertions (0.18% – 0.27%), deletions (0.13% – 0.23%), 
mismatches (0.02% - 0.09%) and ambiguous base (0.01% - 0.09%)363,373. It is proposed that the 
majority of errors seen are introduced before pyrosequencing and that the basic methodology 
of pyrosequencing is sound373,376. The error rate for test fragments (have not undergone PCR) is 
lower than experimental reads, despite test fragments having extensive homopolymers and 
being difficult to read. Furthermore, the errors in experimental reads are not randomly 
distributed amongst the reads. 86% of reads contained no errors whilst nearly 50% of the 
errors detected were in sequences that differed by more than 4% from the reference 
sequence373. Huse et al373 also showed that the test fragments had a more random distribution 
of errors and demonstrated the difference between experimental and test templates was due 
to ‘mixed beads’ and that these were responsible for the majority of the sequencing errors. 
The detection and removal of the sequencing errors, whatever the cause, are therefore 
important to attain a true picture of the diversity of the sample and the development of 
bioinformatics tools attempts to remove these low-quality reads or ‘noise’. There are three 
general approaches to reduce noise and its’ subsequent effects. 
1. Remove sequences reads that had features suggestive of sequencing errors such as 
ambiguous base calls or shorter or longer reads than expected. Huse et al373 adopted 
this approach and were able to reduce the observed error rate to 0.0016 whilst Schloss 
et al377 reduced the rate to 0.0056 which resulted in the removal of 16% of the 
sequences 
2. Trim the regions with low quality scores. Kunin et al367, who sequenced the 16S RNA 
gene of E.coli only, removed regions with an average quality score of less than 27 
reducing the number of OTUs from 16 to the expected 1 
3. Denoising algorithms. A number of algorithms have been introduced which aim to 
reduce errors associated with both PCR amplification and pyrosequencing. These 
include pyronoise378, Amplicon Noise370, QIIME331, and mothur379. These have all been 
compared extensively by Gaspar and Thomas380 who concluded that whilst the effects 
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of noise are removed it is at the potential expense of changing some of the OTUs from 
1 species to another. 
Using a combination of the above methods and management of errors secondary to PCR 
amplification it is possible to reduce the sequencing error rate by 30-fold (0.006 to 0.0002) and 
the number of chimeric sequences by 10-fold (8% to 1%)379. Despite this however, chimeras 
that could not be detected were largely responsible for the identification of spurious OTUs and 
that the number of spurious OTUs increased with sequencing effort.  
What remains unclear is how the metagenomic study is altered by attempts to remove noise. It 
is likely that denoising produces a substantial decrease in the diversity at both the OTU level 
and in terms of phylogenetic diversity381 but prevents inflated estimates of OTU number and a 
bias towards rare taxa370. It is most likely that the role of denoising needs to be conducted on 
an individual level. It is unlikely to impact on the higher taxonomic levels and may not be 
needed but for a more detailed analysis on diversity denoising needs to be combined with 
more reads on a greater number of samples. 
 
There are two factors that may have influenced the results of the pyrosequencing undertaken 
in this thesis. Firstly was the hypervariable used and secondly the decision to ‘denoise’ the 
sequence reads. The 16S rRNA gene consists of conserved and hypervariable (V1 – V9) regions 
with the length of the hypervariable regions varying between 50 and 100 bases. The human 
microbiome project382 used the V3-V5 region whilst Schmalenberger383 determined that the V4 
– V5 region was the best for detecting members of the CFB group, thought to predominate in 
the colonic microbiota. This is contrary to the findings of Chakravorty et al384 who 
demonstrated that V2, V3, and V6 were the best regions for detecting the 110 bacterial species 
they aimed to identify. Further work has shown that the V3 and V6 regions in combination are 
comparable to full sequence reads385 despite other evidence suggesting that the V6 – V9 
regions yield the lowest proportion of calls at genus level, albeit these regions were similar at 
higher taxonomic levels and the authors admited potentially poor coverage of the V6 region385 . 
Whilst it is clear that no region has received universal acceptance a two-region approach is 
most effective for identification377,386 and the hypervariable region is unlikely to be significant 
when analysing the results at the higher taxonomic levels but may be of importance when 
comparisons are made at lower levels with other studies.  
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The data in this thesis was denoised using QIIME and this may be a source of error. QIIME 
results in 3.5x as many changes as Amplicon Noise and Mothur, which altered the number of 
reads the least380. This may impact on the analysis of the reads at the lower taxonomic levels 
however this is felt to be unlikely. When the data was compared to data that had not been 
denoised there were no statistical differences at the taxonomic levels and this is consistent 
with the results of Reeder and Knight381. 
 
3.4.3 COMPOSITION OF THE COLONIC MICROBIOTA IN HEALTHY SUBJECTS 
Analysis of the pyrosequencing data in this study at a phylum level has demonstrated that 85% 
of colonic microbiota in healthy subjects is comprised of Bacteroidetes (40%) and Firmicutes 
(45%). This is consistent with other studies223,225,387-390. However in all of these studies the 
proportion of Bacteroidetes and Firmicutes differs with the proportion of Bacteroidetes ranging 
from 10%388 to 80%389 and the converse is true for the Firmicutes. In this study similar ratios of 
Bacteroidetes:Firmicutes is seen ranging from 67%:28% to 8%:74% respectively. This wide 
variation has been demonstrated in the Eldermet project391 where the ratio of 
Bacteroidetes:Firmicutes ranged from 90% Bacteroidetes to 85% Firmicutes, highlighting the 
importance of a large cohort size. As with other studies proteobacteria was the other 
predominant phyla but actinobacteria were low in number. The Tenericutes comprised 10% of 
the total microbiota. 
Interpretation of the data at a genus level must be done with reservation for the reasons 
outlined in the section above (Technical considerations of pyrosequencing, page 170). The 
predominant genus determined in this study was bacteroides (phylum Bacteroidetes) and this 
is consistent with that found in other studies388-391. Although the other genera detected in this 
study were also detected in the above studies the relative proportions are different. This 
difference reflects the difficulty in comparing results between studies with different 
populations, different ages, small numbers, and sequencing of different hypervariable regions. 
The clinical significance of these results is unknown. 
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3.4.4 CHANGES IN THE GUT MICROBIOTA IN CONSTIPATION 
The PCR-DGGE analysis demonstrated that a difference exists between the microbiota of the 
two groups but was unable to show specifically which bacteria were responsible for this 
difference. The results of FISH studies demonstrated that the numbers of bifidobacteria were 
significantly reduced in constipated subjects but this could not be confirmed by the results of 
pyrosequencing which did not detect the bifidobacterium genus and noted no significant 
difference in the proportion of actinobacteria (Constipated vs. Healthy; 3% vs. 2%). This 
reduction in bifidobacterium was due to an inability to count any hybridised bacteria in five of 
the eight samples suggesting that the number of bacteria was less than 106 / ml. These results 
cannot be blamed on the methodology as it did not occur in all the constipated subjects and in 
any of the healthy controls. All were subjected to the sample methodology and reagents. 
Therefore it can be reported that constipated subjects do suffer with reduced level of 
bifidobacteria, consistent with other published work. It is a widely held belief that 
bifidobacterium spp. are associated with gut health392 and have been shown to be reduced in 
number in constipated subjects compared to healthy controls293, despite contrary evidence 
showing increased numbers in constipation in children292. The supplementation of 
bifidobacteria in both healthy and constipated subjects has been shown to decrease transit 
time and improve the symptoms of constipation392-396. These effects on transit were not always 
associated with a change in faecal mass or bile acid content suggesting a direct effect on 
colonic motility. The precise mechanism however is not clear. Lactobacillus spp. have also been 
shown, when used as a probiotic, to improve transit time or have a positive effect on the 
symptoms of constipation397, however this study was unable to demonstrate any difference in 
lactobacillus counts following FISH or pyrosequencing and confirmed the findings of 
Banaszkiewicz and Szajewska 398. 
Contrary to the FISH data which was unable to show any further differences in the probes 
selected for analysis the pyrosequencing analysis was able to quantify the changes in the 
microbiota in more detail. This lack of difference following FISH may be due to the low 
numbers of subjects (n=8) compared to pyrosequencing (n=16) and also to the limitations of 
FISH as discussed above (Strengths and Limitations of FISH, page 169). Compared to healthy 
controls there was a significant reduction in the proportion of Firmicutes (24% vs. 45%) with an 
increase in Bacteroidetes (66% vs. 40%) at a phylum level. The two phyla still made up 90% of 
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the total bacteria sequenced with no other significant differences seen. At a genus level there 
were significant increases in bacteroides and alistipes (Phylum Bacteroidetes) with reductions 
in Dialister (Phylum Firmicutes). 
Unfortunately there are no previous studies using pyrosequencing which compare constipated 
subjects with healthy controls and therefore direct comparisons cannot be made. However 
investigation of other conditions, in particular IBS, has been carried out and comparison with 
these is useful. Multiple studies have been unable to demonstrate uniform changes between 
IBS subjects and healthy controls. Reductions in the numbers of bifidobacteria287,289,290, 
Bacteroidetes260,289 whilst increases in Firmicutes, specifically veillonella spp.285,289 have been 
noted. The decrease in bifidobacteria confirms the changes seen in the FISH analysis however 
the results of the pyrosequencing do not support the changes in numbers seen in the above 
studies. It is likely that the patients used in the IBS studies are too heterogenous, having 
included patients with all forms of IBS, including IBS-D. The subjects in whom diarrhoea is 
induced by osmotic laxatives have a reduction in the richness of the colonic microbiota with 
decreases in Firmicutes and Bacteriodetes with an increase in Proteobacteria399 and is not 
unreasonable therefore to assume that the microbiota of patients with IBS-C and IBS-D will 
also be different. This will limit comparison with the subjects involved in this work.  
There are two areas of interest surrounding the microbiota in constipation and these are the 
roles of hydrogen sulphide (H2S) and methane (CH4). Endogenous synthesis of H2S in the colon 
follows the metabolism of the amino acid L-Cysteine by the enzymes cystathionine γ-lyase 
(CSE) and cystathionine β-synthase (CBS)400, 401. Exogenous production is secondary to sulphate 
reducing bacteria (SRB) which have been identified in human faeces402 and which metabolise 
hydrogen and short chain fatty acids (SCFA) into H2S. The role of H2S is unclear but it has been 
implicated in increasing colonic secretions and intestinal motility whilst having involvement in 
nociception403-405. It therefore seems logical that an absence or reduction of SRB may have a 
role to play in chronic constipation. SRB however were not detected by pyrosequencing in 
either the constipated or healthy groups and therefore this study cannot support this 
hypothesis. CH4 is produced by colonic anaerobic microflora which ferments unabsorbed 
carbohydrates to produce hydrogen, carbon dioxide, CH4, SCFA, and sulphites. CH4 was thought 
to be physiologically inert but methane production in healthy subjects has been shown to 
inversely correlate with stool frequency and GI transit297, 406 whilst in IBS patients methane 
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production during a lactulose breath test was reported to correlate with the degree of 
constipation407. In patients with slow transit compared to normal transit constipation, CH4 
production was higher following a glucose breath test and this was used a surrogate marker for 
methanogenic flora294. This was confirmed in a meta-analysis of nine studies (including Attaluri 
et al294) which concluded that the presence of CH4 on breath testing was significantly 
associated with IBS-C and functional constipation408. What could not be demonstrated was 
causality but only an association between CH4 and constipation. In this study only 
methanobrevibacter (Phylum Euryarchaeota) could be detected and the proportion was both 
small and detected in one subject in each group (0.053% each) suggesting that the result could 
have been artefactual. There was no significant difference between the two groups but it must 
be noted that the constipated subjects contained patients with both slow and normal transit 
constipation. 
 
 
3.4.5  SUMMARY 
 
The analysis of faecal samples in this work has shown clear differences in the microbiota of 
constipated subjects compared to healthy subjects and these changes differ on the method of 
analysis employed. FISH demonstrated that constipated subjects had a decrease in 
Bifidobacterium spp whilst pyrosequencing demonstrated that constipated subjects had a 
reduced abundance of Firmicutes and an increase in Bacteroidetes at a phyla level. These 
changes were seen down to a genus level. Due to the lack of efficacy of Nalcol™ in clinical 
practice it was not possible to determine if the changes seen in constipation were reversed if 
constipation was improved clinically. 
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CHAPTER 4 
 
 
SUMMARY OF FINDINGS AND FURTHER WORK 
  
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
 
185 
 
4.1 SUMMARY OF CLINICAL TRIAL 
 
The trial found no effect of Nalcol™ in clinical practice. The reasons for this may be due to 
underpowering of the study, incorrect dosage and short duration, or a lack of appreciation of 
the physiological mechanisms of colonic motor control. Nalcol™ was associated with adverse 
effects of abdominal pain and bloating. This work suggests that future studies should be 
conducted with the aim of determining the effective dose and duration, if any, of Nalcol™ in a 
larger sample group and to investigate the role of endogenous opiates in chronic constipation. 
 
 
4.2 FURTHER WORK WITH NALCOL™ 
 
To confirm, with certainty, that the dose of Nalcol™ used was sufficient would be to undertake 
a dose-ranging study. There is no reason why the original patients could not be recruited. The 
trial would still be double-blinded and randomised to address the likely high placebo effect. 
The trial would be conducted without the concomitant use of laxatives and the primary 
outcome measure of the ‘number of patients with ≥3 CSBM/wk’ would be used as this would 
also allow comparison with other trials. All patients would undergo a transit study at the start 
of the screening period and also at the end of the trial which would last for 10 weeks (2 week 
screening period and 8 week trial period). It is suggested that doses of 10mg, 20mg, and 40mg 
b.d would be used along with a placebo (i.e. 4 treatment arms). As this would be a pilot study it 
would be reasonable to enrol 20 patients into each group to determine if a difference existed 
as these numbers have been sufficient in other pilot studies as detailed above. It would also be 
interesting to study these patients using colonic manometry and determine if naloxone had 
any effect on the contractile patterns over a 24h period and this would support the outcome of 
the dose-ranging study. Should a test dose be shown to be effective then this would then be 
used for further work, but to recruit the 120 patients that this trial required would need a 
multi-centred approach. 
A second line of study would be to combine Nalcol™ with a second proven motility agent such 
as prucalopride or lubiprostone. Releasing the endogenous braking system in the presence of 
these motility agents may improve treatment rates in constipated subjects above those seen 
with the individual agents alone. Any increase in response rate with the combined approach 
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would also support the hypothesis that the endogenous opiate system is not responsible for 
the pathophysiolgy of functional constipation. 
 
 
4.3 SUMMARY OF THE ANALYSIS OF THE COLONIC MICROBIOTA IN 
 CONSTIPATION 
 
The analysis of faecal samples in this work has shown clear differences in the microbiota of 
constipated subjects compared to healthy subjects and these changes differ on the method of 
analysis employed. FISH demonstrated that constipated subjects had a decrease in 
bifidobacterium spp whilst pyrosequencing demonstrated that constipated subjects had a 
reduced number of Firmicutes and an increase in Bacteroidetes at a phyla level. These changes 
were seen down to a genus level. Due to the lack of efficacy of Nalcol™ in clinical practice it 
was not possible to determine if the changes seen in constipation were reversed when 
constipation was improved clinically. 
 
 
4.4 FURTHER WORK TO INVESTIGATE THE CHANGES SEEN IN THE MICROBIOTA OF 
 CONSTIPATED SUBJECTS 
 
The results of this study demonstrated a clear difference between healthy and subjects with 
constipation but was undertaken using different techniques which could not be cross validated 
or were not in complete agreement with the current literature. Due to limitations in the 
methodology of FISH it would be worthwhile to repeat the analysis of the both healthy and 
constipated subjects but with a larger cohort at a greater depth using pyrosequencing to fully 
elucidate the changes in constipation. The changes seen could be further investigated to assess 
the role they may have on colonic and systemic physiology. If these changes could be 
confirmed at a genus or species level then this could lead to further targeted trials in the 
treatment of constipation using pre- and probiotics.  
The rationale of surveying the colonic microbiota over the course of a clinical trial in tandem 
with clinical improvement could have delivered interesting results and it is unfortunate that 
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this could not be done here. It remains unclear what effect the changes in colonic microbiota 
seen in constipation have both locally and systemically and what changes in the microbiota 
occur if symptomatic relief is achieved. The advantage of Nalcol™ was that it is receptor-based 
and was therefore thought not to have any impact on the colonic microbiota and although the 
colonic microbiota remained stable over the three study periods it cannot be said that Nalcol 
has no effect on the colonic microbiota and further work would be needed. There is no reason 
to assume that prucalopride would have any effect on the colonic microbiota as it is also 
receptor-based and therefore the study could be repeated with prucalopride and the colonic 
microbiota monitored using the same protocol used in this study. The only potential issue 
would be the recruitment of adequate numbers of subjects both to power the clinical trial or 
the microbiota analysis. This could be achieved with either the enrolment of subjects with IBS-
C or to conduct a multicentred trial. Both have potential limitations however.  As discussed 
earlier the microbiota of patients with IBS-C and that of constipation are different but note 
must be made of the heterogenous patient selection in the IBS trials which may have biased 
the results. A multicentred trial will pose numerous difficulties including stool collection and 
quality control of the sample until it is received at the labarotory. Monitoring the changes in 
the microbiota over time and comparing with clinical outcome will further identify potential 
microbiota involved in the pathophysiology and aetiological of clinical symptoms of 
constipation.  
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PROTOCOL 
Outline Protocol 
Title: Naloxone Hydrochloride SR Gastro-Resistant Sustained Release Capsules as a treatment 
for functional constipation: a randomised, double blind controlled trial in secondary care. 
Medicinal Product: Naloxone Hydrochloride SR Gastro-Resistant Sustained Release 
(Nalcol) in a delayed release oral preparation at a dose of 20mg bd. 
Study Centre: Norfolk and Norwich University Hospital 
Clinical Phase: Phase II 
Objective: The primary objective of this study is to assess the efficacy of Nalcol when used as 
an adjunct to usual laxatives in the treatment of patients with refractory chronic constipation.  
Study design: This is a single-centre, parallel group study involving 120 patients. They will be 
patients who have been referred to secondary care for management of functional constipation 
as defined by Rome III criteria. The Rome Criteria has been developed to diagnose and classify 
functional gastrointestinal disorders. The criteria for functional constipation are listed in the 
introduction and 2 or more of the criteria must be met for a diagnosis of functional 
constipation to be made.  The study group will comprise three consecutive periods. Period 1 
will be a two week observation period where subjects will undergo screening to assess 
suitability for the trial. Period 2 will last for four weeks. A phone call will be made at 1 week 
and an assessment at the end of the period with participants randomised to receive either 
Nalcol or identical placebo capsules. Period 3 is a post trail period of observation, lasting four 
weeks, in which all the patients will be invited to take part and take active Nalcol. Again there 
will be an assessment by phone at 1 week with a face-to-face assessment at the end of the 
period. Period 4 will be open to those participants in whom the Nalcol has had an obvious 
benefit. It will be a prospective, open follow-up period consisting of questionnaires sent by 
post. 
Sample Size: 120 patients (n=60 per group), which will include both male and female, but we 
would anticipate most will be female. 
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Patient Recruitment: Consenting patients, aged 18 years and over, suffering from functional 
constipation, refractory to standard therapy (diet and laxatives) and satisfying 
inclusion/exclusion criteria. These patients will have been referred by their GPs to specialist 
clinics and will have been thoroughly investigated with either a barium enema, transit study or 
perhaps both. Some patients may have undergone biofeedback training. 
Treatment Schedule: Patients will be advised to continue with the measures they normally use 
for constipation (diet and medication) throughout the study. If patients completed their diary 
cards satisfactorily during Period 1 and are willing to enter the trial then they will be admitted 
to the trial proper. This takes places during Period 2 and the subject will be randomised to 
receive either active drug or placebo. All patients will be required to take two capsules (Nalcol - 
10mg / Placebo) twice a day. A note will be made of the total number of capsules used during 
each of the weeks of period 2 and any medication taken for constipation will be recorded on 
the diary. 
Patients will be invited to take part in Period 3 when they will all be given the active trial 
capsules i.e. two 10mg capsules twice a day. The format for this period is as for Period 2. 
Assessments and Analysis: Patients will be recruited from Gastroenterology and surgical clinics 
specialising in chronic constipation and standard assessments done as part of clinic 
investigations will be recorded. They will be counselled and entered into the study by MB, who 
will see them before entry into the trial, at the start of Periods 2 and 3, and at the end of the 
trial. The primary outcome measures will be the patient’s assessment of ‘satisfactory 
improvement’ and a responder to the treatment will be defined by the experience of 
satisfactory improvement on at least 50% of occasions. Diary cards will be used each day and 
details recorded of the patient’s bowel frequency and medication. Disease specific symptom 
severity and quality of life will be assessed at the end of each trail Period using PAC-SYM and 
PAC-QOL questionnaires. Analysis of this data will comprise the secondary outcomes. Faecal 
bacterial analysis will be carried out on a subset of patients who volunteer to have faecal 
sampling via rigid sigmoidoscopy after each of the trial periods i.e. Periods 1, 2 and 3. Those 
patients, who had transit studies as part of their initial work-up, will have these repeated at the 
end of Period 2. 
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1. Introduction and Rationale 
 
 Constipation: Incidence and Prevalence 
Constipation is present in between 10 and 15 percent of the UK population, and as many as 1% 
of women have chronic functional constipation, which often develops when they are young, 
and is unresponsive to dietary manipulation or laxatives. 
Thirteen million general practitioner prescriptions were written for laxatives in England in 
20041. Prevalence data are limited by small samples, problems with definition and the under 
reporting of constipation to health professionals. 
 
Functional Constipation 
First characterised by Preston et al2, patients are usually female with symptoms since 
childhood or early adulthood. Symptoms are often severe and intractable, failing to respond to 
a high fibre diet, high fluid intake, or laxatives. The quality of life is often severely affected by 
symptoms, which together with feelings of anxiety and embarrassment cause many to be 
incapacitated to the extent that they are unable to work or carry out social and domestic 
activities. Whilst much is written about the cause, it is poorly understood and no clearly 
defined pathogenic mechanism has been identified. 
Though there is no universal definition of constipation, there are widely accepted criteria 
defined by international consensus (Rome III)3 as shown below. 
 
 
 
 
 
Rome III Criteria for Functional Constipation 
1. Must include two or more of the following: 
a. Straining (during at least 25% of defecations) 
b. Lumpy or hard stools (on at least 25% of defecations) 
c. Sensation of incomplete defecation (on at least 25% of defecations) 
d. Sensation of anorectal obstruction/blockage (on at least 25% of defecations) 
e. Manual manoeuvres to facilitate defecation (on at least 25% of defecations) 
f. Fewer than three defecations a week 
 
2. Loose stools rarely present unless induced by laxatives 
 
3. Would not normally include patients who satisfy criteria for IBS-C 
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Therapeutic concepts based on 5-HT and opioids in the gut 
The enteric nervous system, through several mediators, plays a major role in the regulation of 
normal gut motility. One of these – serotonin (5-hydroxytryptamine, 5-HT) has receptor sites 
throughout the gut. Recent developments in the pharmaceutical industry have explored the 
role of agonists of 5-HT in patients with constipation and  5-HT4 receptor partial agonists have 
been shown to be of some value in patients with constipation and IBS. 
Opioids are known to have a marked effect on both gut motility and secretion – producing a 
delay in intestinal transit and constipation. The receptor sites for opioids in the enteric nervous 
system are closely interrelated with those for 5-HT, and the functional consequences of this 
relationship determine that similar changes in bowel motility can be achieved by opioid 
antagonists and 5-HT agonists. This role of opioid receptors in the enteric nervous system 
underpins the basis for use of naloxone, an opioid antagonist, in patients with constipation. 
 
 NALOXONE:  Pharmacological effects 
Naloxone is a specific opioid antagonist that is used intravenously to reverse the side effect of 
respiratory depression following treatment with opioids. In the gut, opioids reduce intestinal 
secretion and motility – both of these effects are reversed by the antagonist naloxone4,5. Even 
in large doses, the naloxone does not produce troublesome adverse effects and can therefore 
be given safely. In a pilot study of normal volunteers, 40mg daily was occasionally associated 
with abdominal discomfort and urgency of defecation5. 
 
 NALOXONE: Adverse effects and safety issues 
Naloxone has been used as an intra-venous preparation to treat opioid overdose for many 
decades, with an excellent safety record. Cases of anaphylaxis are rare, severe irreversible side 
effects have not been reported, and there are no reports of permanent disability as a result of 
the drug. It is thought to be safe to the foetus. Furthermore, the formulation of Nalcol used in 
this study produces colonic release of the drug with greatly reduced absorption and a high first 
pass effect such that only approximately 2% of the ingested drug is systemically available. 
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Possible adverse effects are allergic type reactions, nausea, vomiting and colicky abdominal 
pain. In the two previous studies of Nalcol there have been no serious adverse events, and no 
effect on pulse or blood pressure recordings5,6. 
 
 Rationale for topical (colonic) delivery of naloxone 
The role of opioids and opioid antagonists in the gut is thought to be a consequence of their 
local effect – mediated by systemic levels of the drug. It is thought that this local effect can also 
be produced topically by release of the drug in that part of the gut where the effect is desired. 
Release of naloxone in the terminal ileum and first part of the colon, slowly over 6 hours, will 
influence colonic function. The first pass metabolism of naloxone in the liver removes 97% of 
the drug and as a result only very low levels reach the systemic circulation. The slow release of 
naloxone in the colon, in contrast with a bolus release, will limit rises in the systemic level of 
the drug. 
 
 Oral formulation of naloxone – Nalcol 
Naloxone has been formulated in a gelucire, which is not unlike a wax matrix, and produces a 
linear release of the drug over 6 hours. The gelucire is encapsulated and the capsule itself also 
coated with a polyacrylic resin (Eudragit 4/S) to delay release of its contents until the terminal 
ileum. Each capsule contains 10mg of naloxone hydrochloride sustained release and two 
capsules are given twice daily (total of 4 capsules daily). 
 
 Rationale for stool sampling 
There is extensive investigation into the cause of constipation. It has been shown that as 
humans age the bacterial content of the colon decreases, especially in the number of 
bifidobacteria and this predisposes the elderly to constipation and other gastrointestinal 
disease7. Normalisation of these bacterial counts can restore bowel habit to normality in 
elderly populations8,9 and some laxatives e.g. lactulose can be thought of as prebiotic10. This 
does not explain whether the decrease in the bacterial counts is the primary event for the 
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development of increased transit time and subsequent constipation. It could be hypothesised 
that the development of constipation and slowing of transit time for other reasons promotes 
an increase in toxic metabolites which are not removed satisfactorily. These toxic metabolites 
may then alter the environment locally such that the bacterial counts drop. Although it has 
been shown that the use of laxatives can alter bacterial flora10 these laxatives act within the 
bowel lumen and it is not possible to say whether their beneficial effects in constipation are 
due to their effects on the bowel wall and increase in transit time or on the bacterial content of 
the lumen by restoring normal colonic flora.  
However Nalcol should have no direct effect on bacterial flora as its’ proposed mechanism of 
action is on the opioid receptor. Therefore any change in the bacterial population would be as 
a direct effect of a decrease in transit time. If there is no change in the bacterial population 
despite a decrease in transit time it may be reasonable to assume that an alteration away from 
the normal bacterial population is contributory to the aetiology of constipation.  
We would aim to take faecal samples from a subset of patients at the start of Period 1 and at 
the ends of Periods 2 and 3 performing bacterial analysis on these samples. This will determine 
if there is any difference in the use of Nalcol over 8 weeks compared with 4 weeks as some of 
these patients will be randomised to the placebo group initially. The faecal samples would be 
obtained via rigid sigmoidoscopy, a procedure with little in the way of complications11. The 
benefit of sampling the faeces in this way allows us to guarantee the conditions in which the 
faecal sample will be stored after collection. This is important as incorrect storage may result in 
changes to the bacterial content and thus invalidate the data collected.  The sampling would be 
voluntary and is not required from entry into the trial proper. 
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2.  Overview of Study Design 
 
This is a single-centre double-blind placebo controlled study of the efficacy and safety of Nalcol 
given to patients with refractory constipation attending a specialist clinic. The study is 
principally a phase II trial of short-term (4 weeks) effect. It is suspected that Nalcol will have a 
moderate effect, and is used here as an adjuvant to regular laxatives 
The patients will all fulfill criteria for functional constipation (as above) and will have attended 
a specialist gastroenterology or colorectal clinic at the Norfolk and Norwich University Hospital. 
They will have undergone investigation for their constipation with barium enemas and also 
transit studies and their basic management, including dietary and lifestyle advice and 
modification of laxatives, will have been instigated. 
The key treatment phase (Period 2) will last 4 weeks and data over four weeks of treatment 
will be available. Two weeks of pre-treatment data will be collected during the screening 
period before randomisation (Period 1). This will allow an assessment of patient suitability and 
health to ensure that the inclusion criteria are met and permit examination with a rigid 
sigmoidoscope to obtain a stool sample. This initial period will ensure short term symptom 
stability and confirm patient compliance with diary completion. It will allow secondary analyses 
comparing pre-treatment and treated symptom scores and QoL data. A final phase of four 
weeks (Period 3) will allow all patients in the trial to evaluate the treatment and provide 
further observation over a more prolonged duration. Period 4 will be open to those patients in 
whom the Nalcol has had an obvious benefit. Nalcol will be continued and the patients asked 
to complete two questionnaires every month so that long-term efficacy can be assessed. This 
period will continue until the trial has been completed. The length of time that each participant 
spends in this period will therefore vary. Patients will need to attend the hospital to collect 
their Nalcol each month when the completed questionnaire can be returned. Patients will be 
contacted on a monthly basis to check on their progress and monitor for adverse events and 
will be asked to attend the hospital for an outpatient appointment every three months to 
undergo three monthly BP measurement, blood testing and urinanalysis. 
Nalcol is given to relieve symptoms, which may be variable from day-to-day. The tolerability of 
Nalcol tablets is expected to be comparable to that of commonly dispensed stimulant laxatives; 
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with no significant systemic side effects. From previous studies5,6 it is known that 10mg, twice a 
day is effective in increasing gut motility in normal subjects and a group of patients have taken 
40mg daily and occasionally up to 60mg daily for severe symptoms. 40mg daily has therefore 
been chosen to be given to patients in this trial because of the very troublesome symptoms of 
constipation from which they suffer.
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Period 1 
Period 2 
Period 3 
 2 Nalcol capsules, twice a day 
 Phone call after 1 week to check on participant 
 End of Period assessment 
• Hand over completed diary cards 
• QOL questionnaires completed 
 Repeat blood and urine tests for routine analysis 
 End Of Trial 
 Post study check phone call in 4 weeks 
 
 2 capsules, twice a day 
 Phone call after 1 week to check on participant 
 End of Period assessment 
• Hand over completed diary cards 
• QOL questionnaires completed 
• Large Bowel X-ray transit study 
 Participant invited into Period 3 
 Completion of diary cards and quality of life 
questionnaires 
 If initial assessment and diary cards are 
satisfactory and patient is willing to proceed 
then they will be entered into the trial 
Period 4 Long-term Follow-up on Nalcol (selected 
patients 
 PAC-SYM and PAC-QOL monthly by post 
 Blood test, BP and urinanalysis 3 monthly at 
hospital 
 Monthly phone call to check on patients progress 
and monitor for adverse events 
 
Screening and 
Initial Assessment
2 weeks
End of Period 1 
Assessment
Active Compound 
– Nalcol
4 weeks
End of Period 2 
Assessment
Active Compound 
– Nalcol
4 weeks
Final Assessment 
End of Trial
Placebo
4 weeks
End of Period 2 
Assessment
Active Compound 
– Nalcol
4 weeks
Final Assessment 
End of Trial 
Diagram to Summarise the 3 
Periods within the Nalcol Trial 
 Inclusion and exclusion criteria assessed 
 Medical history assessed 
 Examination including rectal examination and 
rigid sigmoidoscopy 
 Consent into trial 
 Blood tests for routine analysis  
Randomisation 
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3. Patient Recruitment 
 
Study Population 
Adults who have been referred to the gastroenterology or colorectal clinics specialising in 
chronic constipation at Norfolk and Norwich University Hospital and remain unsatisfied with 
their symptoms despite initial treatment with diet and laxatives will be considered for inclusion 
into the study. The definition of constipation will be based on the criteria for functional 
constipation (Rome III) as stated in section 1.2 above.  
 
 Inclusion Criteria (all must be met) 
 Age > 18 years 
 Male or Female  
 Satisfy Rome III criteria for functional (slow transit) constipation 
 Symptoms not relieved by diet and laxatives 
 
Exclusion Criteria 
 Severe cardiac, renal or hepatic impairment 
 Severe psychiatric disturbance 
 Mental disorder preventing adequate informed consent 
 Dilatation of the bowel (megarectum or pseudo-obstruction) 
 Concomitant medication with drugs known to cause constipation 
 Known pregnancy, suspected pregnancy, or trying to conceive 
 Currently Breast Feeding 
 Currently participating (or within 1 month) in any other study 
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Patient Numbers 
The primary endpoint will identify responders and non-responders. Recent clinical trials in this 
condition have shown placebo response rates ranging from 15-35%12-15 and as such we have 
chosen a placebo response rate of 25%. A worthwhile treatment response would be 32% 
greater than the placebo given the resistant nature of constipation to medical management. A 
study with a power of 95% that will detect this difference would require 120 patients 
randomized to two equal groups (see Section 7 for further details). 
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4. Endpoints 
 
Endpoints to assess the value of Nalcol as additional medication will be: 
 
Primary Endpoint 
Patient derived assessment of satisfactory improvement of symptoms measured at weekly 
intervals. A responder will have ‘satisfactory’ improvement on at least two of the four weeks in 
the treatment phase16  
 
Secondary Endpoints 
 Stool Frequency and type from daily diaries 
 Laxative use from daily diaries 
 Symptom scores from a weekly patient-completed questionnaire (PAC-SYM) 
 Disease specific quality of life measured weekly (PAC-QOL) 
 Objective improvements in transit time on repeat  X-ray transit studies 
 Normalisation in faecal bacterial counts after treatment with Nalcol (in subset of 
patients)  
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5. Study Procedures 
 
Recruitment 
Patients with functional constipation will be recruited from three possible sources. Firstly there 
will be referral from consultants within gastroenterology and colorectal surgery who see these 
patients as part of their normal working practice. It is envisaged that the majority will be 
referred from clinics which specialise in functional gastrointestinal disorders. Secondly we will 
recruit patients from the department of physiology at the Norfolk and Norwich Hospital. They 
have a record of the patients who have undergone biofeedback training for constipation. 
Thirdly patients will be recruited from the department of radiology at the Norfolk and Norwich 
Hospital. A search dating back five years will identify patients who have undergone transit 
studies for functional constipation. It is expected that there will be some overlap between the 
three groups. 
The recruited patients will then be sent a letter detailing the study and inviting them to take 
part with a follow-up phone call one week after the letter is sent to answer any questions. It is 
hoped that a follow up phone call will increase recruitment. Arrangements will then be made 
to screen those who are keen to participate with a view to entering into the trial. 
 
Screening 
Screening and a decision about whether patients are suitable for the study will be undertaken 
 At the initial interview on the inclusion/exclusion criteria, with medical and social 
background considerations. At this point consent will be taken. 
 At the end of Period 1 after reviewing initial blood and urine tests and on successful 
completion of the diary card and questionnaires 
If for any reason the patient is considered unsuitable at the end of Period 1 then they will not 
be randomised to Period 2 of the trial; they will not be included in the analysis. 
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Screening procedures will include: 
 Explanation of all the procedures involved in the study 
 Details of all current medical therapy including those used to manage constipation 
 Current and past details of medical history – if necessary, referring to the patient’s 
medical notes 
 Provision of a blood sample for routine clinical biochemistry and heamatology tests 
 Urine for routine tests 
 General, abdominal and digital rectal examination 
 Blood Pressure measurement and ECG. 
 
 Sigmoidoscopy and stool sample if consent is obtained (to be performed ONLY if 
accepted into the trial). The stool samples will be stored on ice and at the end of the 
screening clinic transferred by MB to the IFR for preparation prior to freezing. All 
samples will be identified by the participant’s identification number. 
 
Consent and Randomisation 
Patients seen at the start of Period 1 will have the trail discussed and if willing consented into 
the trial. They will undergo routine blood tests and complete a diary card. 
On satisfactory completion of the diary cards and normal routine blood tests the participant 
will be entered into the trial and randomized (1:1) to receive one of the two treatment 
regimes, using a computer –generated randomization sequence. St Mary’s Pharmacy Unit in 
Cardiff will be responsible for the packaging and randomization of the trial capsules. The 
capsules will be stored and dispensed by the pharmacy at the NNUH and this will ensure the 
capsules are appropriately stored and prepared prior to dispensing and ensure both the 
participant and the researchers remain blind to the treatment. 
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Treatment Schedule 
Period 1: Week 1-2:  No treatment – Screening and assessment period 
Period 2: Weeks 3-6:  Randomised to active treatment or placebo 
     Phone call at end of week 3 to check progress 
Period 3: Weeks 7-10:  All patients to receive active drug 
     Phone call at end of week 7 to check progress 
Period 4: Week 11 onwards: Ongoing Nalcol treatment 
     Questionnaires x2 each month 
     Blood tests. BP and urinanalysis every 3 months. 
 
Usual laxatives and other lifestyle measures are taken throughout. No new laxatives to be 
started during the study period. Should patients develop diarrhoea then they will be instructed 
to call MB who will advise about any changes needed. It is thought best to reduce their ‘usual’ 
laxative dosage and rely more on the trial capsule if they appear to be working 
 
Schedule of Assessments  
Phases 
Pre-
Treatment 
Treatment Period Post-Treatment (Nalcol) 
Assessments Wk 1 Wk 2 Wk 3 Wk 4 Wk 5 Wk 6 Wk 7 Wk 8 Wk 9 Wk 10 
Global 
Assessment 
          
Diary           
PAC-SYM           
PAC-QOL           
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Assessments, Patient Diary Cards and Questionnaires 
Throughout the study patients will be asked to complete a diary, recording details related to 
their bowel frequency, laxative use and any adverse events. 
 
Period 1 
At the end of Period 1 patients will be asked to complete two standard questionnaires –  
 One documenting symptoms related to constipation (PAC-SYM) 
 And one quality of life questionnaire (PAC-QOL) 
A global assessment question will be included on the diary card. Their completed diary card for 
the Period 1 will be checked prior to randomisation into the trial proper at the end of Period 1 
They will also be asked to undergo rigid sigmoidoscopy for stool  
 
Period 2 
At the end of Period 2 the following will be completed: 
 Their completed weekly diary cards for the Period 2 will be checked including 
the global assessment question and adverse events noted 
 Complete Questionnaires PAC-SYM and PAC-QOL 
 Check compliance against capsule returned 
 Repeat blood pressure recordings 
 Repeat stool sample in subset of patients 
 Large Bowel X-ray transit study in subset of patients 
Patients will be phoned after the first week. This will ensure that they have understood what is 
expected and answer any queries that they may have. 
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Period 3 
At the end of the study the following procedures will be completed: 
 Review of final diary cards, global assessment question and check for adverse 
events 
 Complete Questionnaires PAC-SYM and PAC-QOL 
 Check compliance against capsule returned 
 Repeat stool sample in subset of patients 
 Repeat blood pressure recordings 
 Repeat blood and urine samples for follow-up heaematology and biochemistry 
testing 
Patients will be called at the end of the first week as per Period 2. 
Those patients completing the study who would like to continue taking the Nalcol in the longer 
term will be given further supplies and arrangements made through the family practitioner. 
Participants will be followed-up by phone four weeks after finishing the trial.  
 
Period 4 
Patients will be asked to complete a PAC-SYM and PAC-QOL questionnaire every month and 
undergo blood tests, BP testing and urinanalysis at hospital every 3 months. The patients will 
be contacted on a monthly basis to ensure that they are tolerating the Nalcol and for any 
adverse events to be reported and will be reviewed in clinic every third month. The 
participants will have the contact details of the MB should they need advice or wish to be seen 
at the hospital sooner.  
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Premature Withdrawal 
On premature withdrawal from the study patients will be asked to complete: 
 PAC-SYM and PAC-QOL questionnaires 
 Diary cards for review to check compliance and adverse effects 
 Routine blood and urine for analysis 
They will be followed-up by phone four weeks after withdrawal. 
 
Analysis of Faecal Samples 
We aim to study faecal samples from a minimum of 30 participants. A minimum of 200mg of 
fresh stool will be needed but it is anticipated that a greater quantity can be easily collected. 
The stool will initially be stored in polythene bags placed over ice until the end of the research 
clinic and then transferred by M.B. to the IFR (i.e. within 4 hours of collection). Here they will 
be divided into 4 batches and frozen. The first sample will be used to determine fresh and dry 
weights, the second to run denaturing gradient gel electrophoresis (DGGE) which will allow the 
bacterial population i.e. the bacterial geni to be determined. The third sample will be prepared 
prior to freezing to allow Fluorescent in situ hybridization (FISH) to take place. This allows the 
bacteria to be counted. The metabolic activity of the bacterial population will also be assessed 
through the analysis of short-chain fatty acids on the fourth sample. These analyses will be 
performed on each of the stool sample taken at the differing stages of the trial and the result 
compared and correlated with the clinical findings. 
Provision of a stool sample is NOT an absolute requirement for entry into the trial. 
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6.  Analysis 
The primary analysis will be a comparison of the responders during Period 2 of the study 
(weeks 3-6) in the treatment group and those in the placebo group. Response is defined as 
those participants who give an assessment of ‘satisfactory improvement’ on at least 50% of 
occasions over the 4 week trial period (Period 2) to the global question on the diary card. 
A number of secondary analyses will be performed to further assess the response to the Nalcol 
treatment: 
 Comparison of stool frequency and type, laxative use, PAC-SYM, and PAC-QOL 
between treatment and placebo groups during Period 2 of the study. PAC-SYM will 
be used to provide an overall symptom score; but each component will also be 
analysed separately to identify changes to individual symptoms. Comparison will 
be made between the pre and post trial transit study as an objective marker of a 
reduction in transit time. 
 Graphical representation of the temporal changes in stool frequency and type and 
analysis to assess any drop-off of effect after eight weeks of use in those receiving 
Nalcol for 8 weeks or in the whole group. 
 A comparison of pre-treatment versus treatment symptom levels in the whole 
(n=120) i.e. Period 1 vs. Period 3 
 Comparison of stool bacterial counts between the treatment and placebo groups in 
the selected subset after each Period. 
 
Statistical Analysis and Power of the Study 
The trial is powered in relation to the primary outcome measure of "satisfactory 
improvement". Previous papers12-15 indicate that the proportion of participants who can be 
expected to show a positive response after placebo is of the order of 25%. An increase in 
response of 32%, to 57% of the participants, is considered to be clinically significant for the 
treatment group. For a power of 95%, this increase in response could be detected at a 
significance level of 0.05 if the total number in the study was 120 (60 in each group). This 
estimate was based on using a Binomial Test and was confirmed using Fishers Exact Test. 
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With regard to symptom outcomes, ANOVA models will be constructed to observe any changes 
in symptoms and quality of life at the end of study periods 1, 2, and 3, with the treatment 
group entered into the model as a factor. Where appropriate, data from variables collected 
prior to Period 2 will be included as covariate values where ignoring these may be to the 
detriment of the model. 
Diary data will be initially presented via descriptive statistics, with any subsequent statistical 
analysis being in accordance with the nature of the data. 
Finally, pre-treatment symptom levels will be compared to symptoms levels at the end of the 
study using appropriate statistical tests, i.e. either ANOVA based (t-test) or non-parametric 
according to the nature of the data. Prior to the analysis of the continuous data, distributions 
(of differences) will be examined within groups to assess normality. Where data fails to meet 
the assumptions of normality, non-parametric equivalents will be applied. However the ANOVA 
model described above is known to be fairly robust to non-extreme departures from normality. 
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7.  Patient Withdrawal, Monitoring, and Safety. 
 
 Participant withdrawal criteria 
No specific withdrawal criteria have been defined for this study. If a participant discontinues 
from the study prematurely (i.e. prior to completion of the protocol), the primary reason will 
be determined and recorded. In all cases the investigator will ensure that the participant 
receives medical follow-up as necessary. Withdrawn participants will not be replaced.  
If a participant discontinues from the study prematurely, every effort will be made to perform 
an early termination visit. This will include retention of any diary information, completion of 
PAC-SYM and PAC-QOL questionnaires and repeat haematology and biochemical tests. 
 
 Monitoring 
The study will be monitored by Messrs Mark Bignell and Michael Rhodes in accordance with 
the guidance in section 5.18 of the ICH Harmonised Guidance for Good Clinical Practice. 
 
 Safety evaluation 
The safety of Nalcol in the treatment of patients with constipation will be evaluated by 
examining the occurrence of all adverse events, abnormal laboratory findings, the use of 
concomitant medications and physical examination findings. Follow-up of each adverse event 
should continue until the event or its sequelae resolve or stabilize at a level that is acceptable 
to the investigator. 
 
An ‘adverse event’ (AE) is any untoward medical occurrence in a trial participant, which does 
not necessarily have to have a causal relationship with the treatment. In order to elicit details 
of any AEs, at each visit the participant will be asked a non-leading question: ‘Do you feel 
different in any way since the last visit?’ 
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An ‘adverse reaction’ (AR) is an untoward or unintended response to an investigational 
medicinal product related to any dose administered. 
These may be: 
 Intensity classification: 
 Mild:  Symptoms do not alter participant’s normal functioning 
 Moderate: Symptoms produce some degree of impairment to function, 
  but are not hazardous, uncomfortable of embarrassing to 
  the participant. 
 Severe:  Symptoms definitely hazardous to the well being,  
  significant impairment of function or incapacitation 
 
Causality classification 
 Probable: Reports including good reasons and sufficient information 
  to assume a causal relationship in the sense that it is  
  plausible, conceivable, or likely. 
 
 Possible: Reports containing sufficient information to indicate the 
  possibility of a causal relationship in the sense of it not  
  being Impossible and not unlikely, although the connection 
  may be uncertain or doubtful (e.g. due to missing data,  
  insufficient evidence, etc) 
 
 Unlikely: Reports of a clinical event, including laboratory test  
  abnormality, with a temporal relationship to drug  
  administration which make a causal relationship  
  improbable, and in which other drugs, chemicals or  
  underlying disease provide plausible explanations  
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 Not related: Reports excluding the possibility of a relationship between 
  the event and the drug treatment, i.e. no reasonable  
  suspected causal relationship to study drug administration 
 
 Unclassified: Reports of a clinical event, including laboratory   
  abnormality, reported as an AE, about which more data are 
   essential for a proper assessment 
 
Serious adverse events (SAE) 
All SAEs regardless of treatment group or suspected relationship to the study drug will be 
reported immediately (within 24h) by telephone to the research coordinator Mr. Mark Bignell. 
SAEs will also be reported immediately to SLA Pharma. 
A SAE is any adverse drug experience occurring at any dose that: 
 Results in death 
 Is life-threatening 
 Results in inpatient hospitalisation or prolongation of existing hospitalisation 
 Results in persistent or significant disability or incapacity 
 Results in congenital abnormality or birth defect 
Important medical events may not result in one of the above may still be considered a serious 
adverse drug experience when, based upon appropriate medical judgment, they may 
jeopardize the subject and may require medical or surgical intervention to prevent one of the 
outcomes listed above. Examples of such medical events include pregnancy, allergic 
bronchospasm requiring intensive treatment in the Emergency Department or at home, blood 
dyscrasias or convulsions that do not result in inpatient hospitalisation, or the development of 
drug dependency or abuse. 
 
Regardless of the above (serious) criteria, any additional adverse experiences that an 
investigator considers serious will be immediately (within 24h of the investigator becoming 
aware) reported. SAEs will be included in the SLA Pharma SAEs database system. 
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The minimum information required from the investigator when reporting a SAE is as follows: 
 Protocol identification number 
 Investigator’s identification (name and centre number) 
 Subject identification number 
 SAE description including criteria for seriousness and the immediate outcome 
The chief investigator will also report all SAEs to the MHRA, REC, Eudravigilance component of 
the EudraCT database within the required reporting timelines. A written acknowledgment is 
required from the ethics committee to confirm that they have received this notification. 
 
SUSAR 
In accordance with the EU directive the Mr. Mark Bignell will report SUSARs (Suspected 
Unexpected Serious Adverse Reactions) to SLA Pharma, Mr. Michael Rhodes, his/her local Trust 
R&D department and the sponsor within 24 hours of becoming aware of the event. The chief 
investigator and sponsor will report SUSARs to the MHRA, REC, Eudravigilance component of 
the EudraCT database within 7 days if the event was fatal of life threatening or 15 days if the 
event was not fatal of life threatening. 
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8. Ethical Considerations 
 
Informed consent 
Subjects will be required to give written informed consent witnessed by a third party. The 
investigator will explain verbally and in writing, the exact nature of the study and the known 
side effects which they might expect. Information regarding the research study will be 
provided to potential participants during discussion in clinic and by a patient information 
leaflet. They will not be expected to make decisions about involvement at this stage, but will be 
encouraged to take the information home and discuss it with their family. Patients will be 
allowed to deliberate for at least 24 hours after the initial discussions before the consent 
process is completed. Patients will be given as much time as they need to decide whether they 
wish to participate in the research study or not. Agreement to participate will be documented 
using a consent form (copies will be available for the investigators, the participant and the 
medical records). 
Patients will be advised that they are free to withdraw from the study at their own request. It 
will be explained that the study has been designed following the edicts of the International 
Conference of Harmonisation – Good Clinical Practice (ICH-GCP) and that they are protected by 
the 2000 Declaration of Helsinki to ensure their rights, safety and well being. Arrangements will 
be made to ensure adequate consent for participants who may have difficulty on 
understanding English or who have impairments (e.g. visual or hearing) that could influence 
the consent process. Independent witnesses will be available to confirm consent in those 
unable to do so in writing. 
 
 Confidentiality 
Identification within the study will be by a pseudonymous coded number effectively ensuring 
anonymity. However, using this number the principle investigators will be able to identify 
subjects rapidly to react to research related information that may influence a patient’s 
management or involvement in the study. A subject’s inclusion in the study will be made clear 
in their medical notes. Other medical professionals involved in non-research related care of the 
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
 
220 
 
subjects will be able to use the information recorded in the notes about study participation and 
contact the principle investigators if needed. 
The main objective of the blood tests is to help identify any adverse effects on the bone 
marrow, liver function or kidney function, so it is vital they are linked to the donor. The DNA 
samples will be anonymous, but the code will be available to the principle researcher so that 
future analysis can be linked to trial outcomes. Once the study is completed, it would be 
acceptable to break the link between data and subject identity so that future genetic analysis 
could not be linked to the individuals concerned. This would be subject of a further LREC 
application and at this stage approval only is sought for storage of samples. 
 
Ethics committee approval 
This protocol will be submitted to the Local Research Ethics Committee in Norwich. The study 
will not begin until ethics approval has been obtained. Any changes or revisions to the study 
protocol will be submitted to the ethical committee as appropriate. 
 
 Information to the patient’s general practitioner 
General practitioners will be informed of their patient’s decision to participate in the study. 
This letter will provide information on the test drug, the nature of the study and possible side 
effects. The GP will be invited to contact the investigator at the hospital if they have any 
enquiries or objections to the subject taking part. 
 
 Indemnity 
All patients will be recruited from NHS sites and the NHS indemnity scheme or professional 
indemnity will apply. The drug naloxone is already very extensively used but this trial 
constitutes a new application with a new formulation of the drug. Once the project Review 
Board approves the study, indemnity will be provided by the trust as per the Trust’s Clinical 
Negligence Scheme for non-negligent harm. This ensures that indemnity issues are adequately 
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covered. Participants will be made aware of the arrangements for potential compensation 
before agreeing to take part. This information is included in the consent form. 
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APPENDICES TO TRIAL PROTOCOL 
 
Appendix 1 – Summary of events in the trial/study 
  
Treatment/Placebo Phase – Period 2 (weeks 3-6) 
1. If above tests and diary card are acceptable on review then proceed with entry into 
study. 
2. Patient randomised to treatment or placebo group 
3. Patients given capsules – 2 capsules, twice a day (total of 40mg). 
4. Patient phoned at end of week 3 
5. Patients complete diary cards for each week 
6. At end of Period 2 (week 6) patients complete 2 questionnaires 
7. End of Period 2 
 Repeat Stool Sample as applicable 
 Repeat blood pressure recordings 
 Diary cards reviewed and AEs noted 
 Compliance checked against number of capsule returned and total number of 
capsules used 
 Repeat Transit study as applicable 
 Patient invited into Period 3 
Recruitment 
1. Patient referred to Constipation Clinic at Norfolk and Norwich University Hospital: 
history, examination and full investigation including barium enema and transit study 
2. Standard treatments (laxatives and life style modification, biofeedback) 
3. Patients not responding to standard treatment offered entry into Nalcol trial 
4. Patients given information sheet 
5. Discussion with investigators and entry into trial at patient request 
Pre-treatment Phase – Period 1 (weeks 1-2) 
1. Inclusion and exclusion criteria confirmed and medical history assessed. 
2. Patient consented into the trial 
3. Digital rectal examination, rigid sigmoidoscopy with rectal biopsy and stool sample 
4. ECG and blood pressure recordings 
5. Blood and urine samples taken for routine analysis 
6. Blood stored for  DNA sampling 
7. Patient completes diary cards and questionnaire at end of second week 
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Nalcol Continuation - Follow-up Period – Period 4 
1. Patients in whom Nalcol is obviously beneficial are invited to continue taking Nalcol 
whilst followed up for long term efficacy and adverse events 
2. PAC-SYM and PAC-QOL carried out monthly 
3. Monthly telephone call to monitor progress 
4. 3 monthly blood tests, BP and urinanalysis at hospital 
 
Post-Treatment Phase – Period 3 (weeks 7-10) 
1. All patients are now invited to Receive Nalcol treatment 
2. Patients given 20mg nalcol (2 capsules) twice a day. 
3. Patients proceed as for Period 2 completing their diary cards weekly and 
questionnaires at the end of the Period (week 10) 
4. End of Study 
 Repeat Stool Sample 
 Repeat blood pressure recordings 
 Diary cards reviewed and compliance checked 
 Repeat Haematological and biochemical testing 
 Patients are invited to continue taking Nalcol 
 Post study check by phone in 4 weeks time 
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Appendix 2 – Initial screening of patients for the study 
 
Inclusion/Exclusion Criteria   Subject Number ………………….. 
 
Date _ _ / _ _ / _ _ _ _      Initials...…………… 
 
This document is to be used on the first contact with patients to decide whether or not to 
proceed. If patients fulfill the criteria for inclusion then they can be given the appropriate 
information literature. 
This document is to be filed in the patient’s Clinical Record Form. 
 
Inclusion Criteria 
 
Subject must fulfill the ‘Rome III’ criteria which define constipation. 
When you are not taking laxatives, at least two of the following six criteria must be fulfilled 
(tick Box) 
1) Passage of less than 3 bowel movements per week 
 
2) Passage of small hard stools on more than 25% of occasions 
 
3) Straining at stool on more than 25% of occasions 
 
4) Feeling of incomplete rectal evacuation for more than 25% of the time 
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5) Sensation of anorectal blockage/obstruction on at least 25% of defecations 
 
6) Manual manouvres on more than 25% of occasions to help defecation  (digital 
evacuation, support of pelvic floor) 
 
If at least 2 of the above are fulfilled the following must all be answered in the affirmative to 
proceed 
 
1) Age 18yrs or more 
 
2) Troubled with constipation for at least 6 months 
 
3) No medical reason to explain constipation 
 
4) Failure of standard treatments (laxatives, lifestyle alteration, biofeedback) 
 
5) Normal barium enema and abnormal transit studies 
 
6) Ability and willingness to co-operate with those conducting the study,  including 
satisfactory completion of diary cards and availability for interviews. 
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Exclusion Criteria 
 
1) Subjects with sensory impairment or any other reason which may lead to poor 
compliance in the study (poor vision for example may make it difficult for them to 
recognize the appearance of their motions) 
 
2) Unable to complete the diary satisfactorily 
 
3) Severe psychiatric disease 
 
4) Very poor general health caused or complicated by cardiac, respiratory, hepatic or 
renal failure 
 
5) Where applicable, women pregnant or breast feeding, and fertile, sexual active women 
who are not practicing effective contraception 
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Appendix 3  Patient Information Sheet 
 
Department of General Surgery 
Colney Lane, Norwich NR4 7UY 
 
Patient Information Sheet 
Why have I been chosen? 
You have been invited to take part because you have severe constipation that has not 
responded well to standard treatments. 
 
What is the purpose of the study? 
The main purpose of the study is to look at the effectiveness of Nalcol capsules in the 
treatment of constipation which does not respond to standard treatments. Nalcol will be used 
in addition to your normal laxatives. 
 
What is Nalcol and how does it work? 
The active drug in Nalcol is called naloxone. Naloxone is not a new drug. It has been used 
routinely across the world for decades as it is the antidote to morphine overdose. Morphine 
and morphine-like drugs such as codeine and Tramadol are painkillers known as opioids. 
Opioids act by binding to opioid receptors found throughout the body, including the gut. The 
body produces its’ own natural opioids, called endorphins. Endorphins also act on opioid 
receptors. When endorphins and other opioids bind to gut opioid receptors they increase the 
transit time of the gut. The transit time of the gut is the time taken for stool to reach the end of 
the colon (the rectum) from the start (the caecum). An increase in this time leads to 
constipation. Naloxone prevents this action. This will reduce the transit time and improve the 
symptoms of constipation. 
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What about safety and possible side effects? 
Unlike many drug trials, this study is not assessing a new drug, but a new way of using a drug 
that has been widely used for many years. The safety record of naloxone is especially good. 
Nalcol is designed so that the drug is released in the large bowel with very little being absorbed 
into the main blood circulation. In the two studies where Nalcol was used no serious side 
effects were noted. We therefore feel that the risk of serious harm is very low. Minor 
temporary side effects which may occur include skin rashes (hypersensitivity), nausea (feeling 
sick), vomiting, and abdominal cramps. These would settle on reducing the dose or on 
complete cessation of the drug. 
Recent data has shown that another opioid anatagonist, Olvimopan (Entereg) has been 
associated with cardiovascular side effects, particularly low blood pressure. The systemic 
absorption of naloxone is expected to be very low (2-3%). The possibility of cardiovascular 
adverse events with naloxone needs to be evaluated further in clinical trials but has been 
reported as common in trials involving Targinact, a fixed combination tablet containing 
naloxone. As such blood pressure monitoring will be carried out each time the participant 
attends for review. 
 
What will happen to me if I take part? 
The study will last 10 weeks for each person taking part in the trial. There will be three periods 
of assessment during the study with a fourth period if the Nalcol is effective. 
Period 1 –  this will be a two week period of observation of your usual symptoms 
with your usual treatment.  
Period 2 -  The second period will consist of four weeks.  During this period you 
will take the ‘trial’ capsules. The trial capsule is either the active drug 
(Nalcol) or a placebo (dummy capsule). You will not be told which 
capsule you are taking and will be randomised to either Nalcol or the 
placebo.  
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Period 3 -  this will also consist of four weeks where every patient in the study will 
receive Nalcol capsules. 
Period 4 - This is a continuation period for those patients in whom the Nalcol is 
effective. 
Throughout the study you will be required to keep a simple diary. This will take 2-3 minutes a 
day to complete. At the end of each period you will also be asked to complete questionnaires 
about your symptoms and quality of life. These will take approximately 10 minutes to 
complete. You will need to make a minimum of four visits to the hospital to see the research 
doctor during the study.  
You will have blood taken at the beginning and the end of the study for routine tests. This 
allows us to assess the function of the bone marrow, liver and kidneys. The volume of blood 
taken will be no more than 45mls (the equivalent of three desert spoons).  A rectal 
examination will be performed at the start of the study. This is to exclude any obstruction to 
your rectum and anal canal that would exclude you from the study.  
We would like to repeat the transit studies on those patients who have had them done as part 
of their initial assessment by their consultant. This would take place at the end of the Period 2.  
 
The Large Bowel Transit Study  
This test gives a measure of whether or not the passage of food through the gut (colon) is slow 
or normal. The test itself is simple – you will be asked to swallow some capsules (containing 
tiny “markers” that show up on x-ray) and then have an x-ray of your abdomen a few days 
later. The distribution of the markers in your colon shows whether your bowel transit is normal 
or slow. Normal transit of contents from the mouth to the anus is less than 72 hours for the 
majority of patients. You will have had a transit study which had been organised by your 
consultant when you were initially assessed and this has shown that you have slow transit 
constipation. The trail capsule aims to reduce your transit time and this will be confirmed by 
repeating the transit study. The results of this investigation will be compared with your diary 
card to look at the effects of the trial capsule. 
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The transit study has very little in the way of risks.  The ‘markers’ used are completely safe and 
pass through the body unchanged. The abdominal X-ray which is taken a few days later is 
equivalent to 2 months of ‘background radiation’. ‘Background radiation’ is normally occurring 
radiation which we are all exposed to. Radiation is all around us. It comes from radioactive 
substances including the ground, the air, building materials and food.  For example a 50 years 
old woman will have been exposed to background radiation for 50 years or 600 months (50 
years x 12 months). That is to say that the abdominal X-ray is a small amount of radiation 
compared to what we are exposed to in our daily life and therefore a single X-ray is unlikely to 
be harmful. 
 
What will happen to the results of my tests? 
The results of your investigations will be kept confidentially in a special folder. The results will 
be available to your GP and specialist. We will analyse the results of the tests and 
questionnaires and discuss the results with you if you wish. We may write a report about our 
findings and attempt to publish this in a medical journal. In this report the results will be 
anonymous with no personal details such as name, date of birth or addresses. If you decide to 
withdraw from the study we will keep the results of your investigations. Any results from the 
study will be kept securely and confidentially in the hospital for a maximum of five years. After 
this time they will be destroyed. 
 
Will my details be kept confidential? 
The results and information collected in the study will be discussed outside the hospital at 
scientific meetings and will be published in scientific journals. However any information about 
you will have the name and address removed so that you cannot be recognised by it. 
 
  
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
 
231 
 
What are the benefits of taking part in the study? 
The experience in other hospitals around the world suggests that investigations such as these 
give useful information about the management of severe constipation. It is hoped that such 
information will help patients now and in the future who have similar problems. If the drug is 
found to be effective, the results of this study may lead to it becoming licensed for 
prescription. This means many other patients can be helped. If the drug personally helps you 
then you will be entered into follow-up period where you will be able to continue taking the 
Nalcol which you will need to collect from the hospital pharmacy at the Norfolk and Norwich 
Hospital. During this time you will be required to complete two questionnaires each month and 
undergo 3 monthly blood test, urine tests, and blood pressure monitoring at the hospital when 
you will also need to attend for a clinic appointment. The lead researcher, Lukasz Kruppa, will 
also contact you monthly by phone to monitor your progress. When the trial has finished this 
follow-up period will also finish. The drug company who make the drug will continue to supply 
it for you. This will continue until a license for the drug is obtained (unless the drug is 
withdrawn for reasons of safety or lack of effect). 
 
What are the disadvantages of taking part in the study? 
We do not anticipate any serious side effects or complications. There is always a small degree 
of risk when starting any new drug and the long-term effects of this drug are uncertain. The 
study will involve a small amount of inconvenience with diaries to fill in and visits to the 
hospital. It is also important that you appreciate that you may take a placebo (dummy tablet) 
for four weeks with no benefit. 
 
Will I be paid to take part in the study? 
Participants will not be paid to enter the study and unfortunately we are unable to reimburse 
participants for travel to and from the hospital. However, as mentioned earlier, you will be able 
to continue taking the Nalcol if it proves effective in improving your symptoms. 
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Do I have to take part in the study and can I withdraw? 
It is up to you to decide whether to take part. If you do decide to take part you will be given 
this information sheet to keep and will be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. Routine blood and 
urine analysis will need to be performed when you withdraw and a phone call will be made 1 
month after withdrawal as routine follow-up. Withdrawal from the trial will not affect the 
standard of care you receive now or in the future. Being involved in the study is completely 
voluntary. 
 
What if I am upset or inconvenienced by taking part in the study? 
If you feel upset at anytime during your involvement or you wish to complain about any aspect 
of the way you have been approached or treated during the study, the normal National Health 
Services complaints processes will be available to you. You will also be able to discuss any 
concerns you have at any time with Mr. M Bignell or Mr. M Rhodes. 
 
Who is coordinating the study? 
Mr. M Bignell, Dr L Kruppa and Dr A. Hart are coordinating the study. Mr. M Bignell will 
perform the assessments during the study and this work will go towards Mr. Bignell earning a 
Doctorate of Medicine (MD). 
 
Has the design of this study been checked by other doctors or scientists? 
Before the study could take place it was checked by pharmaceutical advisors of the Medicines 
and Healthcare products Regulatory Agency (MHRA), who have principally assessed the safety 
of the product. It has been approved by the Project Review Committee of the hospital trust 
and the Local Ethics Committee. They have checked the aims and design of the study. The 
Committee is made up of nurses, doctors, lay people, and possibly scientists. Their job is to 
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make certain that any studies involving patients in the UK are carried out safely and sensibly 
and in a way that will be beneficial to patients now and in the future. 
 
What do I do now? 
If you would like to help with the study please contact your consultant who will organise for 
you to meet Mr. M Bignell  or Dr L Kruppa to discuss the trial further or contact Mr. Bignell 
directly on 01603 286 418 or 07921 004 585. 
 
Thank you for your cooperation. 
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Period 1 
Randomisation 
Period 2 
Period 3 
 2 Nalcol capsules, twice a day 
 Phone call after 1 week to check on participant 
 End of Period assessment 
• Hand over completed diary cards 
• QOL questionnaires completed 
 Repeat blood and urine tests for routine analysis 
 End Of Trial 
 Post study check phone call in 4 weeks 
 
 2 capsules, twice a day 
 Phone call after 1 week to check on participant 
 End of Period assessment 
• Hand over completed diary cards 
• QOL questionnaires completed 
• Large Bowel X-ray transit study 
 Participant invited into Period 3 
 Inclusion and exclusion criteria assessed 
 Medical history assessed 
 Examination including rectal xamination and 
rigid sigmoidoscopy 
 Consent into trial 
 Blood tests for routine analysis 
 Completion of diary cards and quality of life 
questionnaires 
 If initial assessment and diary cards are 
satisfactory and patient is willing to proceed 
then they will be entered into the trial 
Diagram to Summarise the 3 
Periods within the Nalcol Trial 
Screening and 
Initial Assessment
2 weeks
End of Period 1 
Assessment
Active Compound 
– Nalcol
4 weeks
End of Period 2 
Assessment
Active Compound 
– Nalcol
4 weeks
Final Assessment 
End of Trial
Placebo
4 weeks
End of Period 2 
Assessment
Active Compound 
– Nalcol
4 weeks
Final Assessment 
End of Trial 
Period 4 Long-term Follow-up on Nalcol (selected 
patients 
 PAC-SYM and PAC-QOL monthly by post 
 Blood test, BP and urinanalysis 3 monthly at 
hospital 
 Monthly phone call to check on patients progress 
and monitor for adverse events 
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Appendix 4 – GP Letter 
 
 
Department of General Surgery     
   Colney Lane  Norwich NR4 7UY 
 
 
Date _ _ / _ _ /_ _ _ _ 
 
Dear Dr ……………., 
 
Your patient ………………………………………of …………………………………….. 
Has kindly agreed to participate in a ten week placebo controlled trial investigating the 
potential role of oral naloxone (Nalcol) for constipation, where current measures used by 
the patient are not entirely satisfactory. 
Naloxone is an opioid antagonist that has a beneficial effect in patients with constipation. 
The drug affects bowel motility and intestinal secretion with a shortening of the whole gut 
transit time. A small group of patients with constipation have had improvement in their 
symptoms whilst taking the formulation of naloxone. The only side effects encountered 
have been some urgency with defecation and slight abdominal discomfort. 
The ten week study will comprise of three periods. In Period 1 (2 weeks) patients will 
continue with the measures they usually use to manage constipation. In Period 2 (4 weeks) 
they will also be given the trial capsule (randomised to either the active drug or the 
placebo) and continue with other measures. In Period 3 (4 weeks) they will all be treated 
with the active drug. 
Period 4 will run after completion of the trial for those patients in whom Nalcol has been 
effective. They will be given the opportunity to continue taking the Nalcol under 
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supervision of the hospital. They will be asked to complete a monthly questionnaire and 
will be telephoned each month to monitor their progress. Every three months they will 
attend an outpatient clinic at the hospital where they will undergo routine blood testing, 
blood pressure measurement, and urinanalysis. Once both trials have concluded we will 
then make arrangement for the patients to continue the Nalcol on a named patient basis in 
agreement with the pharmaceutical company. 
The dose of naloxone in each capsule is 10mg, and the total number of capsules used in 
Periods 2 and 3 will be two capsules, twice a day. Throughout the ten weeks, patients will 
keep a diary card of their symptoms and complete questionnaires at the end of each 
period. 
We do not anticipate any serious adverse effects from this treatment, but have warned 
about the possibility of hypersensitivity, nausea, vomiting and abdominal cramps. 
We have provided the patient with information sheets and a contact phone number, but if 
you require any further information, please do not hesitate to contact me. 
Patients who wish to continue taking Nalcol after the study will be given the opportunity to 
do so via SLA Pharma, the pharmaceutical company supplying the drug. 
 
Yours sincerely 
 
 
Mark Bignell 
Research Coordinator 
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Appendix 5 – Consent Form 
 
CONSENT FORM 
 
 
 
 
 
Title of project 
NALOXONE HYDROCHLORIDE SR GASTRO-RESISTANT SUSTAINED RELEASE CAPSULES AS A 
TREATMENT FOR FUNCTIONAL CONSTIPATION: A RANDOMISED, DOUBLE BLIND 
CONTROLLED TRIAL IN SECONDARY CARE 
 
Name of Researchers: Mr. Mark Bignell, Dr. L Krupa and Dr. A Hart 
 
Please initial box 
 
 I confirm that I have read and understand the information sheet for the   
 above study and have had the opportunity to ask questions. 
 
 I understand that my participation is voluntary and that I am free to  
withdraw at any time, without giving any reason, without my medical care or  
legal rights being affected. 
  
Patient Identification Addressograph 
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 I understand that sections of any medical notes may be looked at by  
responsible individuals from Norfolk and Norwich University NHS Foundation  
Trust or from regulatory authorities where it is relevant to my taking  
part in research. I give permission for these individuals to have access to  
my records. 
 
 I understand that the investigators would like to inform my GP of my  
participation in the study. I give permission for my GP to be informed. 
 
 I agree to take part in the above study. 
 
 
 
___________________  _________________  __________________ 
Name of Patient  Date    Signature 
 
 
___________________  _________________  __________________ 
Name of Researcher  Date    Signature 
 
1 copy for patient; 1 for researcher; 1 to be kept with the hospital notes 
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Appendix 6  PAC-SYM – Patient Assessment of Constipation 
PAC-SYM ©  PATIENT ASSESSMENT OF CONSTIPATION 
This questionnaire asks you about your constipation symptoms in the past week. 
Answer each question according to your symptoms, as accurately as possible. There are 
no right or wrong answers. 
For each symptom below, please indicate how severe your symptoms have been 
during the past week. If you have not had the symptoms during the past week, tick 0. if 
the symptom seemed mild, tick 1. If the symptom seemed moderate, tick 2. If the 
symptom seemed severe, tick 3. If the symptom seemed very severe, tick 4. Please be 
sure to answer every question. 
 
How severe have each of these symptoms 
been in the past week? 
Absent 
0 
Mild 
1 
Moderate 
2 
Severe 
3 
Very 
Severe 
4 
Discomfort in your stomach 
 
     
Pain in your stomach 
 
     
Bloating in your stomach 
 
     
Stomach cramps 
 
     
Painful bowel movements 
 
     
Rectal burning during or after a bowel 
movement 
 
     
Rectal bleeding or tearing during or after 
a bowel movement 
 
     
Incomplete bowel movement, as though 
you didn’t ‘finish’ 
 
     
Stools that were too hard 
 
     
Stools that were too small 
 
     
Straining or squeezing to try to pass stools 
 
     
Feeling like you had to pass a stool but 
you couldn’t (false alarm) 
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Appendix 7  PAC-QOL – Patient Assessment of Constipation 
PAC-QOL ©  PATIENT ASSESSMENT OF CONSTIPATION 
The following questions are designed to measure the impact constipation has had on 
your daily life during the past week. For each question, please tick one box. 
 
The following questions ask you 
about the intensity of your 
symptoms. To what extent, during 
the past week…. 
 
Not at all 
0 
A little bit 
1 
Moderately 
2 
Quite a bit 
3 
Extremely 
4 
Have you felt bloated to the point of 
bursting? 
 
     
Have you felt heavy because of your 
constipation? 
 
     
 
The next few questions ask you 
about the effects of constipation on 
your daily life. How much time, 
during the past week…. 
None of 
the time 
0 
A little of 
the time 
1 
Some of 
the time 
2 
Most of the 
time 
3 
All of the 
time 
4 
Have you felt any physical 
discomfort? 
 
     
Have you felt the need to open your 
bowel but not been able to? 
 
     
Have you felt embarrassed to be with 
other people? 
 
     
Have you been eating less and less 
because of not being able to have 
bowel movements? 
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The next few questions ask you 
about the effects of constipation on 
your daily life. To what extent, 
during the past week…. 
Not at all 
0 
A little bit 
1 
Moderately 
2 
Quite a bit 
3 
Extremely 
4 
Have you had to be careful about 
what you eat? 
 
     
Have you had a decreased appetite? 
 
     
Have you been worried about not 
being able to choose what you eat 
(for example, at a friend’s)? 
 
     
Have you been embarrassed about 
staying in the toilet for so long when 
you were away from home? 
 
     
Have you been embarrasses about 
having to go to the toilet so often 
when you were away from home? 
 
     
Have you been worried about having 
to change your daily routine (for 
example, traveling, being away from 
home)? 
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The next few questions ask you 
about your feelings. How much of the 
time, during the past week…. 
None of 
the time 
0 
A little of 
the time 
1 
Some of 
the time 
2 
Most of the 
time 
3 
All of the 
time 
4 
Have you felt irritable because of your 
condition? 
 
     
Have you been upset by your 
condition? 
 
     
Have you felt obsessed by your 
condition? 
 
     
Have you felt stressed by your 
condition? 
 
     
Have you been less self-confident 
because of your condition? 
 
     
Have you felt in your control of your 
situation? 
 
     
Have you been worried about not 
knowing when you are going to open 
your bowels? 
 
     
Have you been worried about not 
being able to open your bowels when 
you needed to? 
 
     
Have you been more and more 
bothered by not being able to open 
your bowels? 
 
     
 
 
 
 
The next questions ask about your 
life with constipation. How much of 
the time, during the past week…. 
 
None of 
the time 
0 
A little of 
the time 
1 
Some of 
the time 
2 
Most of the 
time 
3 
All of the 
time 
4 
Have you been afraid your condition 
will get worse? 
 
     
Have you felt that your body was not 
working properly? 
 
     
Have you had fewer bowel 
movements than you would like? 
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The next questions ask you about 
how satisfied you are. To what 
extent, during the past week…. 
 
Not at all 
0 
A little bit 
1 
Moderately 
2 
Quite a bit 
3 
Extremely 
4 
Have you been satisfied with how 
often you open your bowels? 
 
     
Have you been satisfied with the 
regularity with which you open your 
bowels? 
 
     
Have you been satisfied with your 
bowel function? 
 
     
Have you been satisfied with your 
treatment? 
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APPENDIX 2  DIARY CARD 
 
 
       Patient Number  ________ 
       Patient Initials     ________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
Study of Nalcol Therapy in Functional Constipation 
 
 
 
 
 
DIARY CARD 
 
 
 
 
 
 
 
Should you wish to have advice on issues at any time during the study or wish to withdraw 
you may contact the trial co-ordinator, Mr Bignell, on 07928 941828 between the hours of 
08.30hrs and 17.00hrs, Monday to Friday. In case of emergency please contact your GP or 
local A&E with a copy of the patient information leaflet and this diary card. 
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Explanation of Terms used in the Diary Card 
 
 
 
1. Frequency - Number of stools each day 
 
2. Type of stool – As per the stool chart (next page) 
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Type of Stool Chart 
 
 
 
 
Type 1: Stools appear in separate, hard lumps, similar 
to nuts.  
 
Type 2: Stools are sausage-like in appearance but 
lumpy with deep cracks separating the hard lumps.  
 
Type 3 (Normal): Stools come out similar to a sausage 
but with cracks in the surface. 
 
Type 4 (Normal): Stools are smooth and soft in the 
form of a sausage or snake. 
 
Type 5: Stools form soft blobs with clear-cut edges, 
and easily pass through the digestive system. Soft 
diarrhoea. 
 
Type 6: Stools have fluffy pieces with ragged edges. 
Considered mushy stools, they indicate diarrhoea;  
 
Type 7: Stool is mostly liquid with no solid pieces. 
Passed quickly through the colon; is indicative of 
severe diarrhoea. 
 
 
 
Look at the stool in the toilet before you use toilet paper, and note the type of stool you 
have passed. Types 1,2, and 3 are the most common in people with constipation 
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Explanation of Diary Card for Weeks 1 and 2 
 
 
 
 
 
 The purpose of this week is to identify your usual bowel habit and weekly 
requirement of laxative usage.  
 
 Please complete the diary at the end of each day as accurately as possible 
recording any laxatives used during that day.  
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Week 1 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 1 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Explanation of Diary Card for Weeks 3-6 
 
 
 
 
 For the next four weeks you should take the trial capsule twice a day. 
 
 Continue to take your regular laxative medication as needed. 
 
 Please complete the diary at the end of each day as accurately as possible 
recording any laxatives used during that day. 
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Week 3 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 4 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 5 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 6 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Explanation of Diary Card for Week 7-10 
 
 
 
 
 In weeks 3 to 6 you have either been taking the active drug, Nalcol, or a placebo. 
You are now invited to take the active medication, Nalcol, for four weeks 
 
 
 Continue to take your regular laxative medication as needed. 
 
 
 Please complete the diary at the end of each day as accurately as possible 
recording any laxatives used during that day. 
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Week 7 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 8 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 9 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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Week 10 Pre-Trial       
 
Date _ _ / _ _ / _ _ _ _     Patient Number _________ 
       Patient Initials   _________ 
       Sex -   MALE / FEMALE 
       DOB      _ _ / _ _ / _ _ _ _ 
 
 
 
 
Day 1 2 3 4 5 6 7 
Frequency        
Type of Stool        
 
 
 
 
  
Day 
Name of medication taken on any day for constipation with any 
comments you may wish to make 
1 
 
 
2 
 
 
3 
 
 
4 
 
 
5 
 
 
6 
 
 
7 
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APPENDIX 3  PROTOCOLS FOR DNA EXTRACTION AND   
   PURIFACATION FOR DOWN STREAM ANALYSIS 
 
QIAamp® DNA EXTRACTION PROTOCOL 
 
1. Weigh 180-220mg stool in a 2ml microcentrifuge tube (not provided) and place 
tube on ice. 
 
2. Add 1.4ml Buffer ASL to each stool sample. Vortex continuously for 1 min or until 
the stool sample is thoroughly homogenised. 
It is important to vortex the samples thoroughly. This helps ensure maximum DNA 
concentration in the final eluate. 
 
3. Heat the suspension for 5 min at 70oC. 
This heating step increases total DNA yield 3- to 5-fold and helps to lyse bacteria 
and other parasites. The lysis temperature can be increased to 95oC for cells that 
are difficult to lyse (such as Gram-positive bacteria) 
 
4. Vortex for 15 seconds and centrifuge sample at full speed for 1 minute to pellet 
stool particles. 
 
5. Pipet 1.2ml of the supernatant into a new 2ml microcentrifuge tube and discard 
the pellet. 
 
6. Add 1 InhibitEX tablet to each sample and vortex immediately and continuously for 
1 min or until the tablet is completely suspended. Incubate suspension for 1 min at 
room temperature to allow inhibitors to adsorb to the InhibitEX matrix. 
 
7. Centrifuge sample at full speed for 3 min to pellet inhibitors bound to InhibitEX 
matrix. 
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8. Pipet all the supernatant into a new 1.5ml centrifuge tube and discard the pellet. 
Centrifuge the sample at full speed for 3 min. 
 
9. Pipet 15 µl proteinase K into a new 1.5ml microcentrifuge tube. 
 
10. Pipet 200 µl supernatant from step 8 into the 1.5 ml microcentrifuge tube 
containing proteinase K. 
 
11. Add 200 µl Buffer AL and vortex for 15 s. 
Note: Do not add proteinase K directly to Buffer AL 
It is essential that the sample and Buffer AL are thoroughly mixed to form a 
homogenous solution. 
 
12. Incubate at 70oC for 10 min. 
 
13. Add 200 µl of ethanol (96-100%) to the lysate, and mix by vortexing. 
 
14. Label the lid of a new QIAamp spin column placed in a 2 ml collection tube. 
Carefully apply the complete lysate from step 13 to the QIAamp spin column 
without moistening the rim. Close the cap and centrifuge at full speed for 1 min. 
Place the QIAamp spin column in a new 2ml collection tube, and discard the tube 
containing the filtrate. 
Close each spin column in order to avoid aerosol formation during centrifugation 
If the lysate has not completely passed through the column after centrifugation, 
centrifuge again until the QIAamp spin column is empty. 
 
15. Carefully open the QIAamp spin column and add 500 µl Buffer AW1. Close the cap 
and centrifuge at full speed for 1 min. Place the QIAamp spin column in a new 2ml 
collection tube, and discard the tube containing the filtrate. 
 
16. Carefully open the QIAamp spin column and add 500 µl Buffer AW2. Close the cap 
and centrifuge at full speed for 3 min. Discard the collection tube containing the 
filtrate. 
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Note: Residual buffer AW2 in the eluate may cause problems in downstream 
applications. Some centrifuge rotors may vibrate upon deceleration, resulting in the 
flow-through, which contains Buffer AW2, contacting the QIAamp spin column. 
Removing the QIAamp spin column and collection tube from the rotor may also 
cause flow-through to come into contact with the QIAamp spin column. 
 
17. Recommended: Place the QIAamp spin column in a new 2 ml collection tube and 
centrifuge at full speed for 1 min. 
This step helps to eliminate the chance of possible Buffer AW2 carryover. 
 
18. Transfer the QIAamp spin column into a new, labelled 1.5 ml microcentrifuge tube. 
Carefully open the QIAamp spin column and pipet 200 µl Buffer AE directly onto 
the QIAamp membrane. Close the cap and incubate at room temperature, then 
centrifuge at full speed for 1 min to elute DNA. 
 
 
E.Z.N.A.® CYCLE-PURE SPIN PROTOCOL 
 
1. Perform agarose gel/ethidium bromide electrophoresis to analyse PCR Product. 
 
2. Determine the volume of the PCR reaction. Transfer the sample into a clean 1.5 ml 
microcentrifuge tube and add 4-5 volumes of CP buffer. For PCR products smaller 
than 200 bp, add 6 volumes of CP buffer. 
 
3. Vortex thoroughly to mix. Briefly spin the tube to collect any drops from inside of 
the lid. 
 
4. Place a HiBind DNA Mini Column into a provided 2ml collection tube. 
 
5. Add the mixed sample from step 3 to the HiBind DNA Mini Column and centrifuge 
at 13 000 x g for 1 minute at room temperature. Discard the flow-through liquid 
and place the HiBind Mini Column back into the same collection tube. 
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6. Add 700 µl of DNA Wash Buffer and centrifuge at 13 000 x g for 1 minute. Discard 
the flow-through liquid and place the HiBind DNA Mini Column back into the same 
collection tube. 
DNA Wash Buffer must be diluted with absolute ethanol before use. If refrigerated, 
DNA Wash Buffer must be brought back to room temperature before use. 
 
7. Add 500 µl of DNA Wash Buffer and centrifuge at 13 000 x g for 1 minute. Discard 
the flow-through liquid and place the HiBind DNA Mini Column back into the same 
collection tube. 
 
8. Centrifuge the empty HiBind DNA Mini Column for 2 min at maximal speed (≥13 
000 x g) to dry the column matrix. 
Do Not skip this step. It is critical for the removal of ethanol from the HiBind DNA 
Column 
9. Place the HiBind DNA Mini Column into a new, clean 1.5 ml microcentrifuge tube. 
Depending on the desired concentration of the final product, add 30-50 µl of 
Elution Buffer (10mM Tris, pH 8.5) or water directly onto the centyre of the column 
matrix. Let it sit at room temperature for 2 minutes. Centrifuge for 1 minute at 13 
000 x g to elute the DNA. 
This represents approximately 80-90% of bound DNA. An optional second elution 
will yield any residual DNA, though at a lower concentration. 
 
ELECTROPHORESIS WITH AGAROSE GEL 
 
1. 0.7g agarose powder mixed with 100mls of 0.5x TBE buffer and weigh. 
 
2. Heat to ensure agarose dissolves and then add TBE buffer if necessary. 
 
3. Pour into electrophoresis box to form gel plate. 
 Place combs into box. 
 Pour slowly to avoid bubbles. 
 Use small pipette tip to remove bubbles. 
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4. Once gel has set: 
 Cover gel with TBE buffer. 
 Carefully remove comb. 
 Add DNA to wells (4µl DNA, 2µl Loading Dye). 
 Use 4µl of ladder in first well. 
 
5. Connect to power. 
 Band runs black to red (-ve to +ve). 
 80-90V, 20mA. 
 
6. Once gel has run transfer to Ethidium Bromide and leave for 30 minutes. 
 
7. Remove and Wash. 
 
8. Place on camera, filter II, UV transillumination. 
 
9. Take photo, print and save. 
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APPENDIX 4  DGGE PROTOCOL BIORAD SYSTEM 
 
Add dH2O to the cylinders of the gradient maker and switch on the stir and mixing systems 
and the pump at the maximum speed (9.9mL/min). Refill the cylinders with water one 
more time to rinse them. Make sure there is a beaker for the waste. 
Clean the glass plates (2 large and 2 small), the combs and the spacers with detergent. Dry 
and clean them with 70% ethanol. 
Switch off the stir and mixing system and the pump and dry the cylinders. 
Prepare the platform for the gels 
Place grey strips on the white platform 
Prepare the large plate with the spacers, and place the small plate on top of it 
Place the clamps both sides of the glass plates as the arrows indicate 
Make sure the spacers are completely aligned on the bench 
Place the cardboard between the 2 plates and make sure it can be moved 
Adjust the screws until they cannot be moved (don’t tighten the screws too much since the 
glass plates and clamps might break) 
Check again that the spacers are completely aligned with the plates 
Place the gel sandwich on the white platform 
 
Prepare the Ammonium persulfate (APS) 10% 
This is the catalyst that can be kept frozen. Weigh 200mg and dissolve in 2ml dH2O 
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Preparation of the Gradient gel 
Collect TEMED and the 60%, 40%, and 0% acrylamide solutions from the fridge 
Put a new needle on the tube 
Switch on the stirrer and make sure the connection is closed. Set the pump speed to 4.0mL 
/ min 
Add 11ml of 60% acrylamide to the cylinder in the left (closed to pump), and 11ml of 40% 
acrylamide to the cylinder in the right 
Add 15µl of TEMED (take care, toxic) and 45µL of 10% APS to each cylinder. When TEMED 
and APS get added the acrylamide starts polymerising therefore do not  wait too long 
before continuing. 
Place the needle in the middle between the glass plates of the gel sandwich, start the pump 
and immediately after you see the acrylamide in the white tube open the connection. 
Once the cylinders are empty remove the needle from the tube and put it in the  beaker. 
Add H2O to the cylinders to wash them and increase the pump speed to  9.9mL/min. When 
the cylinders are empty close the connection and stop the pump. Dry the cylinders with a 
tissue. 
 
Preparation of the Stacking Gel 
Start the stirrer and make sure the connection between both cylinders is closed 
Fill the left hand cylinder with 7ml of 0% acrylamide 
Add 11µL of TEMED and 30µl of 10% APS to the cylinder 
Start the pump and once all the water has been removed from the tube select a pump 
speed of 1.0mL/min and place the needle between the glass plates to pour the stacking gel 
Remove the needle, switch of the pump, and quickly place the comb 
Rinse the tube with dH2O 
Repeat the same process for the other gel 
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Leave the gels at least 2-3 hours to polymerise 
Wash the bench with ethanol 
 
Preparing the buffer and loading the gels 
Fill the gel tank with 1x TAE until the ‘fill’ line (approx 7 litres) 
Top up with 20ml of 50X TAE to 1L of dH2O 
Pre-heat the buffer to 60oC at least 1 hour before starting to load the gel 
Mix the samples in a microtitre plate and then mix with 5µl of loading buffer 
Remove the gels from the white platform and put them in a yellow one 
Place the gel in the yellow platform into the bath making sure the red button is on the right 
hand side 
Remove the comb in the back gel and load it with a syringe. Then do the same with the 
front gel 
Switch on the pump and let the buffer reach the black part in the top of the bath 
Run the electrophoresis at 50V for 16hours 
 
Staining the gels 
Prepare 2 trays with 300ml of 1x TAE 
Switch off the DGGE and take out the gels 
Remove the spacers carefully and also the small glass plate (upper plate) 
Put the transparency on the gel, turn it and remove the large glass plate 
Put the gels in the tray with the TAE 
Add 5µL of SYBr Green to each tray (1 spots in each corner) and leave them approximately 
45 minutes on the shaker at the minimum speed in the dark 
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Wash the gels for 15 min in 300ml of dH2O in the dark 
Scan the gels using ‘PHAROS’ scanner (Bio-Rad) and using the manufacturer’s instructions 
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APPENDIX 5  FLUORESCENCE IN SITU HYBRIDISATION (FISH)  
   PROTOCOL 
 
Faecal sample preparation (not lactobacillus/enterococcus probes) 
Weigh the sample and add PBS to make a 1 / 10 (w/v) solution 
Homogenise the sample in an Eppendorf with 0.5mls of PBS 
Transfer to a 7ml plastic tube and washout Eppendorf with the remaining PBS for the 
sample 
Repeat homogenisation until complete then split sample equally between two 2ml 
Eppendorf tubes 
Centrifuge for 2 min at 1500 rpm to remove particulate matter 
Remove 375µl of supernatant and add 1125µl of filtered 4% paraformaldehyde solution in 
a 1.5ml microcentrifuge tube.  
Always add paraformaldehyde then supernatant and paraformaldehyde needs to be cold 
(40C prior to use) 
Mix and store overnight at 40C 
Take the 1.5ml of fixed sample and centrifuge at 13000 rpm for 5 min 
Remove the supernatant and resuspend the pellet in 1ml of filtered PBS 
Repellet by centrifuging at 13000 rpm for 5 min 
Wash the pellet a second time and repeat the above step 
Remove as much supernatant as possible and resuspend the pellet in 150µl of filtered PBS 
Add 150µl of 96% ethanol, mix well and store at -200C for at least 1 hour 
THE ETHANOL/PBS SAMPLES COULD BE STORED FOR UPTO 3 MONTHS 
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Faecal sample preparation (lactobacillus/enterococcus probes) 
Weigh the sample. A volume of PBS will be required to make a 1 / 10 (w/v) solution 
Homogenise the sample in an Eppendorf with 0.5mls of PBS 
Transfer to a 7ml plastic tube and washout Eppendorf with the remaining PBS for the 
sample 
Repeat homogenisation until complete then split sample equally between two 2ml 
Eppendorf tubes 
Centrifuge for 2 min at 1500 rpm to remove particulate matter 
Remove 375 µl of supernatant and add 1125µl of filtered 4% paraformaldehyde solution in 
a 1.5 ml microcentrifuge tube.  
Always add paraformaldehyde then supernatant and paraformaldehyde needs to be cold 
(40C prior to use) 
Mix and store overnight at 40C 
Take the 1.5ml of fixed sample and centrifuge at 13000 rpm for 5 min 
Remove the supernatant and resuspend the pellet in 1ml of filtered PBS 
Repellet by centrifuging at 13000 rpm for 5 min 
Wash the pellet a second time and repeat the above step 
Remove as much supernatant as possible and resuspend in 145µl of Lactobacillus enzyme 
buffer 
Incubate at 370C for 2 hours 
Add 5µl of 4% paraformaldehyde solution and leave at 40C for 10 minutes 
Repellet by centrifuging at 13000 rpm for 5 min 
Remove the supernatant and resuspend the pellet in 1ml of filtered PBS 
Repellet by centrifuging at 13000 rpm for 5 min 
Wash the pellet a second time and repeat the above step 
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Remove as much supernatant as possible and resuspend the pellet in 150µl of filtered PBS 
Add 150µl of 96% ethanol, mix well and store at -200C for at least 1 hour 
  
Hybridisation (all probes) 
In a 0.5ml eppendorf tube: 
Add 16µl of the fixed cells (PBS/EtOH @-20) to 264µl of filtered hybridisation buffer 
(prewarmed in the oven) 
It is important that the above mixture is close to the hybridisation temperature  before it is 
added to the probe. If it has cooled it should be rewarmed in the oven to the appropriate 
temperature (see later table) 
Take a 2nd 0.5ml microcentrifuge tube and add the appropriate volume of the probe 
(50ng/µl, 200C). Then as quick as possible pipette 90µl of the above mixture into the probe 
tube, vortex and return to the hybridisation oven. Ensure that the lids are firmly closed to 
prevent evaporation. 
The volume of hybridisation mix may not be the same for all probes (see table 1) 
Leave overnight to hybridise 
 
Washing (all probes) 
Take a 7ml Sterilin tube and add 5ml of filtered prewarmed washing buffer and 20µL of 
DAPI (4,6-diamidino-2-phenylindole, 500ng/µl) 
Add hybridised sample and leave Sterilin tubes in the oven for 30 min. Any remaining 
hybridised sample should be returned to the oven if the dilution is not known (max. 24h). 
Set up the apparatus using a wet filter (0.2µm), matt side up 
Pour the sample mixture onto the filter and switch on the vacuum pump 
Rinse the Steriliin tube and glass tube of the filtering apparatus with prewarmed washing 
buffer using a syringe 
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Remove the filter and place it onto a glass slide  
Put a drop of Slow Fade on top of the filter and place a glass cover slip onto this 
Store the slide in the dark at 40C to minimise fading 
 
Counting (all probes) 
Place the slide onto a microscope, add a drop of immersion oil and use the Flour 100 lens 
Start with UV light to find DAPI stained bacteria then switch to the green light to count the 
organisms hybridised with the probe 
Count the number of organisms inside the target box, focusing up and down to see all of 
the bacteria. On average there should be 20-30 cells. If more or less then dilutions will need 
to be adjusted. 
Count 15 random fields then dispose of the slide 
Uncounted slides should be stored in the dark at 40C 
 
Quantities of hybridisation mixture 
The volume of hybridisation mixture prepared depends on the volume planned to be used 
the next day during the washing stage. (e.g if 100µl is required then make sure that at least 
120µl are prepared to allow for some evaporation) 
The volume of hybridisation mixture used during the washing stage depends on how many 
bacteria you expect to find in the sample. In general higher bacterial numbers correspond 
to lower volumes (dilutions and vice versa). 
The volume of the hybridisation mix has an upper limit that depends on the total number of 
bacteria count (DAPI count) 
The ratio of hybridisation mixture (fixed cells and hybridisation buffer) and probes is 
ALWAYS 1:10 
Avoid using small volumes (5:45) because of overnight evaporation 
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Table 2 – Probes, Temperatures, Hybridisation Mixture Volumes and Times. 
 
In the case of DAPI HPLC (filtered) water is used instead of a probe. These volumes are for 
faecal samples. They are not absolute values but are starting points that may have to be 
adjusted according to samples and test substrates. 
Probe Target Genus Temp 
(0C) 
Probe 
Volume 
(µl) 
Sample 
Volume 
(µl) 
Hybridised 
Mixture 
Volume 
(µl) 
Optimum 
Hybridisation 
Time (h) 
Bac 303 Bacteroides spp. 45 10 90 20  
15-17 
 
Max time - 
24 
Bif 164 Bifidobacterium 
spp. 
50 10 90 20 
Erec 482 C.coccoides 
Eubacterium 
rectale gp. 
52 10 90 20 
Chis 150 C.histolyticum gp. 50 15 135 100 
Ec 1531 E.coli 37 15 135 100 
Lab 158 Lactobacillus spp. 
Enterococcus spp. 
45 15 135 100 
Srb 687 Desulfovibrio spp. 48 15 135 100 3 
Max time – 4 Eub 338 Total Bacteria 48 10 90 10 
DAPI Total DNA Any 10 90 5 Nil 
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Solutions and buffers 
All solutions and buffers were made up as described below; 
 
PBS:  1 PBS tablet was added into 100ml of distilled water and then autoclaved. The pH 
was adjusted to 7.4 and filtered through 0.2µm filter paper and then stored at 40C 
4% PARAFORMALDEHYDE:  A 16% paraformaldehyde vial (10ml) was dilute to 4% with 
filtered PBS solution (above) 
LACTOBACILLUS ENZYME BUFFER: 23mM Tris-HCl, 585mM Sucrose, and 5mM CaCl2 were 
combined and then stirred until dissolved. 10mM EDTA and 30mg Taurocholic Acid were 
then added and dissolved. The pH was adjusted to 7.6 and then the solution was filtered 
through 0.2µm filter paper and stored at room temperature. Prior to use 2mg/ml lysosyme 
(50 000U) and 1mg/ml lipase (100-400U, Porcine Pancreas Type II) were added. 
HYBRIDISATION BUFFER (NOT EUB 338, SRB 687, OR EC 1531 PROBES): 30mM Tris-Hcl, 1.36 
M NaCl, and 1.5ml of 10% SDS solution were combined. The pH was adjusted to 7.2 and the 
solution filtered through 0.2µm filter paper and store at room temperature. Prior to use it 
was stored in hybridisation oven 
HYBRIDISATION BUFFER (EC 1531 PROBE): 40mM Tris-HCl, 1.8M NaCl, and 2ml of 10% SDS 
solution were combined and the pH adjusted to 7.2. The solution was filtered through 
0.2µm filter paper and stored at room temperature. Prior to use 35% formamide was 
added and the solution filtered through 0.2µm filter paper and store in hybridisation oven. 
HYBRIDISATION BUFFER (DESULFOVIBRIO spp. AND EUB 338 PROBES): 20mM Tris-HCl, 0.9 
M NaCl, and 100µl of 10% SDS solution were combined and the pH adjusted to 7.2. The 
solution was then filter through 0.2µm filter paper and stored at room temperature. Prior 
to use 10% formamide was added for Desulfovibrio spp., filtered through 0.2µm filter paper 
and store in the hybridisation oven whilst 20% formamide was added for total bacteria, 
filtered through 0.2µm filter paper and stored in the hybridisation oven. 
WASHING BUFFER (NOT EUB 338 OR SRB 687 PROBES): 20mM Tris-HCl and 0.9 M NaCl 
were combined, the pH adjusted to 7.2, and the solution filtered through 0.2µm filter 
paper and stored at room temperature. Prior to use the solution was stored in the 
hybridisation oven. 
Mark Bignell BSc (Hons), MRCS  MD Thesis, 2013 
 
277 
 
 
WASHIING BUFFER FOR SRB 687 PROBE: 20mM Tris-HCl, 0.386 M NaCl, and 1ml of 10% SDS 
were combined and the pH adjusted to a pH of 7.2. The solution was then filtered through 
0.2µm filter paper and stored at room temperature. Prior to use it was stored in the 
hybridisation oven. 
WASHING BUFFER FOR EUB 338 PROBE: 20 mM Tris-HCl, 0.166 M NaCl, and 1ml of 10% SDS 
were combined and the pH adjusted to a pH of 7.2. The solution was then filtered through 
0.2µm filter paper and stored at room temperature. Prior to use it was stored in the 
hybridisation oven. 
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6. ABBREVIATIONS 
 
5-HT  5-HYDROXYTRYPTAMINE (SEROTONIN) 
ACH  ACETYLCHOLINE 
ATP  ADENOSINE 5’-TRIPHOSPHATE 
BAC 303 Bacteroides spp 
Bif 164  Bifidobacterium spp. 
BFI  BOWEL FUNCTION INDEX 
CCD  CHARGED COUPLE DEVICE 
CFB  CYTOPHAGA-FLAVOBACTERIUM-BACTEROIDES 
cGMP  CYCLIC GUANOSINE MONOPHOSPHATE  
CIC  CHLORIDE CHANNELS 
CNS  CENTRAL NERVOUS SYSTEM 
CSBM  COMPLETE SPONTANEOUS BOWEL MOVEMENT 
CTA  CLINICAL TRIAL AUTHORISATION 
CTFR  CYSTIC FIBROSIS TRANSMEMBRANE REGULATOR 
DGGE  DENATURING GRADIENT GEL ELECTROPHORESIS 
DNA  DEOXYRIBONUCLEIC ACID 
EAS  EXTERNAL ANAL SPHINCTER 
EC  ENTEROCHROMAFFIN 
ECG  ELECTROCARDIOGRAM 
EGC  ENTERIC GLIAL CELLS 
EMG  ELECTROMYOGRAM 
ENS  ENTERIC NERVOUS SYSTEM 
EPSP  EXCITATORY POST SYNAPTIC POTENTIAL 
Erec 482 C.coccoides-Eubacterium rectale gp 
FGID  FUNCTIONAL GASTROINTESTIINAL DISORDERS 
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FC  FUNCTIONAL CONSTIPATION 
FISH  FLUORSCENT IN-SITU HYDRIDISATION 
GC-C  GUANYLATE CYCLASE C 
GCP  GOOD CLINICAL PRACTICE 
GI  GASTROINTESTINAL  
H&E  HEMATOXYLIN AND EOSIN 
HAPCs  HIGH AMPLITUDE PROPAGATING CONTRACTIONS 
HFD  HIGH FAT DIET 
IAS  INTERNAL ANAL SPHINCTER 
IBD  INFLAMMATORY BOWEL DISEASE 
IBS  IRRITABLE BOWEL SYNDROME 
IBS-C  IRRITABLE BOWEL SYNDROME – CONSTIPATION 
IBS-D  IRRITABLE BOWEL SYNDROME – DIARRHOEA 
IBS-M  IRRITABLE BOWEL SYNDROME – MIXED  
ICC  INTERSTITIAL CELLS OF CAJAL 
ICH   INTERNATIONAL CONFERENCE ON HARMONISATION 
IFR  INSTITUE OF FOOD RESEARCH 
IHC  IMMUNOHISTOCHEMISTRY 
IL  INTERLEUKIN 
IMP  INVESTIGATIONAL MEDICINAL PRODUCT 
IPANs  INTRINSIC PRIMARY AFFERENT NEURONES 
IQR  INTERQUARTILE RANGE 
IRAS  INTEGRATED RESEARCH APPLICATION SYSTEM 
ITT  INTENTION TO TREAT 
JPUH  JAMES PAGET UNIVERSITY HOSPITAL 
LAB 158 Lactobacillus / enterococcus 
LAPCs  LOW AMPLITUDE PROPAGATING CONTRACTIONS 
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MCT  MUSCULAR COORDINATION TRAINING 
MHRA  MEDICINES AND HEALTHCARE PRODUCTS REGULATORY AGENCY 
NNUH  NORFOLK AND NORWICH UNIVERSITY HOSPITAL 
NO  NITRIC OXIDE 
OIC  OPIOID INDUCED CONSTIPATION 
PAC-QOL PATIENT ASSESSMENT OF CONSTIPATION – QUALITY OF LIFE 
PAC-SYM PATIENT ASSESSMENT OF CONSTIPATION – SYMPTOMS 
PCR  POLYMERASE CHAIN REACTION 
PED  PELVIC EVACUATORY DISORDER 
PEG  POLYETHYLENE GLYCOL 
PFD  PELVIC FLOOR DYSSYNERGIA 
PR  PROLONGED RELEASE 
PS  PROPAGATING SEQUENCES 
qPCR  QUANTITATIVE POLYMERASE CHAIN REACTION 
QOL  QUALITY OF LIFE 
R&D  RESEARCH AND DEVELOPMENT 
RCT  RANDOMISED CONTROLLED TRIAL 
REC  RESEARCH AND ETHICS COMMITTEE 
rRNA  RIBOSOMAL RIBONUCLEIC ACID  
Rf  RETARDATION FACTOR 
SBM  SPONTANEOUS BOWEL MOVEMENT 
s.d.  STANDARD DEVIATION 
SERT  SEROTONIN REUPTAKE TRANSPORTER 
SNS  SACRAL NERVE STIMULATOR 
SPS  SODIUM PICO SULPHATE 
STC  SLOW TRANSIT CONTIPATION 
STC + IRA SUBTOTAL COLECTOMY AND ILEORECTAL ANASTOMOSIS 
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TMF  TRIAL MASTER FILE 
TNF-α  TUMOUR NECROSIS FACTOR ALPHA 
UEA  UNIVERSITY OF EAST ANGLIA 
VIP  VASOACTIVE INTESTINAL PEPTIDE 
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